

**The Role of the Intestine in the Metabolism of Thyroid Hormones  
and in the Regulation of Thyroidal Status in the Rainbow Trout,  
*Oncorhynchus mykiss***

by

**Kathryn A. Kohel**

**Submitted to the Faculty of Graduate Studies  
in Partial Fulfillment of the Requirements  
for the Degree of**

**Doctor of Philosophy**

**Department of Zoology  
University of Manitoba  
Winnipeg, Manitoba**

**© Kathryn A. Kohel, May 2004**

**THE UNIVERSITY OF MANITOBA**  
**FACULTY OF GRADUATE STUDIES**  
\*\*\*\*\*  
**COPYRIGHT PERMISSION**

**The Role of the Intestine in the Metabolism of Thyroid Hormones**  
**and in the Regulation of Thyroidal Status in the Rainbow Trout,**  
*Oncorhynchus mykiss*

**BY**

**Kathryn A. Kohel**

**A Thesis/Practicum submitted to the Faculty of Graduate Studies of The University of**  
**Manitoba in partial fulfillment of the requirement of the degree**  
**Of**  
**DOCTOR OF PHILOSOPHY**

**Kathryn A. Kohel © 2004**

**Permission has been granted to the Library of the University of Manitoba to lend or sell copies of this thesis/practicum, to the National Library of Canada to microfilm this thesis and to lend or sell copies of the film, and to University Microfilms Inc. to publish an abstract of this thesis/practicum.**

**This reproduction or copy of this thesis has been made available by authority of the copyright owner solely for the purpose of private study and research, and may only be reproduced and copied as permitted by copyright laws or with express written authorization from the copyright owner.**

## Table of Contents

	Page
Acknowledgements.....	iv
Abstract.....	v
List of Figures.....	vii
List of Tables.....	xvi
List of Abbreviations.....	xviii
Chapter 1     General Introduction.....	1
Chapter 2     Selected Literature Review.....	10
Chapter 3 <i>In vitro</i> Thyroid Hormone Metabolism and Assay Conditions for Intestinal Metabolism of the Thyroid Hormones, 3',5',3,5-tetraiodothyronine and 3',3,5-triiodothyronine, in Rainbow Trout.....	27
Introduction.....	27
Materials and Methods.....	30
Results.....	38
Discussion.....	46
Chapter 4     Effects of Dietary Thyroid Hormone Challenges (T <sub>4</sub> and T <sub>3</sub> ) on Intestinal Metabolism of Thyroid Hormones in Rainbow Trout.....	80
Introduction.....	80
Materials and Methods.....	82
Results.....	85
Discussion.....	89
Chapter 5     Development of an <i>In vivo</i> Method to Assess the Acute Uptake of Thyroxine and Triiodothyronine by Enterohepatic Tissues of Rainbow Trout.....	106
Introduction.....	106
Materials and Methods.....	110
Results.....	119
Discussion.....	123

	Page
Chapter 6    Effects of Chronic Dietary Thyroid Hormone Challenges on <i>In vivo</i> Uptake of Thyroxine and Triiodothyronine by Enterohepatic Tissues of Rainbow Trout.....	141
Introduction.....	141
Materials and Methods.....	143
Results.....	149
Discussion.....	153
Chapter 7    General Discussion.....	169
References.....	175
Appendices.....	188



## Acknowledgements

I would like to thank Dr. Eales for the opportunity to work in his lab and to thank him for his patience, guidance and support in many forms while I exerted my independence and learned from him. It was a great pleasure to learn from someone with such a depth of knowledge and the ability to create complete, coherent, and precise research from it. I would like to reinforce my appreciation of his patience, especially while I was working in the residence halls, demonstrating, and teaching at the University of Manitoba or while I was teaching at Alfred University and finishing my dissertation. That sentiment of appreciation is also extended to my committee members. I would like to thank Tara Narayansingh for the opportunity to work for her. I appreciate all of the talks and encouragement that brought focus to many areas of my life. I would also like to thank all of the people in the department, who have provided intellectual stimulation or just plain friendship: Christa Dubesky, Hope McGaha, James Plohman, Chandra Chambers, Susanna Wiens, Kenny Finnson, Glenn Fines, and the countless others who have come and gone. Finally, I would like to thank my parents for their support throughout my years at the University of Manitoba. I would like them to know that the light at the end of the tunnel is not the train that I was expecting, so everything is OK. I hope they find comfort in my sigh (of happiness) because I really did profit from this adventure, got a job doing what I love, and ended up living in the same country as them.

## Abstract

In rainbow trout, peripheral tissues regulate thyroidal status, or the availability of 3',3,5-triiodothyronine ( $T_3$ ). Hence, the intestine with access to thyroid hormones (TH) through diet, blood supply, biliary supply, and potential TH metabolism may contribute to thyroidal status.

To evaluate the role of the intestine in TH metabolism, assay conditions for *in vitro* TH metabolism in pyloric caeca (PC), middle intestine (MI), and distal intestine (DI) were characterized. In the intestine, mainly DI, thyroxine ( $T_4$ ) complete outer-ring deiodination ( $T_4$ cORD),  $T_4$ ORD,  $T_4$  inner-ring deiodination ( $T_4$ IRD),  $T_3$ ORD,  $T_3$ IRD, and iodoprotein (IP) production were active. Cofactor was not required.

To evaluate the role of the intestine in regulating TH metabolism during physiological challenges to thyroidal status, fish were fed  $T_4$  or  $T_3$  for 7 days. In MI,  $T_3$  challenge increased  $T_4$ cORD,  $T_4$ IP,  $T_4$ IRD, and  $T_3$ ORD. In DI,  $T_4$  challenge increased  $T_4$ ORD.  $T_3$  challenge increased  $T_4$ ORD and  $T_3$ IRD. However,  $T_4$ cORD and  $T_4$ IRD were always active. In both intestinal regions,  $T_3$  was degraded and formation of  $T_3$  was prevented.







To evaluate the role of the intestine in supplying TH, *in vivo* uptake of  $T_4$  and  $T_3$  from intestinal sections into enterohepatic tissues (liver, blood and gall bladder) was measured. If TH were accumulated in bile, enterohepatic circulation (EHC), or TH cycling from intestine to liver to blood and back to intestine, could occur. From the MI section, more  $T_3$  than  $T_4$  was absorbed. It did not contribute to  $T_4$  or  $T_3$  EHC. Acute increases of  $T_4$  or  $T_3$  were metabolized peripherally and cleared via bile. In MI-DI

section, more  $T_4$  than  $T_3$  was absorbed.  $T_4$  EHC was greater than  $T_3$  EHC. Acute increases in  $T_4$  or  $T_3$  increased  $T_4$  or  $T_3$  EHC.

To evaluate the role of the intestine in supplying TH after physiological challenges, alterations in *in vivo* uptake of  $T_4$  and  $T_3$  from MI-DI section into enterohepatic tissues were measured.  $T_4$  challenge increased  $T_4$  EHC, and  $T_3$  and  $T_4$  challenges created  $T_3$  EHC. Biliary TH in the intestine may enter into circulation. However, TH challenges also increased intestinal TH metabolism. Thus, TH EHC may serve as an extrathyroidal source of TH, or TH metabolism may salvage I.

In conclusion, the intestine is more sensitive to increases in  $T_3$ , and it has mechanisms to prevent large increases in systemic  $T_3$ . However, intestinal TH metabolism, with peripheral metabolism, contributes to  $T_4$  regulation by reducing the amount of  $T_4$  absorbed from or returning to the intestine. Thus in rainbow trout, intestinal control of TH metabolism and the regulation of thyroidal status represents both a primitive intestinal control of  $T_3$  and  $T_4$  metabolism and absorption with a more derived central control of  $T_4$ .

## List of Figures

	Page
Figure 1-1. General thyroid model. The hypothalamus, through stimulatory pathways (+; thyrotropin releasing hormone, TRH) and inhibitory pathways (-), controls anterior pituitary secretion of thyrotropin (thyroid stimulating hormone, TSH). Thyroidal secretion of T <sub>4</sub> is stimulated by TSH. T <sub>4</sub> in the blood is mainly bound to plasma proteins, but the small free fraction exchanges with tissues. In the peripheral tissues, T <sub>4</sub> can be enzymatically deiodinated to T <sub>3</sub> , which exchanges with the blood or it binds to receptors to elicit biological actions such as development, growth, and reproduction.....	6
Figure 1-2. The structure of radiolabeled thyroxine (*T <sub>4</sub> ) with an asterisk indicating the site of <sup>125</sup> I on the outer ring. The pathways for outer-ring deiodination (ORD;  ) and inner-ring deiodination (IRD;  ) for T <sub>4</sub> are indicated. Additional TH metabolism pathways, such as T <sub>4</sub> complete deiodination (T <sub>4</sub> cORD;  ) , T <sub>3</sub> ORD (  ) , T <sub>4</sub> iodoprotein production (T <sub>4</sub> IP;  ) , and T <sub>3</sub> iodoprotein production (T <sub>3</sub> IP;  ) can also be followed by measuring radiolabeled products.....	7
Figure 1-3. Possible pathways of TH metabolism including glucuronide conjugation, sulfate conjugation, outer-ring deiodination, inner-ring deiodination, decarboxylation, deamination, and ether-link cleavage.....	8
Figure 1-4. Diagram of sources of TH in the intestine, including the diet, bile, metabolism and systemic circulation, that may contribute to TH enterohepatic circulation (EHC) from the blood to the liver to the bile to the intestine and back to the blood.....	9
Figure 3-1. Diagram of regions of intestine sampled, including the pyloric caeca (PC), middle intestine (MI), and distal intestine (DI).....	54
Figure 3-2. Methods for preparing microsomal fractions from liver and regions of the intestine (PC, MI, and DI) used in the <i>in vitro</i> TH metabolism assays.....	55

- Figure 3-3. Procedures for TH metabolism assay and analysis of products formed. TH labeled with  $^{125}\text{I}$  on the outer ring ( $^*\text{T}_4$  or  $^*\text{T}_3$ ) allowed measurement of the products formed from various active TH metabolism pathways. The products were analyzed using LH-20 column separation to determine total TH metabolism, followed by protein precipitation with trichloroacetic acid (TCA) to determine TH iodoprotein (IP) production. In addition, the products, after adding methylmercaptoimidazole (MMI) were analyzed using high performance liquid chromatography (HPLC) to separate specific  $\text{T}_4$  metabolites to determine active pathways for  $\text{T}_4$  metabolism ( $\text{T}_4\text{ORD}$ ,  $\text{T}_4\text{IRD}$ ,  $\text{T}_4\text{cORD}$ ) or to separate specific  $\text{T}_3$  metabolites to determine active pathways for  $\text{T}_3$  metabolism ( $\text{T}_3\text{ORD}$ ,  $\text{T}_3\text{IRD}$ )..... 56
- Figure 3-4. Specific TH metabolism pathways and the representative HPLC radioactivity profiles demonstrating the specific TH metabolites determined from the area under the curve..... 57
- Figure 3-5. Rate of total  $\text{T}_4$  metabolism (presumed  $^*\text{I}$  and/or  $^*\text{IP}$ ) at DTT concentrations of 0, 5, 10, 15, or 20 mM as determined by LH-20 column chromatography after  $^*\text{T}_4$  incubation with liver (n=12), pyloric caeca (n=22), middle intestine (n=14), or distal intestine (n=25) microsomes. Activities were calculated as pmoles of  $\text{T}_4$  converted to product per hour per milligram of microsomal protein ( $\pm\text{s.e.}$ ). N.A. denotes not assayed. Asterisks indicate significant differences at  $p\leq 0.05$ ... 58
- Figure 3-6.  $\text{T}_4\text{cORD}$ ,  $\text{T}_4\text{ORD}$ , and  $\text{T}_4\text{IRD}$  activities at DTT concentrations of 0 mM (■) or 10 (□) mM as determined by HPLC separation of  $^*\text{I}$ ,  $^*\text{T}_3$ , and  $^*\text{rT}_3$  as well as IP production as determined by LH-20 column chromatography followed by TCA precipitation of  $^*\text{IP}$  after  $^*\text{T}_4$  incubation with liver (n=6), pyloric caeca (n=10), middle intestine (n=3), or distal intestine (n=18) microsomes. Activities were calculated as pmoles of  $\text{T}_4$  converted to product per hour per milligram of microsomal protein ( $\pm\text{s.e.}$ ). N.A. denotes not assayed. N.D. denotes non-detectable. Asterisks indicate significant differences at  $p\leq 0.05$ ..... 59
- Figure 3-7. Rate of total  $\text{T}_3$  metabolism (presumed  $^*\text{I}$  and/or  $^*\text{IP}$ ) at DTT concentrations of 0 or 10 mM as determined by LH-20 column chromatography after  $^*\text{T}_3$  incubation with liver (n=21), pyloric caeca (n=7), middle intestine (n=0), or distal intestine (n=4) microsomes. Activities were calculated as pmoles of  $\text{T}_3$  converted to product per hour per milligram of microsomal protein ( $\pm\text{s.e.}$ ). N.A. denotes not assayed. Asterisks indicate significant differences at  $p\leq 0.05$ ..... 60

Figure 3-8.  $T_3$ ORD and  $T_3$ IRD activities at DTT concentrations of 0 (■) or 10 (□) mM as determined by HPLC separation of  $^*I$  and  $^*T_2$  as well as IP production as determined by LH-20 column chromatography followed by TCA precipitation of  $^*IP$  after  $^*T_3$  incubation with liver (n=7), pyloric caeca (n=3), middle intestine (n=3), or distal intestine (n=4) microsomes. Activities were calculated as pmoles of  $T_3$  converted to product per hour per milligram of microsomal protein ( $\pm$ s.e.). N.A. denotes not assayed. N.D. denotes non-detectable..... 61

Figure 3-9. Rate of total  $T_4$  metabolism (presumed  $^*I$  and/or  $^*IP$ ) at glutathione (GSH) concentrations of 0, 0.5, 1, 2, or 4 mM as determined by LH-20 column chromatography after  $^*T_4$  incubation with liver (n=1), pyloric caeca (n=1), middle intestine (n=1), or distal intestine (n=1) microsomes. Activities were calculated as pmoles of  $T_4$  converted to product per hour per milligram of microsomal protein. N.A. denotes not assayed..... 62

Figure 3-10. Rate of total  $T_4$  metabolism (presumed  $^*I$  and/or  $^*IP$ ) without DTT over a range of incubation times (30, 60, 75, 90, 105, or 120 min) as determined by LH-20 column chromatography followed by TCA precipitation of  $^*IP$  after  $^*T_4$  incubation with liver (n=1), pyloric caeca (n=1), middle intestine (n=1), or distal intestine (n=1) microsomes. Activities were calculated as pmoles of  $T_4$  converted to product per hour per milligram of microsomal protein. N.A. denotes not assayed..... 63

Figure 3-11. Rate of total  $T_4$  metabolism (presumed  $^*I$  and/or  $^*IP$ ) without DTT over a range of pH values (6.5, 7.0, 7.2, 7.5, 8.0, 8.8, or 9.5) as determined by LH-20 column chromatography after  $^*T_4$  incubation with liver (n=1-2), pyloric caeca (n=1-6), middle intestine (n=1-5), or distal intestine (n=1-5) microsomes. Activities were calculated as pmoles of  $T_4$  converted to product per hour per milligram of microsomal protein ( $\pm$ s.e.). N.A. denotes not assayed..... 64

Figure 3-12.  $T_4$ cORD,  $T_4$ ORD, and  $T_4$ IRD activities without DTT at pH of 7.2 (n=3), 8.0 (n=1), or 8.8 (n=2) as determined by HPLC separation of  $^*I$ ,  $^*T_3$ , and  $^*rT_3$  as well as IP production as determined by LH-20 column chromatography followed by TCA precipitation of  $^*IP$  after  $^*T_4$  incubation with liver microsomes. Activities were calculated as pmoles of  $T_4$  converted to product per hour per milligram of microsomal protein ( $\pm$ s.e.). N.A. denotes not assayed. N.D. denotes non-detectable..... 65

Figure 3-13. T<sub>4</sub>cORD, T<sub>4</sub>ORD, and T<sub>4</sub>IRD activities without DTT at pH of 7.2 (n=3), 8.0 (n=4), 8.8 (n=4), or 9.4 (n=1) as determined by HPLC separation of \*I, \*T<sub>3</sub>, and \*rT<sub>3</sub> as well as IP production as determined by LH-20 column chromatography followed by TCA precipitation of \*IP after \*T<sub>4</sub> incubation with pyloric caeca microsomes. Activities were calculated as pmoles of T<sub>4</sub> converted to product per hour per milligram of microsomal protein ( $\pm$ s.e.). N.D. denotes non-detectable..... 66

Figure 3-14. T<sub>4</sub>cORD, T<sub>4</sub>ORD, and T<sub>4</sub>IRD activities without DTT at pH of 7.2 (n=5), 8.0 (n=4), 8.8 (n=2), or 9.4 (n=1) as determined by HPLC separation of \*I, \*T<sub>3</sub>, and \*rT<sub>3</sub> as well as IP production as determined by LH-20 column chromatography followed by TCA precipitation of \*IP after \*T<sub>4</sub> incubation with middle intestine microsomes. Activities were calculated as pmoles of T<sub>4</sub> converted to product per hour per milligram of microsomal protein ( $\pm$ s.e.). N.D. denotes non-detectable.....67

Figure 3-15. T<sub>4</sub>cORD, T<sub>4</sub>ORD, and T<sub>4</sub>IRD activities without DTT at pH of 7.2 (n=5), 8.0 (n=2), 8.8 (n=2), or 9.4 (n=1) as determined by HPLC separation of \*I, \*T<sub>3</sub>, and \*rT<sub>3</sub> as well as IP production as determined by LH-20 column chromatography followed by TCA precipitation of \*IP after \*T<sub>4</sub> incubation with distal intestine microsomes. Activities were calculated as pmoles of T<sub>4</sub> converted to product per hour per milligram of microsomal protein ( $\pm$ s.e.). N.D. denotes non-detectable.....68

Figure 3-16. Rate of total T<sub>4</sub> metabolism (presumed \*I and/or \*IP) at DTT concentration of 10 mM over a range of pH 7.2, 8.0, or 8.8 as determined by LH-20 column chromatography after \*T<sub>4</sub> incubation with liver (n=1-2) or distal intestine (n=1) microsomes. Activities were calculated as pmoles of T<sub>4</sub> converted to product per hour per milligram of microsomal protein ( $\pm$  s.e.)..... 69

Figure 3-17. T<sub>4</sub>cORD, T<sub>4</sub>ORD, and T<sub>4</sub>IRD activities at DTT concentration of 10 mM at pH of 7.2 (n=4) or 8.0 (n=3) as determined by HPLC separation of \*I, \*T<sub>3</sub>, and \*rT<sub>3</sub> as well as IP production as determined by LH-20 column chromatography followed by TCA precipitation of \*IP after \*T<sub>4</sub> incubation with liver. Activities were calculated as pmoles of T<sub>4</sub> converted to product per hour per milligram of microsomal protein ( $\pm$ s.e.). N.A. denotes not assayed. N.D. denotes non-detectable.... 70

Figure 3-18. T<sub>4</sub>cORD, T<sub>4</sub>ORD, and T<sub>4</sub>IRD activities at DTT concentration of 10 mM at pH of 7.2 (n=1), 8.0 (n=1), or 8.8 (n=1) as determined by HPLC separation of \*I, \*T<sub>3</sub>, and \*rT<sub>3</sub> as well as IP production as determined by LH-20 column chromatography followed by TCA precipitation of \*IP after \*T<sub>4</sub> incubation with distal intestine microsomes. Activities were calculated as pmoles of T<sub>4</sub> converted to product per hour per milligram of microsomal protein. N.D. denotes non-detectable... 71

Figure 3-19. T<sub>3</sub>ORD and T<sub>3</sub>IRD activities without DTT at pH of 7.2 (n=1-3), 8.0 (n=1), or 8.8 (n=3) as determined by HPLC separation of \*I and \*T<sub>2</sub>, as well as IP production as determined by LH-20 column chromatography followed by TCA precipitation of \*IP after \*T<sub>3</sub> incubation with liver microsomes. Activities were calculated as pmoles of T<sub>3</sub> converted to product per hour per milligram of microsomal protein. N.D. denotes non-detectable..... 72

Figure 3-20. T<sub>3</sub>ORD and T<sub>3</sub>IRD activities without DTT at pH of 7.2 (n=4), 8.0 (n=1), or 8.8 (n=2) as determined by HPLC separation of \*I and \*T<sub>2</sub>, as well as IP production as determined by LH-20 column chromatography followed by TCA precipitation of \*IP after \*T<sub>3</sub> incubation with pyloric caeca microsomes. Activities were calculated as pmoles of T<sub>3</sub> converted to product per hour per milligram of microsomal protein ( $\pm$ s.e.). N.D. denotes non-detectable..... 73

Figure 3-21. T<sub>3</sub>ORD and T<sub>3</sub>IRD activities without DTT at pH of 7.2 (n=1), 8.0 (n=1), or 8.8 (n=1) as determined by HPLC separation of \*I and \*T<sub>2</sub>, as well as IP production as determined by LH-20 column chromatography followed by TCA precipitation of \*IP after \*T<sub>3</sub> incubation with middle intestine microsomes. Activities were calculated as pmoles of T<sub>3</sub> converted to product per hour per milligram of microsomal protein ( $\pm$ s.e.). N.A. denotes not assayed. N.D. denotes non-detectable..... 74

Figure 3-22. T<sub>3</sub>ORD and T<sub>3</sub>IRD activities without DTT at pH of 7.2 (n=3), 8.0 (n=1), or 8.8 (n=2) as determined by HPLC separation of \*I and \*T<sub>2</sub>, as well as IP production as determined by LH-20 column chromatography followed by TCA precipitation of \*IP after \*T<sub>3</sub> incubation with distal intestine microsomes. Activities were calculated as pmoles of T<sub>3</sub> converted to product per hour per milligram of microsomal protein ( $\pm$ s.e.). N.A. denotes not assayed. N.D. denotes non-detectable..... 75



Figure 3-23. T<sub>3</sub>ORD and T<sub>3</sub>IRD activities at DTT concentration of 10 mM at pH of 7.2 (n=1), 8.0 (n=1), or 8.8 (n=1) as determined by HPLC separation of \*I and \*T<sub>2</sub>, as well as IP production as determined by LH-20 column chromatography followed by TCA precipitation of \*IP after \*T<sub>3</sub> incubation with liver microsomes. Activities were calculated as pmoles of T<sub>3</sub> converted to product per hour per milligram of microsomal protein. N.D. denotes non-detectable.....76

Figure 3-24. T<sub>3</sub>ORD and T<sub>3</sub>IRD activities at DTT concentration of 10 mM at pH of 7.2 (n=3), 8.0 (n=1), or 8.8 (n=1) as determined by HPLC separation of \*I and \*T<sub>2</sub>, as well as IP production as determined by LH-20 column chromatography followed by TCA precipitation of \*IP after \*T<sub>3</sub> incubation with pyloric caeca microsomes. Activities were calculated as pmoles of T<sub>3</sub> converted to product per hour per milligram of microsomal protein ( $\pm$ s.e.). N.D. denotes non-detectable.....77

Figure 3-25. T<sub>3</sub>ORD and T<sub>3</sub>IRD activities at DTT concentration of 10 mM at pH of 7.2 (n=3), 8.0 (n=1), or 8.8 (n=1) as determined by HPLC separation of \*I and \*T<sub>2</sub>, as well as IP production as determined by LH-20 column chromatography followed by TCA precipitation of \*IP after \*T<sub>3</sub> incubation with distal intestine microsomes. Activities were calculated as pmoles of T<sub>3</sub> converted to product per hour per milligram of microsomal protein. N.D. denotes non-detectable.....78

Figure 3-26. Rate of T<sub>4</sub>IP production at DTT concentrations of 0 (■) or 20 (□) mM as determined by LH-20 column chromatography followed by TCA precipitation of \*IP after \*T<sub>4</sub> incubation with 0.2 mg/mL bovine serum albumin (BSA; n=4). Activities were calculated as pmoles of T<sub>4</sub> converted to IP per hour per milligram of BSA protein ( $\pm$ s.e.) .....79

Figure 4-1. Plasma T<sub>4</sub> (■) and T<sub>3</sub> (□) levels for control (C, n=9), T<sub>4</sub> treatment (T<sub>4</sub>, n=9), and T<sub>3</sub> treatment (T<sub>3</sub>, n=9) over 0, 2, and 7 days of dietary TH challenges. Bars represent means ( $\pm$  s.e.). Asterisks indicate Significant differences at  $p \leq 0.05$  in T<sub>4</sub> or T<sub>3</sub> levels between treated and control fish at that day.....95

Figure 4-2. Rate of microsomal T<sub>4</sub>cORD activity for control (C), T<sub>4</sub> treatment (T<sub>4</sub>), and T<sub>3</sub> treatment (T<sub>3</sub>) over 0, 2, and 7 days of dietary TH challenges. Activity was determined by HPLC separation of \*T<sub>4</sub> metabolism products after incubation with liver (n=3-9), pyloric caeca (n=3-9), middle intestine (n=3-9), and distal intestine (n=3-9) at DTT concentrations of 0 mM (■) or 10 mM (□). Bars represent means (± s.e.). Asterisks indicate significant differences at p≤0.05 in activity between treated and control fish at that day. ND denotes non-detectable.... 96

Figure 4-3. Rate of microsomal T<sub>4</sub>ORD activity for control (C), T<sub>4</sub> treatment (T<sub>4</sub>), and T<sub>3</sub> treatment (T<sub>3</sub>) over 0, 2, and 7 days of dietary TH challenges. Activity was determined by HPLC separation of \*T<sub>4</sub> metabolism products after incubation with liver (n=3-9), pyloric caeca (n=3-9), middle intestine (n=3-9), and distal intestine (n=3-9) at DTT concentrations of 0 mM (■) or 10 mM (□). Bars represent means (± s.e.). Asterisks indicate significant differences at p≤0.05 in activity between treated and control fish at that day. ND denotes non-detectable.... 97

Figure 4-4. Rate of microsomal T<sub>4</sub>IRD activity for control (C), T<sub>4</sub> treatment (T<sub>4</sub>), and T<sub>3</sub> treatment (T<sub>3</sub>) over 0, 2, and 7 days of dietary TH challenges. Activity was determined by HPLC separation of \*T<sub>4</sub> metabolism products after incubation with liver (n=3-9), pyloric caeca (n=3-9), middle intestine (n=3-9), and distal intestine (n=3-9) at DTT concentrations of 0 mM (■) or 10 mM (□). Bars represent means (± s.e.). Asterisks indicate significant differences at p≤0.05 in activity between treated and control fish at that day. ND denotes non-detectable.... 98

Figure 4-5. Rate of microsomal T<sub>4</sub>IP production for control (C), T<sub>4</sub> treatment (T<sub>4</sub>), and T<sub>3</sub> treatment (T<sub>3</sub>) over 0, 2, and 7 days of dietary TH challenges. Activity was determined by HPLC separation of \*T<sub>4</sub> metabolism products after incubation with liver (n=3-9), pyloric caeca (n=3-9), middle intestine (n=3-9), and distal intestine (n=3-9) at DTT concentrations of 0 mM (■) or 10 mM (□). Bars represent means (± s.e.). Asterisks indicate significant differences at p≤0.05 in activity between treated and control fish at that day..... 99

Figure 4-6. Rate of microsomal T<sub>3</sub>ORD activity for control (C), T<sub>4</sub> treatment (T<sub>4</sub>), and T<sub>3</sub> treatment (T<sub>3</sub>) over 0, 2, and 7 days of dietary TH challenges. Activity was determined by HPLC separation of \*T<sub>3</sub> metabolism products after incubation with liver (n=3-9), pyloric caeca (n=3-9), middle intestine (n=3-9), and distal intestine (n=3-9) at DTT concentrations of 0 mM (■) or 10 mM (□). Bars represent means (± s.e.). Asterisks indicate significant differences at p≤0.05 in activity between treated and control fish at that day. ND denotes non-detectable.... 100

Figure 4-7. Rate of microsomal T<sub>3</sub>IRD activity for control (C), T<sub>4</sub> treatment (T<sub>4</sub>), and T<sub>3</sub> treatment (T<sub>3</sub>) over 0, 2, and 7 days of dietary TH challenges. Activity was determined by HPLC separation of \*T<sub>3</sub> metabolism products after incubation with liver (n=3-9), pyloric caeca (n=3-9), middle intestine (n=3-9), and distal intestine (n=3-9) at DTT concentrations of 0 mM (■) or 10 mM (□). Bars represent means (± s.e.). Asterisks indicate significant differences at p≤0.05 in activity between treated and control fish at that day. ND denotes non-detectable.... 101

Figure 4-8. Rate of microsomal T<sub>3</sub>IP production for control (C), T<sub>4</sub> treatment (T<sub>4</sub>), and T<sub>3</sub> treatment (T<sub>3</sub>) over 0, 2, and 7 days of dietary TH challenges. Activity was determined by HPLC separation of \*T<sub>3</sub> metabolism products after incubation with liver (n=3-9), pyloric caeca (n=3-9), middle intestine (n=3-9), and distal intestine (n=3-9) at DTT concentrations of 0 mM (■) or 10 mM (□). Bars represent means (± s.e.). ND denotes non-detectable..... 102

Figure 4-9. Summary of TH metabolism pathways in the trout liver. For control fish, pathways that were active are designated by black arrows. For T<sub>4</sub>-treated and T<sub>3</sub>-treated fish, pathways that were increased significantly are designated by thick black arrows, and pathways that were decreased significantly are designated by thin black arrows. Pathways that were not measured are designated by thin gray arrows..... 103

Figure 4-10. Summary of TH metabolism pathways in the trout MI. For control fish, pathways that were active are designated by black arrows. For T<sub>4</sub>-treated and T<sub>3</sub>-treated fish, pathways that were increased significantly are designated by thick black arrows. Pathways that were not measured are designated by thin gray arrows..... 104

Figure 4-11. Summary of TH metabolism pathways in the trout DI.  
For control fish, pathways that were active are designated by black arrows. For T<sub>4</sub>-treated and T<sub>3</sub>-treated fish, pathways that were increased significantly are designated by thick black arrows. Pathways that were not measured are designated by thin gray arrows..... 105

Figure 5-1. Methods used for characterization of *in vivo* absorption of TH from a double-ligated intestinal section. The set-up demonstrates the flow of water and anesthesia over the gills while the intestine was exposed. The double-ligated intestinal sections demonstrate where ligatures were tied to make MI sections and MI-DI sections. The site of injection in the MI, as indicated, was consistent for both sections.... 135

Figure 6-1. Plasma T<sub>4</sub> levels (■) and plasma T<sub>3</sub> levels (□) after 7 days of dietary TH challenges for control fish (C, n=32), fish fed 12 ppm T<sub>4</sub> (T<sub>4</sub> TRT, n=33), and fish fed 12 ppm T<sub>3</sub> (T<sub>3</sub> TRT, n=36). Bars represent means (± s.e.)..... 166

## List of Tables

	Page
Table 5-1. Comparisons of the injectate standard (STANDARD) and the injected intestinal section (INTESTINE) when analyzed for the percent of the radioactivity remaining as labeled hormone (%*TH) after one hour. Injectate was *T <sub>4</sub> or *T <sub>3</sub> with a low dose (200 fmoles) or high dose (100 pmoles) of the corresponding unlabeled TH. Intestine includes luminal contents and tissue from the double-ligatured MI or MI-DI section that was injected with *TH. N.A. denotes not assayed.....	136
Table 5-2. Effects of duration of pre-experimental fasting on the fate of *T <sub>3</sub> injected one hour previously into the lumen of the double-ligatured MI-DI section.....	137
Table 5-3. Net loss of *T <sub>4</sub> and *T <sub>3</sub> injected one hour previously into the lumen of the double-ligatured MI section and MI-DI section, accompanied by either a low dose (200 fmoles) or a high dose (100 pmoles) of the corresponding unlabeled TH. N.A. denotes not assayed. Letters indicate significant differences at $p \leq 0.050$ .....	138
Table 5-4. Fate of *T <sub>4</sub> injected one hour previously into the lumen of the double-ligatured MI section, accompanied by either a low dose (200 fmoles) or a high dose (100 pmoles) of the corresponding unlabeled TH. N.A. denotes not assayed. Letters indicate significant differences at $p \leq 0.050$ .....	139
Table 5-5. Fate of *T <sub>3</sub> injected one hour previously into the lumen of the double-ligatured MI section, accompanied by either a low dose (200 fmoles) or a high dose (100 pmoles) of the corresponding unlabeled TH. N.A. denotes not assayed. Letters indicate significant differences at $p \leq 0.050$ .....	140
Table 6-1. Effects of 7 days of dietary T <sub>4</sub> challenge (T <sub>4</sub> TRT) or dietary T <sub>3</sub> challenge (T <sub>3</sub> TRT) on the fate of *T <sub>4</sub> injected one hour previously into the lumen of the intestinal section, accompanied by either a low dose (200 fmoles) or a high dose (100 pmoles) of unlabeled T <sub>4</sub> . Numbers represent percent total injectate/mg of tissue x g of body weight/500 g (%/mg) $\pm$ s.e. Letters indicate significant differences at $p \leq 0.050$ .....	167

Table 6-2. Effects of 7 days of dietary T <sub>4</sub> challenge (T <sub>4</sub> TRT) or dietary T <sub>3</sub> challenge (T <sub>3</sub> TRT) on the fate of *T <sub>3</sub> injected one hour previously into the lumen of the intestinal section, accompanied by either a low dose (200 fmoles) or high dose (100 pmoles) of unlabeled T <sub>3</sub> . Numbers represent percent total injectate/mg of tissue x g of body weight/500 g (%/mg) ± s.e. N.A. denotes not assayed. Letters indicate significant differences at p ≤ 0.050.....	168
---	-----

**List of Abbreviations**

ANS	8-anilo-1-naphthelene sulfonic acid
ANOVA	Analysis of variance
BSA	Bovine serum albumin
°C	Celsius
Ci	Curie
D	Dark
d.f.	Degrees of freedom
DI	Distal intestine
DTT	Dithiolthreitol
EHC	Enterohepatic circulation
f	Femto
GSH	Glutathione
g	Gram; Force of gravity
I <sup>-</sup>	Iodide
*I <sup>-</sup>	Radioactive iodide
IRD	Inner-ring deiodination
IP	Iodoprotein
K <sub>d</sub>	Enzyme mean apparent dissociation constant
K <sub>m</sub>	Enzyme affinity (Michaelis-Menten Constant)
L	Liter; Light
L	Liver

MET	metabolism
MMI	Methylmercaptoimidazole
MI	Middle intestine
$\mu$	Micro
m	Milli
min	Minute(s)
M	Molar
MS222	Tricaine methanesulfonate
n	Nano
NEI	Non-extractable iodoproteins
ORD	Outer-ring deiodination
ppm	Parts per million
p	Pico
PC	Pyloric caeca
RIA	Radioimmunoassay
rT <sub>3</sub>	Reverse triiodothyronine
*rT <sub>3</sub>	Radioactive reverse triiodothyronine
TRT	Treatment
T <sub>2</sub>	Diiodothyronine
*T <sub>2</sub>	Radioactive diiodothyronine
T <sub>3</sub>	Triiodothyronine
*T <sub>3</sub>	Radioactive Triiodothyronine
T <sub>3</sub> -G	Glucuronidated triiodothyronine



$T_4$	Thyroxine
$*T_4$	Radioactive thyroxine
$T_4\text{-G}$	Glucuronidated thyroxine
TH	Thyroid hormone
$*TH$	Radioactive/radioiodine-labeled thyroid hormone
12L:12D	12-h light:12-h dark photoperiod
v/v	Volume/volume
$V_{\max}$	Maximal velocity of enzyme reaction

## Chapter 1

### General Introduction

The thyroid gland, whether a discrete and encapsulated gland (mammals, birds, reptiles, and amphibians) or dispersed follicles (fish) couples iodide ( $I^-$ ) from the blood with tyrosine to form 3',5',3,5-tetraiodothyronine (thyroxine,  $T_4$ ) and triiodothyronine ( $T_3$ ) (McNabb, 1992).  $T_4$  is the main hormone released from the thyroid, yet 3',3,5-triiodothyronine ( $T_3$ ) is the biologically more active form which binds with higher affinity to nuclear receptors and elicits physiological responses (Oppenheimer *et al.*, 1972).  $T_4$  is converted outside of the thyroid to  $T_3$  by deiodinase enzymes (Leonard and Visser, 1986).

Regulation of thyroidal status, or the availability of  $T_3$  to bind receptors, is attributed to two main mechanisms of control: central and peripheral (Figure 1-1). The central control model, which is considered the main mechanism of control in mammalian studies, involves the hypothalamus as the central or master regulator, initiating the hypothalamus-pituitary-thyroid control of thyroid hormones (TH) released to circulation (McNabb, 1992; Eales and Brown, 1993). Negative feedback of TH at the hypothalamus and pituitary allows modulation of TH secreted.

In teleost fish, mainly  $T_4$  and negligible amounts of  $T_3$  are released from the thyroid (Chan and Eales, 1975; Eales 1979a; Grau *et al.*, 1986; Byamungu *et al.*, 1992). Only  $T_4$  has been shown to have negative feedback effects at the hypothalamus (Peter 1971, 1972) and pituitary (Baker 1965, 1969a, b; Sage 1968; Sage and Bromage, 1970). Thus, central control is limited to the regulation of  $T_4$  secretion from the thyroid, not  $T_3$  availability (Eales and Brown, 1993; Kuhn, 1993; Eales, 1995).

Peripheral control, or the metabolism of  $T_4$  and  $T_3$  in the tissues, can contribute to the availability of  $T_3$  to bind to receptors (McNabb, 1992). Since plasma  $T_3$  often circulates at a higher concentration than  $T_4$  (Chan and Eales, 1975; Eales, 1979a; Grau *et al.*, 1986; Byamungu *et al.*, 1992), peripheral control is considered the main regulator of  $T_3$  availability in teleost fish (Eales, 1985). In peripheral tissues such as the liver, conversion of  $T_4$  to  $T_3$  by deiodination provides circulating  $T_3$  (Leatherland, 1981; Pimlott and Eales, 1983; MacLatchy and Eales, 1993; Eales *et al.*, 1993) (Figure 1-2). With increased levels of  $T_3$ , hepatic tissues adjust circulating  $T_3$  levels by removing the  $T_4$  substrate (Sweeting and Eales, 1992b) or by removing the biologically active  $T_3$  (MacLatchy and Eales, 1993). Thus, thyroidal status is maintained by deiodination based on the physiological state of peripheral tissues (Eales and Brown, 1993, Eales *et al.*, 1993). In addition to deiodination, other established and potential forms of TH metabolism include conjugation, deamination, ether-link cleavage, and covalent bonding to proteins (Van Middlesworth, 1974; DiStefano, 1988) (Figure 1-3). Clearance pathways such as urinary, branchial, biliary, and excretory pathways can also reduce available TH. Hence, peripheral tissues with access to TH and the ability to metabolize and clear TH may contribute to the regulation of thyroidal status. The intestine, known as an excretory pathway, may play a part in clearance of TH, but it is unknown if the tissue is capable of metabolizing TH.

The intestine has access to TH through the diet, the systemic blood, and the bile (Figure 1-4), yet the role of the intestine as a peripheral tissue contributing to the regulation of thyroidal status has not been studied extensively in any species. In lampreys (Eales *et al.*, 1997), hagfish (McLeese *et al.*, 2000), and sturgeon (Plohman *et al.*, 2002b),

several TH metabolism pathways were active, possibly contributing to thyroidal status. The only investigation into intestinal TH metabolism of in rainbow trout, was conducted by Law and Eales in 1973. In rainbow trout, the intestine demonstrated significant liberation of  $^*I$ , indicating the presence of TH metabolism pathways. Therefore, considering the mass of tissue and the possible influx of TH from the diet, the blood, or the bile, the intestine may provide a large pool of TH for metabolism and absorption to circulation. Thus, if TH metabolism (e.g. deiodination) occurs in the intestine, it may have a significant role in regulating thyroidal status.

Even though the intestine is mainly associated with an excretory role, it may actually serve as a dynamic pool of materials from which metabolism, temporary storage, and absorption take place. This conversion of TH and entry into circulation may comprise part of a TH enterohepatic circulation (EHC) which involves the cycling of substances from the blood to the liver to the bile to the intestine and back to the blood (Figure 1-4). Thus with EHC, the intestine is not solely considered an excretory route for TH.  $T_4$  and  $T_3$ , can follow the EHC pathway, depending on the form of iodothyronine released into the bile and the extent of its absorption from the intestine. In mammals, biliary-excreted TH can contribute to the intestinal pool of TH (DiStefano, 1988; DiStefano *et al.*, 1992). From the intestine, unconjugated TH can be absorbed extensively and re-enter the enteric circulation (Briggs *et al.*, 1953; Chung and van Middlesworth, 1964; Sternlicht *et al.*, 1984; Hazenbarg *et al.*, 1988; DiStefano, 1988; DiStefano *et al.*, 1988; Rutgers *et al.*, 1989; DiStefano *et al.*, 1992). Thus, a TH EHC is created, which may contribute to the regulation of whole-body TH (DiStefano *et al.*, 1993c). The same could be true for teleost fish.

There is limited knowledge of TH EHC in teleost fish. Previous studies have investigated individual components of TH EHC, and hence the potential for completion of the EHC, by evaluating intestinal access to TH through biliary supply and by evaluating reentry of TH to the plasma through absorption of TH from the intestine. There is abundant evidence for TH uptake by the liver and TH excretion into the bile (Sinclair and Eales, 1972; Eales and Sinclair, 1974; Finnson and Eales, 1996). Thus, the biliary route represents a source of TH released to the intestine, with more  $T_4$  than  $T_3$  delivered in its native, unconjugated form. Indirect evidence of intestinal absorption of TH has been documented in rainbow trout by measuring increased levels of plasma TH after ingestion of TH-supplemented diets (Higgs *et al.*, 1979; Higgs *et al.*, 1982; Cyr and Eales, 1990; Eales *et al.*, 1990; Eales and Finnson, 1991; Sweeting and Eales, 1992; Fines *et al.*, 1999) or injection of TH into the intestine (Collicutt and Eales, 1974; Eales and Sinclair, 1974; Whitaker and Eales, 1993). There was consistently a greater increase in plasma  $T_3$  than  $T_4$ . These studies suggested that negligible cycling of TH occurred, since little TH or TH conjugates were absorbed from the intestine. Considering its tissue mass, the intestine cannot be ignored as a potentially large pool of TH for absorption to the circulation and EHC.

Prior to this research, the role of the intestine in the metabolism of TH and the regulation of thyroidal status in rainbow trout, *Oncorhynchus mykiss*, had not been addressed in a systematic manner. The selected literature review (Chapter 2) supports the view that the intestine serves as more than an excretory route for TH. The present study provides further support for the role of the intestine in TH regulation by: 1) characterizing intestinal TH metabolism pathways (Chapter 3); 2) measuring altered

activity of intestinal TH metabolism pathways after physiological challenges of chronic dietary  $T_4$  and  $T_3$  (Chapter 4); 3) measuring uptake of TH from the intestine into enterohepatic tissues (Chapter 5); and 4) measuring altered uptake of TH from the intestine into enterohepatic tissues after physiological challenges of chronic dietary  $T_4$  and  $T_3$  (Chapter 6). These investigations have helped to define the role of the intestine in TH metabolism and regulation of thyroidal status (Chapter 7).




Figure 1-1. General thyroid model for teleost fish. The hypothalamus, through stimulatory pathways (+; thyrotropin releasing hormone, TRH) and inhibitory pathways (-), controls anterior pituitary secretion of thyrotropin (thyroid stimulating hormone, TSH). Thyroidal secretion of  $T_4$  is stimulated by TSH.  $T_4$  in the blood is mainly bound to plasma proteins, but the small free fraction exchanges with tissues. In the peripheral tissues,  $T_4$  can be enzymatically deiodinated to  $T_3$ , which exchanges with the blood or it binds to receptors to elicit biological actions such as development, growth, and reproduction.




Figure 1-2. The structure of radiolabeled thyroxine (\*T<sub>4</sub>) with an asterisk indicating the site of <sup>125</sup>I on the outer ring. The pathways for outer-ring deiodination (ORD; ———→) and inner-ring deiodination (IRD; ———→) for T<sub>4</sub> are indicated. Additional TH metabolism pathways, such as T<sub>4</sub> complete deiodination (T<sub>4</sub>cORD; .....→), T<sub>3</sub>ORD (.....→), T<sub>4</sub> iodoprotein production (T<sub>4</sub>IP; — · —→), and T<sub>3</sub> iodoprotein production (T<sub>3</sub>IP; — · —→) can also be followed by measuring radiolabeled products.






Figure 1-3. Possible pathways of TH metabolism including glucuronide conjugation, sulfate conjugation, outer-ring deiodination, inner-ring deiodination, decarboxylation, deamination, and ether-link cleavage.




Figure 1-4. Diagram of sources of TH in the intestine, including the diet, bile, metabolism and systemic circulation, that may contribute to TH enterohepatic circulation (EHC) from the blood to the liver to the bile to the intestine and back to the blood.

## Chapter 2

### Selected Literature Review

This chapter reviews thyroid hormone (TH) regulation, TH metabolism (focusing on deiodination), enterohepatic circulation, and the role of the intestine in these processes for both higher vertebrates and teleost fish. The information for mammalian studies is more extensive than that found for teleost fish. The mammalian literature demonstrates the importance of the intestine in TH regulation through enterohepatic circulation, but there are limited studies on intestinal TH metabolism. There is less information on the role of the intestine in peripheral TH regulation and metabolism. In a few species of fish, there is information on intestinal TH metabolism. In teleost fish, there is some knowledge of TH biliary supply to the intestine and TH intestinal absorption. Hence, the potential role of the intestine as a peripheral regulator of thyroidal status is reviewed.

#### **Overview of central control model for regulation of thyroid hormones**

The thyroid system must be able to regulate thyroidal status, or the availability of 3',3,5-triiodothyronine ( $T_3$ ), based on the physiological state of the animal. The regulation of thyroidal status is attributed to both a central control model and a peripheral control model. The central control model of TH regulation involves the hypothalamus as the central or master regulator (McNabb, 1992; Eales and Brown, 1993). In all vertebrates, the brain releases thyrotropin-releasing hormone (TRH) to stimulate thyrotropin (thyroid stimulating hormone, TSH) from the pituitary. TSH, the most important factor influencing function of the thyroid gland, stimulates almost all aspects of production and release of both 3',5',3,5-tetraiodothyronine (thyroxine,  $T_4$ ) and  $T_3$ . In

mammals,  $T_4$  accounts for 94% of the TH secreted by the thyroid, while  $T_3$  accounts for the remaining 6% (McNabb, 1992). For teleost fish,  $T_3$  has not been detected from the thyroid (Eales and Brown, 1993; Kuhn, 1993). Overall,  $T_4$  is the main iodothyronine produced by the thyroid.  $T_4$ , which is considered a prohormone, is converted to  $T_3$  in peripheral tissues, and it elicits physiological responses by binding to nuclear receptors in the target cell (Oppenheimer *et al.*, 1972).

In higher vertebrates, the main regulation of  $T_4$  production, and  $T_3$  conversion, is attributed to feedback control at the hypothalamus and the anterior pituitary. This central control of the hypothalamic-pituitary-thyroid axis is based on circulating free TH. The hypothalamic release of TRH is negatively controlled by feedback from circulating TSH and TH (Spira and Gordon, 1986). At the anterior pituitary, TSH is negatively controlled by feedback from TH (Spira *et al.*, 1979). Circulating  $T_3$  and  $T_3$  produced locally from  $T_4$  decrease the production of TSH  $\alpha$  and  $\beta$  subunits (Chin *et al.*, 1985; Shupnik *et al.*, 1989) and the release of TSH (Tong, 1974). Thus, central control in higher vertebrates is regulated by  $T_3$ , which in turn regulates  $T_3$  availability.

In teleost fish, central control mechanisms also include hypothalamic control of TSH release from the pituitary (Peter and McKeown, 1975; Bromage *et al.*, 1976; Peter and Fryer, 1983; Dickhoff and Darling, 1983; Eales and Himick, 1991) and TSH-stimulated release of  $T_4$  from the thyroid (Chan and Eales, 1975, 1976; Brown *et al.*, 1978; Milne and Leatherland, 1980; Ng *et al.*, 1982; Swanson *et al.*, 1988; Inui *et al.*, 1989; Grau *et al.*, 1986).  $T_4$ -mediated, not  $T_3$ -mediated, negative feedback at the hypothalamus (Peter, 1971, 1972) and pituitary (Baker, 1965, 1969a, b; Sage, 1968; Sage and Bromage, 1970) regulates the central control mechanism. Thus, central control is

limited to the regulation of  $T_4$  secretion from the thyroid, not  $T_3$  availability (Eales and Brown, 1993; Kuhn, 1993; Eales, 1995).

### **Overview of peripheral control model for regulation of thyroid hormones in teleosts**

More emphasis is placed on peripheral regulation of TH than central regulation in teleost fish. In the central control model, levels of thyroid hormones available for binding to the nuclear receptors in tissues were modulated by the brain and pituitary. In the peripheral control model, immediate requirements of TH by the active tissues are regulated by the tissues themselves.

In teleost fish, plasma  $T_4$  and  $T_3$  regulation are largely independent of each other (Grau *et al.*, 1986; Eales and Himick, 1991; Eales and Brown, 1993). Plasma  $T_3$  often circulates at a higher concentration than  $T_4$ , yet only  $T_4$  is secreted by the thyroid (Chan and Eales, 1975; Eales, 1979a; Grau *et al.*, 1986; Byamungu *et al.*, 1992). In addition, plasma  $T_4$  (Baker, 1965; Peter, 1971), not plasma  $T_3$  (Eales *et al.*, 1990), suppresses TSH release. Thus, central control determines the plasma  $T_4$  levels. Peripheral control, in contrast, regulates  $T_3$  availability.

Evidence supports peripheral control as the primary control of thyroidal status in teleost fish. A lack of correlation between plasma  $T_4$  and plasma  $T_3$  is demonstrated when TSH or  $T_4$  challenges do not elevate plasma  $T_3$  levels. TSH injection results in an increase in plasma  $T_4$ , yet plasma  $T_3$  levels remain unaffected (Chan and Eales, 1975; Brown *et al.*, 1978; Milne and Leatherland, 1978). Additionally,  $T_4$  challenges do not significantly change plasma  $T_3$  levels (Fok and Eales, 1984; Swanson *et al.*, 1988; Kuhn, 1993). These studies support extrathyroidal regulation of  $T_3$  availability.

With peripheral control, changes in circulating TH would not result in a change in thyroidal output as seen in central control. Instead, peripheral autoregulation of  $T_3$  is controlled by TH metabolism. There are many forms of TH metabolism that can contribute to peripheral control of TH (see Overview of TH metabolism and Figure 1-3). Deiodination, the step-wise remove of I from iodothyronines (see Deiodination in mammals and Figure 1-2), is a main contributor to peripheral control of  $T_3$  availability, especially in the liver. For example, a dose-dependent increase in plasma  $T_3$  results in a decrease in the conversion of  $T_4$  to  $T_3$  through a decrease in hepatic  $T_4$  outer-ring deiodination ( $T_4$ ORD) (Eales *et al.*, 1990). Increased plasma  $T_3$  through dietary supplementation also decreases hepatic high- $K_m$  (low substrate affinity)  $T_4$ ORD while increasing hepatic  $T_4$  inner-ring deiodination ( $T_4$ IRD), which converts  $T_4$  to inactive reverse  $T_3$  ( $rT_3$ ), and  $T_3$  inner-ring deiodination ( $T_3$ IRD), which converts  $T_3$  to  $T_2$  (Eales and Finnson, 1991; Sweeting and Eales, 1992a; MacLachy and Eales, 1993). In addition, low- $K_m$   $T_4$ ORD in the gill and high- $K_m$   $T_4$ ORD in the kidney are inhibited. At the cellular level, direct  $T_3$  autoregulation of  $T_4$ ORD in hepatocytes has been demonstrated to maintain  $T_3$  homeostasis (Sweeting and Eales, 1992b). Thus, various deiodinase pathways are coordinated in the trout to maintain a set point for  $T_3$  levels available as demonstrated by a decrease in  $T_3$  formation and degradation of excess  $T_3$  following increased plasma  $T_3$  levels.

Peripheral control may not only contribute to plasma pools of  $T_3$  but also derive  $T_3$  for local tissue use. For example, teleost fish contain both a high- $K_m$  (10 nM substrate level; low enzyme-substrate affinity) and a low- $K_m$  (0.1 nM substrate level; high enzyme-substrate affinity)  $T_4$ ORD that converts  $T_4$  to  $T_3$ . Liver contains both isozymes, while

gills have low- $K_m$  isozymes and kidneys have high- $K_m$  isozymes (MacLatchy and Eales, 1992b). The different substrate affinities may be attributed to different roles of the enzymes. A high- $K_m$  isozyme requiring high  $T_4$  substrate levels, such as the one detected in liver and kidney (Leatherland, 1981; Flett and Leatherland, 1989; MacLatchy and Eales, 1992b), is correlated with the plasma as the source of hormone. The greater the amount of  $T_3$  derived from circulation, the more predominant the high- $K_m$  isozyme. Hence the liver, which has both high- and low- $K_m$  isozymes, derives 50% of intracellular  $T_3$  from plasma  $T_4$ . The kidney only has a high- $K_m$  isozyme, and 72% of receptor-bound  $T_3$  is derived from plasma. Conversely, gills only have low- $K_m$  enzymes, or high enzyme-substrate affinity, which functions at the low substrate level predicted to exist intracellularly. Thus, 28% of receptor-bound  $T_3$  is from the plasma (Eales *et al.*, 1993).

With this metabolism, peripheral tissues are able to maintain  $T_3$  availability and maintain  $T_3$  homeostasis both in the plasma and in the tissues. Hence, peripheral tissues with deiodinating activity and access to circulating thyroid hormones exert a role in regulation of thyroid hormone metabolism and thyroidal status.

### **Overview of thyroid hormone metabolism**

There are many types of TH metabolism that can occur, and specific pathways of metabolism include ether-link cleavage, conjugation, deamination, decarboxylation, covalent binding to proteins, and deiodination (Van Middlesworth, 1974; Burger, 1986; DiStefano, 1988) (Figure 1-3). Of these, ether-link cleavage of  $T_4$  or  $T_3$ , which results in an unstable quinone and 3,5-diiodotyrosine after breaking the ether-link bond, has not been detected in teleost fish (Visser, 1990).

Side chain modification includes deamination and oxidative decarboxylation of the alanine side chain resulting in acetic acid analogs such as 3,5,3',5'-tetrathyroacetic acid (tetrac) and 3,5,3'-triiodothyroacetic acid (triac) (Burger, 1986).

Conjugation, which can include sulfation or glucuronidation is the addition of sulfate or glucuronic acid, respectively, to the phenolic hydroxyl group. These reactions increase water-solubility of TH which enhances their excretion in bile and urine (Visser, 1990). Glucuronidation is the initial step in enterohepatic circulation of thyroid hormones (DiStefano, 1988), and  $T_4$  is the main iodothyronine involved (Gershengorn *et al.*, 1987). Glucuronidated TH are excreted in the bile and then enter the intestine (Visser, 1990). However, these conjugates can be deconjugated by bacteria in the intestine, and liberated iodothyronines can be reabsorbed (DiStefano, 1988). Therefore, glucuronidation does not necessarily lead to an irreversible loss of thyroid hormones. In contrast, sulfated thyroid hormones, primarily  $T_3$ , are not detected in the bile of rats (Sekura *et al.*, 1981). Hepatic sulfation accelerates deiodination of most iodothyronines, metabolizing them before entry into bile (Visser, 1994; Visser *et al.*, 1990).

In teleost fish, glucuronidated TH have been detected in marine plaice, brook trout, and rainbow trout (Sinclair and Eales, 1972; Collicutt and Eales, 1974; Finnson and Eales, 1997). Hepatic glucuronidation of TH occurs by more than one isozyme in trout. TH are eliminated by conjugation and entry into the bile, since they are neither deconjugated nor deiodinated by trout liver (Finnson *et al.*, 1999). In teleost fish, sulfation of TH occurs in the liver ( $rT_3 > T_4 = T_3$ ), however, deiodination of these sulfates is negligible (Finnson and Eales, 1998; Finnson *et al.*, 1999). Unlike mammals, sulfation does not lead to a loss or excretion of TH; it may allow cellular storage of TH.



Iodothyronines have been documented to be covalently bonded to protein, resulting in non-extractable iodoproteins (NEI). Interest in NEI peaked during 1970's when they were detected in the thyroid, plasma, mammary gland, salivary gland, and stomach. The protein component may be thyroglobulin or albumin, but the exact nature of the protein is not always known. The actual structure of these NEI has not been determined. Furthermore, biological properties of the NEI have not been assessed (Ui, 1974).

Deiodination is a stepwise and sequential removal of iodide ( $I^-$ ) from iodothyronines (Figure 1-2). Several different isozymes have been detected in tissues that can remove  $I^-$  from the outer ring or the inner ring of the iodothyronines. Deiodination can activate or inactivate iodothyronines. For example, outer-ring deiodination can produce the biologically active form,  $T_3$ , from  $T_4$ , or the activation of  $T_4$  can be prevented by inner-ring removal of  $I^-$ , resulting in the biologically inactive iodothyronine,  $rT_3$ .

As mentioned, metabolism of iodothyronines through any pathway can play an important function in overall thyroid hormone regulation. For example, deiodination can increase plasma  $T_3$  available for tissues. It can also increase cellular  $T_3$  centrally in the brain or peripheral tissues, adding to both central and peripheral control.

### **Deiodination in mammals**

In mammals, stepwise removal of  $I^-$  is performed by at least three deiodinase isozymes, type I, II, and III. These isozymes remove either outer-ring iodide or inner-ring  $I^-$ . They also vary with respect to tissue location, substrate preference, substrate affinity, interaction with thiol cofactors, and interaction with inhibitors (Leonard and Visser,

1986). In rats and human, 80% of  $T_4$  is degraded extrathyroidally by outer-ring deiodinases.

Type I isozyme, found in liver, kidney, and thyroid, is capable of outer- and inner-ring deiodination (ORD and IRD, respectively). It converts  $T_4$  to  $T_3$  by outer-ring removal of iodine, or it can inactivate  $T_4$  to  $rT_3$  through inner-ring deiodination (Hesch and Koehrle, 1986). Studies on  $T_4$  as the substrate suggest that type I deiodinase contributes to plasma  $T_3$  levels (Crantz *et al.*, 1982). Even though it was first recognized for activating  $T_4$ ,  $rT_3$  is its preferred substrate, and the main role of type I deiodinase may be to dispose of  $rT_3$ . Hence  $rT_3$  can compete with  $T_4$  as a substrate, inhibiting  $T_3$  production (Hesch and Koehrle, 1986). Kinetic studies of the enzyme reveal a high- $K_m$  enzyme (approximately 1  $\mu M$ ; low substrate affinity) that is stimulated by thiols, exhibits ping-pong kinetics, and is inhibited by propylthiouracil (PTU), iodoacetate (IA), and iopanoic acid (IPA).

Type II isozyme is also capable of outer-ring conversion of  $T_4$  to  $T_3$ . However, it is located in the central nervous system, pituitary, brown adipose tissue, placenta, and skin. In addition, it is a low- $K_m$  isozyme (approximately 1 nM; high substrate affinity), which correlates with suspected cellular  $T_4$  levels. Thus, it has been speculated that type II deiodinase is mainly involved in central regulation as an internal indicator of thyroidal status (Hesch and Koehrle, 1986). Type II is stimulated by thiols, exhibits sequential kinetics, is not affected by PTU, but is inhibited by IA and IPA.

Type III isozyme is an inner-ring deiodinase found in the central nervous system and placenta. It prefers  $T_3$  as a substrate over  $T_4$ , so it is considered a deactivating isozyme by degrading  $T_3$  to 3,3'- $T_2$  and  $T_4$  to  $rT_3$  (Leonard and Visser, 1986). It is a low-

$K_m$  isozyme (approximately 40 nM) that is stimulated by thiols through sequential kinetics. PTU has no effect, but IA and IPA are inhibitory.

### **Role of the intestine in deiodination in higher vertebrates**

Few studies have characterized intestinal TH metabolizing capabilities. Of the few studies, a comparison was made of intestinal deiodination to hepatic deiodination. Galton *et al.* (1991) measured rat intestinal TH metabolism. ORD activity was highest in the fetal intestine and very low in the adult intestine, whereas the opposite was true for liver ORD activity. IRD activity was also present in the intestine. Suvarna *et al.* (1993) measured intestinal ORD activity in chickens. It was similar in biochemical characteristics to hepatic ORD activity in mammals (Leonard and Visser, 1986) and birds (Freeman and McNabb, 1991; McNabb *et al.*, 1991; Darras *et al.*, 1992). In adult chickens, intestinal ORD was lower than hepatic ORD, but it was higher than activity measured in rats.

### **Deiodination in teleosts**

In teleost fish, several isozymes exist, but they differ in characteristics from mammalian isozymes. Since deiodination plays a crucial role in peripheral control of thyroid hormone,  $T_4$ ORD is important in controlling thyroidal status by regulating  $T_3$  levels for receptor binding.

In the liver, a high- $K_m$  (approximately 10 nM) and a low- $K_m$  (approximately 0.1 nM)  $T_4$ ORD converts  $T_4$  to  $T_3$ . The different substrate affinities may determine different roles of the  $T_4$ ORD's. The high- $K_m$  isozyme may supply plasma  $T_3$  levels, while the low- $K_m$  isozyme supplies intracellular  $T_3$  (Eales *et al.*, 1993). An inner-ring deiodinase is also located in the liver, however its activity is only induced under stress or increased plasma

$T_3$  (Eales *et al.*, 1993). In the kidney, a high- $K_m$   $T_4$ ORD has been detected, while a low- $K_m$   $T_4$ ORD is reported in the gills.

### **Role of the intestine in deiodination in fish**

Intestinal deiodination has been measured in the intestine of a few species of fish. Intestinal deiodination activities in the Atlantic cod (Cyr *et al.*, 1997) and American plaice (Adams *et al.*, 2000) were low. In sturgeon, activities of intestinal deiodination pathways ( $T_4$ ORD,  $T_4$ IRD,  $T_3$ IRD, and  $rT_3$ IRD) were significant, and in this species,  $T_4$ ORD may contribute to plasma  $T_3$ . However, intestinal deiodination was lower than hepatic deiodination (Plohman *et al.*, 2002). In lampreys (Eales *et al.*, 1997, 1999),  $T_4$ ORD was active in the intestine.  $T_4$ IRD and  $T_3$ IRD were negligible in the larval intestine but present in that of the upstream-migrant lampreys. In hagfish (McLeese *et al.*, 2000), intestinal  $T_4$ ORD,  $T_4$ IRD, and  $T_3$ IRD were active. In both the lamprey and the hagfish, intestinal deiodination ( $T_4$ ORD) predominated over hepatic deiodination. Thus, intestinal deiodination may represent ancestral TH metabolism pathways that are actively retained in more “primitive” fish lineages but still present in teleost fish.

As far as intestinal metabolism of TH of teleosts is concerned, a preliminary study evaluated the deiodinating activity through trichloroacetic acid (TCA) precipitation of protein-bound radiothyronines and thin layer chromatography (TLC) separation of products. These techniques measured deiodination of  $T_4$  double-labeled with  $^*I$  and incubated with whole tissue homogenates (Law and Eales, 1973). Even without dithiolthreitol as an enzyme cofactor, deiodinase or other enzyme activity was detected by the presence of free  $^*I$  not precipitated by TCA and by peaks of radiolabeled-products on

TLC. Thus, these results indicate the breakdown of TH and the occurrence of TH metabolism in the intestine.

### **Importance of iodide availability**

The metabolism of TH liberates  $I^-$ , which can be recycled for the synthesis of TH in the thyroid. Other sources of  $I^-$  include intestinal transport from food or gill transport from water. There are varying amounts of  $I^-$  (5  $\mu\text{g/dL}$  in seawater; 1  $\mu\text{g/dL}$  to 0.01  $\mu\text{g/dL}$  in freshwater) (Eales, 1979). Yet, freshwater teleosts (salmonids) may attain levels of plasma  $I^-$  ranging from 100 to 200  $\mu\text{g/dL}$  which exceed environmental levels (Leloup, 1970; Gregory and Eales, 1975).

The branchial and intestine  $I^-$  transporters (presumably  $\text{Na}^+/I^-$  symporters) are quite efficient at maintaining plasma  $I^-$  levels (Hunn and Fromm, 1966; Leloup, 1970; Gregory and Eales, 1975). Even when subjected to low dietary  $I^-$  levels, the branchial  $I^-$  pump was able to elevate plasma  $I^-$  over normal levels (Higgs and Eales, 1971).

Unlike mammals, certain teleosts exhibit a plasma pre-albumin protein which non-covalently and reversibly binds  $I^-$  (Leloup, 1970). This protein contributes to high plasma  $I^-$  levels by reducing filtration loss of  $I^-$  at renal, gill, integumentary or gut exchanges surfaces (Gregory and Eales, 1975).

Another difference from mammals is the physiological response of rainbow trout to elevated  $I^-$  levels. In humans and rats, the Wolff-Chaikoff effect occurs when an acute excess of  $I^-$  inhibits thyroidal secretion (DeGroot and Stanbury, 1975). In rainbow trout, acute  $I^-$  excess results in an increase of plasma  $T_4$  (Eales *et al.*, 1986a).

Overall, the rainbow trout in its low- $I^-$ , freshwater environment has the ability to obtain or conserve  $I^-$ , ensuring TH production.

### **Role of cofactors in deiodination**

Thiol cofactors such as dithiolthreitol (DTT), dihydrolipoamide, or monogluthathione (GSH) provide an exogenous thiol that significantly increases trout microsomal deiodination activity in the liver (Pimlott and Eales, 1983; Shields and Eales, 1986). Sulfhydryl groups or selenocysteine residues are found at the deiodinase enzyme catalytic site in mammals (Visser, 1979; Kohrle, 1996). Thiols can reduce the deiodinase enzyme, forming a catalytically active enzyme. The exogenous thiol cofactor is believed to replace an endogenous biological equivalent. In mammals, GSH is an effective thiol cofactor for ORD in intestinal tissues (Galton *et al.*, 1991) and hepatic and kidney tissues (Goswami and Rosenberg, 1988). In rainbow trout microsomal assays, DTT is effective as a cofactor (Eales *et al.*, 1993). The exogenous thiol cofactor is believed to replace an endogenous biological equivalent. In fact, Galton *et al.*, (1991) suggested that GSH may be an activator of ORD *in vivo*. The nature of an endogenous cofactor in fish is not yet understood.

*In vivo*, deiodinase enzymes may not be regenerated by thiol cofactor (Kohrle *et al.*, 1993). Binding and deiodination may promote enzyme translocation and degradation (St. Germain and Croteau, 1989).

### **Role of the intestine in thyroid hormone enterohepatic circulation in higher vertebrates**

In mammals, the intestine has an extensive role in enterohepatic circulation which cycles THs from the liver to the intestine and back to the liver. Transport of TH from the liver to the intestine includes mesenteric arterial or biliary supply (Briggs *et al.*, 1953; Chung and van Middlesworth, 1964; Sternlicht *et al.*, 1984; Hazenbarg *et al.*, 1988;

DiStefano, 1988). TH entering the intestine can be conjugated, whereby can sulfate or glucuronide replaces the phenolic hydroxyl, or unconjugated, intact form (DiStefano, 1988). In the bile, 75% of TH are conjugated. Of those conjugated, approximately 91% are glucuronidated and 9% are sulfated (DiStefano, 1988). Transit time for TH in the intestine and possible binding of the hormones allow for temporary storage of the hormone in the intestine (Chung and van Middlesworth, 1964, DiStefano, 1988). Some of these hormones remain bound to luminal contents, hence the intestine is an excretory pathway (Chung and van Middlesworth, 1964). However, unbound hormone can be absorbed from the intestine, providing another source of TH for possible biological actions (Albert *et al.*, 1952; Albert and Keating, 1952; Chung and van Middlesworth, 1964; Cottle and Veress, 1965; DiStefano *et al.*, 1992).

Besides providing a source of hormone from luminal storage, the intestinal tissue itself may regulate metabolism of TH, as mentioned previously. In addition, bacteria in the intestine are capable of binding and oxidatively degrading  $T_4$  and  $T_3$  (DiStefano *et al.*, 1993b) The bacteria are also known to deconjugate glucuronidated or sulfated TH (Taurog *et al.*, 1952; Williams *et al.*, 1965; de Herder *et al.*, 1985, 1986; Hazenburg *et al.*, 1988; Rutgers *et al.*, 1989; Nguyen *et al.*, 1993; DiStefano *et al.*, 1993a).

Conjugation of TH decreases the absorptive properties of the hormones from the intestine. Deconjugation by bacteria may allow further deiodination to occur as a clearance route and an I<sup>-</sup> salvaging mechanism, or it may allow absorption from the intestine. Depending on the luminal pool of hormones, metabolism, and uptake of hormones, the intestine could provide a significant source of TH and I<sup>-</sup>.

### **Role of the intestine in thyroid hormone enterohepatic circulation in teleosts.**

There is limited knowledge of TH EHC in teleost fish. Previous studies have investigated individual components of TH EHC, and hence the potential for completion of the EHC, by evaluating intestinal access to TH through biliary supply and by evaluating reentry of TH to plasma through absorption of TH from the intestine. The fish intestine may, therefore, contribute to the regulation of thyroidal status if TH discharged from bile or obtained through the diet is absorbed from the intestine and contributes to available systemic TH.

In salmonids and other teleost fish, there is abundant evidence for TH uptake by the liver and TH excretion into the bile. Marine plaice, *Pleuronectes platessa* (Osborn and Simpson, 1969), Atlantic salmon, *Salmo salar* (Eales, 1969), brook trout, *Salvelinus fontinalis* (Eales, 1969, 1970; Eales *et al.*, 1971; Sinclair and Eales, 1972; Eales and Sinclair, 1974), rainbow trout (*Oncorhynchus mykiss*), channel catfish (*Ictalurus punctatus*), brown bullhead (*I. nebulosus*), black bullhead (*I. melas*), burbot (*Lota lota*), goldeye (*Hiodon alosoides*), freshwater drum (*Aplodinotus grunniens*), white suckers (*Catostomus commersoni*), and hornyhead chub (*Nocomis biguttatus*) accumulated T<sub>4</sub> or T<sub>3</sub> in the bile (Sinclair and Eales, 1972).

Experiments to determine the forms and amounts of TH accumulated in the bile have followed the fate of administered \*TH. After an intraperitoneal injection of \*T<sub>4</sub> into fasted brook trout, over 50% of the radioactivity accumulated in the bile was radiolabeled \*T<sub>4</sub> (\*T<sub>4</sub>) (Sinclair and Eales, 1972). After an intraperitoneal \*T<sub>4</sub> injection into rainbow trout, \*T<sub>4</sub> and its less absorbable conjugates were also accumulated in the bile after 24 h. After a similar injection of \*T<sub>3</sub>, mainly \*T<sub>3</sub> conjugates (rather than \*T<sub>3</sub>) were



accumulated in bile of rainbow trout (Finnson and Eales, 1996). Furthermore, feeding brook trout caused the rapid release of bile into the intestine (Eales and Sinclair, 1974). Thus in salmonid fish studied to date, the biliary route represents a source of TH released to the intestine, with more  $T_4$  than  $T_3$  delivered in its native, unconjugated form.

There is far less information for teleost fish on the completion of EHC with TH uptake from the intestine. Just as the intestine is a main site for absorption of nutrients such as amino acids, glucose, and fatty acids, it would make sense that it is also the site for absorption of amino acid derivatives such as TH. The absorption of TH from the intestine has been evaluated through changes in physiological parameters attributed to TH actions and through measurements of increased plasma TH levels. Feeding  $T_3$  to fish has promoted effects such as growth, food consumption, and food conversion that are attributed to TH actions (Higgs *et al.*, 1979; Woo *et al.*, 1991; Moon *et al.*, 1994).  $T_4$ , at higher levels, had limited effects on food consumption (Higgs *et al.*, 1979). Indirect evidence of intestinal absorption of TH has been documented in rainbow trout by measuring increased levels of plasma TH after ingestion of TH-supplemented diets (Higgs *et al.*, 1979; Higgs *et al.*, 1982; Cyr and Eales, 1990; Eales *et al.*, 1990; Eales and Finnson, 1991; Sweeting and Eales, 1992b; Fines *et al.*, 1999). There was consistently a greater increase in plasma  $T_3$  than  $T_4$  with the same dietary TH dose.

More direct measurements of TH uptake from the intestine have been made by following  $^3H$  TH injected into the lumen of a fish intestine. In starved channel catfish, 20-25% of the radioactivity associated with  $^3H$   $T_4$  or  $^3H$   $T_4$  and its glucuronidated form ( $^3H$   $T_4$ -G) were absorbed after 24 h from the lumen of a ligatured middle intestine (Collicutt and Eales, 1974). In brook trout, between 12-36% of the radioactivity associated with  $^3H$   $T_4$  or

\*T<sub>4</sub> and \*T<sub>4</sub>-G injected into a double-ligated intestinal loop of middle intestine and distal intestine was lost from the intestinal lumen after 24 h (Eales and Sinclair, 1974). When starved rainbow trout were injected with \*T<sub>4</sub> and then fed, the biliary accumulated \*T<sub>4</sub> and \*T<sub>4</sub>-G were released to the intestine, but there was no increase in plasma \*T<sub>4</sub> relative to unfed controls (Eales and Sinclair, 1974). This suggested that negligible cycling of TH occurred, since little TH or TH conjugates were absorbed from the intestine in comparison to the amount returning to the intestine. Thus in teleost fish, the intestine is traditionally considered an excretory pathway for TH. Though, considering its mass of tissue, the intestine cannot be ignored as a possible large pool of TH for absorption to the circulation and EHC.

Based on the above, and since a given level of dietary T<sub>3</sub> increased circulating T<sub>3</sub> levels to a greater degree than dietary T<sub>4</sub> increased circulating T<sub>4</sub> levels (Higgs *et al.*, 1979, 1982), it is believed that T<sub>4</sub> was more poorly absorbed than T<sub>3</sub> from the digestive tract. A study by Whitaker and Eales (1993) was conducted to compare T<sub>4</sub> and T<sub>3</sub> absorption from the intestinal lumen of rainbow trout. Large doses of \*T<sub>4</sub> or \*T<sub>3</sub> were injected into the middle intestine, via an anal catheter, and uptake was measured over a period of 48 h. In agreement with the above studies, T<sub>3</sub> was removed from the intestine and entered blood and tissues more extensively than T<sub>4</sub>.

In summary, there is considerable evidence that high proportions of TH are secreted in fish bile. It has been concluded that significant biliary excretion of unconjugated TH occurs, mainly in the form of T<sub>4</sub>. There is far less information on what appears to be limited uptake from the intestine. However, the existing data suggest that,

at least in salmonid fish, a higher proportion of  $T_3$  than  $T_4$  can enter the circulation from the intestinal lumen.

## Chapter 3

### ***In vitro* Thyroid Hormone Metabolism and Assay Conditions for Intestinal Metabolism of the Thyroid Hormones, 3',5',3,5-tetraiodothyronine and 3',3,5-triiodothyronine, in Rainbow Trout**

#### **Introduction**

In teleost fish, the thyroid gland iodinates and couples tyrosines to form 3',5',3,5-tetraiodothyronine (thyroxine,  $T_4$ ).  $T_4$  is the main hormone released from the thyroid, yet 3',3,5-triiodothyronine ( $T_3$ ) is the biologically more active form which binds with higher affinity to nuclear receptors and elicits physiological responses. The regulation of plasma  $T_4$  level is attributed to central control mechanisms which include hypothalamic control of thyroid stimulating hormone (TSH) release from the pituitary (Peter and McKeown, 1975; Bromage *et al.*, 1976; Peter and Fryer, 1983; Dickhoff and Darling, 1983; Eales and Himick, 1991), TSH-stimulated release of  $T_4$  from the thyroid (Chan and Eales, 1975, 1976; Brown *et al.*, 1978; Milne and Leatherland, 1980; Ng *et al.*, 1982; Swanson *et al.*, 1988; Inui *et al.*, 1989; Grau *et al.*, 1986), and  $T_4$  negative feedback at the hypothalamus and pituitary (Peter, 1971, 1972; Baker, 1965, 1969a,b; Sage, 1968; Sage and Bromage, 1970). However, plasma  $T_3$  often circulates at a higher concentration than  $T_4$  (Chan and Eales, 1975; Eales, 1979a; Grau *et al.*, 1986; Byamungu *et al.*, 1992), and plasma  $T_4$  and plasma  $T_3$  regulation are largely independent of each other (Grau *et al.*, 1986; Eales and Himick, 1991; Eales and Brown, 1993). In peripheral tissues, such as the liver, conversion of  $T_4$  to  $T_3$  by deiodination provides circulating  $T_3$  (Leatherland, 1981; Pimlott and Eales, 1983; MacLatchy and Eales, 1993; Eales *et al.*, 1993). This

deiodination and other thyroid hormone (TH) metabolism pathways determine  $T_3$  homeostasis. Thus, peripheral metabolism is deemed important in regulating thyroidal status, or the availability of  $T_3$  to bind to receptors, in teleost fish.

In rainbow trout, the main control of  $T_3$  homeostasis is deiodination in peripheral tissues (Eales *et al.*, 1993; Eales, 1995; Figure 1-2). The liver is a main contributor to regulation of thyroidal status. It exhibits outer-ring deiodination (ORD) and inner-ring deiodination (IRD) pathways, including  $T_4$ ORD,  $T_4$ IRD, and  $T_3$ IRD, that work together to autoregulate  $T_3$  intracellularly and to provide  $T_3$  for other tissues that may primarily derive their source of  $T_3$  from the plasma pool (Eales *et al.*, 1993). Other established and potential forms of TH metabolism include conjugation, deamination, ether-link cleavage, and covalent bonding to proteins (Van Middlesworth, 1974; Hennemann, 1986; DiStefano, 1988; Figure 1-3). Tissues other than the liver may contribute to  $T_3$  homeostasis and the plasma pool of  $T_3$  if they have access to a large source of  $T_4$  and have metabolizing capabilities such as deiodination.

The role of the intestine as a peripheral tissue contributing to the regulation of thyroidal status has not been studied extensively in any species. The intestine has access to TH through the diet, the systemic circulation, and the bile (Figure 1-4). However, few studies have characterized intestinal TH metabolizing capabilities. In the few studies conducted to date, a comparison to hepatic deiodination has usually been made. Galton *et al.* (1991) measured rat intestinal TH metabolism and reported that ORD activity was highest in the fetal intestine but very low in the adult intestine, whereas the opposite was true for liver ORD activity. IRD activity was also present in the intestine. Survarna *et al.* (1993) measured intestinal ORD activity in chickens, and it was similar in biochemical

characteristics to hepatic ORD activity in mammals (Leonard and Visser, 1986) and birds (Freeman and McNabb, 1991; McNabb *et al.*, 1991; Darras *et al.*, 1992). In adult chickens, intestinal ORD was lower than hepatic ORD, but it was higher than activity measured in rats. In juvenile and adult sea lamprey, T<sub>4</sub>ORD activity was greater in the intestine than the liver (Eales *et al.*, 1997). In hagfish, T<sub>4</sub>ORD, T<sub>4</sub>IRD, and T<sub>3</sub>IRD could be measured (McLeese *et al.*, 2000). Similar to lampreys, intestinal T<sub>4</sub>ORD activity greatly exceeded that of liver. In lake sturgeon, Plohman *et al.* (2001) measured T<sub>4</sub>ORD, T<sub>4</sub>IRD, T<sub>3</sub>IRD, and reverse T<sub>3</sub>ORD (rT<sub>3</sub>ORD) activities in liver and intestine and showed that the intestine may contribute significantly to plasma T<sub>3</sub> levels and rT<sub>3</sub> deiodination. The only investigation into intestinal TH metabolism in rainbow trout was conducted by Law and Eales in 1973. Precipitation with trichloroacetic acid (TCA) and identification of products using thin-layer chromatography (TLC) was used to measure deiodination of T<sub>4</sub> double-labeled with radioactive iodide (\*I) and incubated with whole-tissue homogenates. The intestine demonstrated significant liberation of \*I, indicating the presence of TH metabolism pathways. Therefore, considering the mass of tissue and the possible influx of TH from the diet, blood, or bile, the intestine may provide a large pool of TH for metabolism and absorption to circulation. Thus, if TH metabolism, such as deiodination, occurs in the intestine, it may have a significant role in regulating thyroidal status.

This chapter reports investigations on the types of TH metabolism pathways that occurred in the various regions of the trout intestine, and it defined the conditions for *in vitro* measurement of these pathways using microsomal assays. The regions of the intestine investigated for TH metabolism were the pyloric caeca (PC), middle intestine

(MI), and distal intestine (DI). Liver TH metabolism was also measured as a reference. Liver TH metabolism pathways in rainbow trout were known, and the *in vitro* microsomal assay conditions were previously established. Activities of the TH metabolism pathways were measured using LH-20 column chromatography, protein precipitation, and high-performance liquid chromatography (HPLC). Determination of the assay conditions for the various TH metabolism pathways involved examination of cofactor concentration, incubation time, and pH. Demonstration of TH metabolism pathways in the intestine would define a potential role of the intestine in contributing to thyroidal status by regulating the availability of TH to enter into circulation or to be excreted.

## **Materials and Methods**

### **Fish maintenance**

Rainbow trout were obtained from the Rockwood Hatchery (Gunton, Manitoba) and held at the University of Manitoba in running, aerated, dechlorinated, City of Winnipeg water at 12°C, on a 12-h light:12-h dark (12L:12D) photoperiod. Sexually immature trout (200-500 g) were fed 1% of body mass of commercial trout feed diet (Martin Feed Mills, Elmira, Ontario; 3.2 mm diameter; manufacturer's analysis: protein 42%, crude fat 16%, fiber 3%, sodium 0.35%, calcium 1%, phosphorus 0.7%, vitamin A 7500 IU/kg, vitamin C 180 IU/kg, vitamin D<sub>3</sub> 2500 IU/kg, vitamin E 95 IU/kg) once daily at 9 AM.

## **Sampling**

Fish were anesthetized with 0.067 g/L of tricaine methanesulfonate (MS222; Syndel Laboratories, Vancouver), and killed by a blow to the head. The liver, PC, MI, and DI were removed (Figure 3-1). Sections of the intestine were opened and washed with Cortland saline (7.24 g NaCl, 0.22 g  $\text{CaCl}_2 \cdot 2 \text{H}_2\text{O}$ , 0.38 g KCl, 0.41 g  $\text{NaH}_2\text{PO}_4$ , 0.12 g  $\text{MgSO}_4$ , 1.00 g  $\text{NaHCO}_3$  per L  $\text{H}_2\text{O}$ ). Each tissue was frozen in liquid nitrogen and stored at  $-76^\circ\text{C}$ .

## **Microsomal fraction preparations**

Microsomes were prepared from individual liver, PC, MI, and DI tissues following the modified procedures of Shields and Eales (1986) (Figure 3-2). Tissues were partially thawed and minced in 4 vol (w/v) 0.1 M Tris-HCl buffer (12.12 g TRIS, 3.72 g EDTA, 1.0 M HCl per L  $\text{H}_2\text{O}$ ) containing 0.25 M sucrose and 1 M Na-EDTA at pH 7.2. In a Wheaton homogenization chamber, the tissue was disrupted with a Polytron homogenizer and further broken down with 3 strokes of a motorized pestle (Tri-R Instruments, Inc.). The resulting homogenate was filtered through 2 layers of cheesecloth and transferred to 26.3-mL Beckman centrifuge tubes.

Samples were centrifuged for 20 min at 730 g to pellet the nuclear fraction using a Beckman L8-55 ultracentrifuge. The post-nuclear fraction (supernatant) was centrifuged for 20 min at 25,200 g to pellet the mitochondrial/lysosomal fraction. The supernatant containing the post-mitochondrial fraction was centrifuged for 67 min at 110,000 g to separate the microsomal pellet from the cytosol. The pellet was resuspended in 1-2 mL of buffer to obtain a protein concentration between 4-16 mg/mL. All microsomes were stored at  $-76^\circ\text{C}$  until analysis.



### TH metabolism assay

The TH metabolism assay was based on the microsomal TH deiodinase assay of Shields and Eales (1986) as adapted by Frith and Eales (1996) (Figure 3-3). Microsomal fractions were partially thawed on ice and diluted with 0.1 M Tris-HCl buffer (pH 7.2; this varied when determining assay pH conditions), containing 1 mM Na-EDTA and at 0 mM or 10 mM dithiothreitol (DTT; this concentration varied when determining assay DTT concentration), to a final protein concentration of 0.2-0.8 mg/mL. A volume of 0.5 mL of the above preparations was pre-incubated in darkness for 30 min in a shaking water bath (12°C, 140 rpm).

After pre-incubation for 30 min in the dark, the assay reaction was initiated by adding 10  $\mu$ L of either T<sub>4</sub> substrate or T<sub>3</sub> substrate to the microsomal fraction for 45 min (this varied when determining assay incubation time). For all assays, TH substrate consisted of an equal volume of non-radioactive TH added to purified radioactive TH (\*TH) to produce a final substrate concentration of 0.16 nM T<sub>4</sub> or 0.19 nM T<sub>3</sub> at  $10 \times 10^6$  cpm/mL. The TH portion of the substrate consisted of T<sub>4</sub> or T<sub>3</sub> (Sigma) dissolved in 5  $\mu$ L MeOH, then brought up to final concentration in 0.1 N NaOH. The \*TH portion of the substrate consisted of <sup>125</sup>I outer-ring labeled T<sub>4</sub> (\*T<sub>4</sub>; specific activity 1250  $\mu$ Ci/ $\mu$ g, New England Nuclear) or <sup>125</sup>I outer-ring labeled T<sub>3</sub> (\*T<sub>3</sub>; specific activity 3300  $\mu$ Ci/ $\mu$ g, New England Nuclear) purified on an LH-20 column, removing the free iodide contamination (I<sup>-</sup>) with 3 mL H<sub>2</sub>O and eluting the \*TH fraction with 2.5 mL ethanolic-ammonia (EtOH:NH<sub>4</sub>OH; 99:1 v/v). The purified \*TH (>92% TH) was dried at 30°C under a stream of air and reconstituted to final concentration in 0.1 N NaOH.

For T<sub>4</sub> complete ORD (T<sub>4</sub>cORD) measurement, outer-ring double radioiodine-labeled T<sub>4</sub> (\*\*T<sub>4</sub>) and single radioiodine-labeled T<sub>4</sub> (\*T<sub>4</sub>) were used as substrates to determine if T<sub>4</sub>cORD activity involved the complete removal of both outer-ring I from the T<sub>4</sub> substrate.

After 30 min, the incubate reaction was stopped with 10 µL of 2 mM potassium iodide (KI). This time was varied when determining assay incubation time.

### **Overview of the analyses of TH metabolites and TH pathways**

The incubate was separated into two aliquots (Figure 3-3). One aliquot was used to determine both total TH metabolism by using LH-20 column separation (see Total TH metabolism section) and iodoprotein (IP) production by using trichloroacetic acid (TCA) protein precipitation (see IP production section). The other aliquot was used to measure activities of specific TH metabolism pathways by using HPLC separation of radiolabeled products (see Specific TH metabolism pathways section).

Initially during determination of assay procedures, only total TH metabolism pathways and IP production were measured. However, there were limitations of the assay due to the extent of various ORD and IRD pathways active in the intestine. By using LH-20 column chromatography, only the \*I and/or \*IP released during metabolism, not the iodothyronines formed, could be measured. Increases or decreases in individual pathways could not be determined, only changes in overall amounts of TH metabolism. A more specific characterization of types of active TH metabolism pathways was undertaken by using HPLC separation of radiolabeled products. Thus, changes in activity within the pathways could be measured under altered assay conditions. Despite the greater

specificity of HPLC separation, LH-20 column separation followed by TCA protein precipitation was still necessary for measurement of IP production.

### ***Total TH metabolism***

A 200- $\mu$ L aliquot of the incubate was added to an LH-20 column and eluted with 300  $\mu$ L of H<sub>2</sub>O. The eluate contained <sup>\*</sup>I<sup>-</sup> removed by ORD and/or radioiodine-labeled IP (<sup>\*</sup>IP) produced. However, it did not contain the iodothyronines, which remained on the column. The initial water fraction was counted for 10 min in the gamma counter (Beckman Gamma 8000 or Packard Cobra II Auto-gamma), and the radioactivity, measured, in counts per minute (cpm), was used to calculate pmoles of TH substrate converted to I<sup>-</sup> or IP per hour per milligram of microsomal protein (Total TH metabolism; see Appendix I and II for calculations).

### ***IP production***

The total TH metabolism fraction was further analyzed to determine the proportion of its radioactivity that was <sup>\*</sup>IP. For this purpose, the radioiodine-incorporated proteins were precipitated from the H<sub>2</sub>O fraction by adding 25% TCA and centrifuging at 1420 g for 15 min in an IEC Centra-M centrifuge. After discarding the supernatant, the radioactive precipitate was counted in the gamma counter to determine <sup>\*</sup>IP production. Activity was expressed as pmoles of TH substrate converted to IP per hour per milligram of microsomal protein (see Appendix III for calculations).

### ***Specific TH metabolism pathways***

To the remaining 300  $\mu$ L of incubate, 650  $\mu$ L of methylmercaptoimidazole (MMI) in methanol (115 mg MMI/mL methanol) was added and centrifuged at 1420 g for 5 min. A volume of 400  $\mu$ L of the supernatant was analyzed in a Gilson-IBM binary gradient

HPLC with a C-18 150 x 4.6 mm Econosphere column (5  $\mu$ m, Alltech) to separate \*TH metabolism products using the procedures of Sweeting and Eales (1992). Products were eluted at 1 mL/min with an isocratic flow of 40% acetonitrile (0.1% trifluoroacetic acid) and 60% H<sub>2</sub>O (0.1% trifluoroacetic acid) over 20 min.

With T<sub>4</sub> substrate, T<sub>4</sub>cORD (\*T<sub>4</sub> completely deiodinated from both positions on the outer ring so that only \*I<sup>-</sup> remained as a labeled product), T<sub>4</sub>ORD (\*T<sub>4</sub> deiodinated from one position on the outer ring, producing equal amounts of \*T<sub>3</sub> and \*I<sup>-</sup>), and T<sub>4</sub>IRD (\*T<sub>4</sub> deiodinated from one position on the inner ring, producing only \*rT<sub>3</sub> as a labeled product) can be followed. With T<sub>3</sub> substrate, T<sub>3</sub>ORD (\*T<sub>3</sub> deiodinated from the one remaining labeled position on the outer ring so that only \*I<sup>-</sup> remains as a labeled product) and T<sub>3</sub>IRD (\*T<sub>3</sub> deiodinated from one position on the inner ring, producing only \*T<sub>2</sub>) can be followed (Figure 2-1). The area under the product curve can be used to calculate the percent of TH substrate degraded to that product (Figure 3-4). Using this percent conversion and the substrate level in the incubate, activities of specific TH metabolism pathways were expressed as pmoles of TH substrate converted to product per hour per milligram of microsomal protein (see Appendix IV and V for calculations).

For T<sub>4</sub>cORD, the amount of activity was calculated by subtracting T<sub>4</sub>ORD (using the area under the \*T<sub>3</sub> curve; which is equivalent to the outer-ring \*I<sup>-</sup> removed to form \*T<sub>3</sub>) from total \*I<sup>-</sup> production (using the total area under the \*I<sup>-</sup> curve). This left only the I<sup>-</sup> removed by T<sub>4</sub>cORD, which left no other radiolabeled products to follow. In order to obtain the HPLC data used in the calculations, proteins were precipitated with MeOH. Therefore, total I<sup>-</sup> production did not include IP production, as seen in total T<sub>4</sub>

metabolism calculated from the LH-20 H<sub>2</sub>O elution (see Appendix VI for total \*I production and T<sub>4</sub>cORD calculations).

### **Assay conditions for intestinal TH metabolism**

Assay conditions for PC, MI, and DI were determined by varying cofactor concentration, incubation time, and pH. In most instances, the liver TH metabolism assay was used as a reference, since optimal assay conditions were previously determined for rainbow trout deiodination pathways in hepatic tissue (Eales *et al.*, 1993).

#### ***Cofactor concentration***

Cofactor requirements were determined for TH metabolism assays. The thiol cofactor allows the deiodinase enzyme to function by reducing the deiodinase enzyme, rendering the catalytic site functional (Kohrle, 1996). For microsomal assays, DTT replaces a presumed endogenous thiol cofactor, and the concentration was optimized. Glutathione (GSH), a potential endogenous thiol cofactor, was also tested in TH metabolism assays. Initially, total T<sub>4</sub> metabolism was measured for liver, PC, MI, and DI using ranges of thiol cofactor concentrations of 0 mM to 20 mM DTT and 0 mM to 4 mM GSH. Total T<sub>3</sub> metabolism was measured using 0 mM and 10 mM DTT. Next, specific TH metabolism pathways were measured by using either T<sub>4</sub> or T<sub>3</sub> substrate at both 0 mM and 10 mM DTT.

#### ***Incubation time***

Incubation time for T<sub>4</sub> metabolism assays were tested over a range of 30 to 120 min for 0 mM DTT. These assays determined incubation time for liver, PC, MI, and DI by measuring the amount of total T<sub>4</sub> metabolism.

## ***pH***

Assay pH for both T<sub>4</sub> metabolism and T<sub>3</sub> metabolism was determined. For liver, PC, MI, and DI without DTT, total T<sub>4</sub> metabolism was examined over pH values of 6.5 to 9.5. Activities of specific T<sub>4</sub> metabolism pathways and T<sub>4</sub>IP production were measured over pH values of 7.2 to 9.4. For liver and DI with 10 mM DTT, total T<sub>4</sub> metabolism, specific T<sub>4</sub> metabolism pathways, and T<sub>4</sub>IP production were further investigated over pH values of 7.2 to 8.8. Specific T<sub>3</sub> metabolites and T<sub>3</sub>IP production were measured for liver, PC, MI, and DI at 0 mM DTT and 10 mM DTT over pH values of 7.2 to 8.8.

## ***Mechanisms of IP formation***

To gain further insight into the formation of \*IP, microsomes were incubated with \*I and compared with microsomes incubated with \*T<sub>4</sub>. To determine the possible source of the protein bound as IP, \*T<sub>4</sub> substrate was incubated with 0.20 mg/mL bovine serum albumin (BSA) as a protein source instead of microsomal protein while using 0 mM or 20 mM DTT.

## ***Statistics***

Using the SPSS statistics package, the univariate analysis of variance (ANOVA) was used to compare the effects of DTT concentrations on the rate of either total T<sub>4</sub> metabolism or total T<sub>3</sub> metabolism. These were followed by LSD post hoc multiple comparisons to determine significant differences due to DTT concentrations. The tests were performed individually for liver, PC, MI, and DI. Univariate ANOVA was also used to compare the rates of each specific T<sub>4</sub> metabolism pathway at either 0 mM or 10 mM DTT and to compare the rates of each specific T<sub>3</sub> metabolism pathway at either 0 mM or 10 mM DTT. These were followed by LSD post hoc multiple comparisons to

determine significant differences among activities in the pathways. Each test was performed individually for liver, PC, MI, and DI. Results were determined statistically significant at  $p \leq 0.05$ . Sample sizes were too small for the other treatments to perform statistics.

## **Results**

### **Effects of DTT cofactor concentration on total T<sub>4</sub> metabolism**

DTT concentrations of 0, 5, 10, 15, or 20 mM were used to determine assay conditions for total T<sub>4</sub> metabolism (Figure 3-5). For the liver, total T<sub>4</sub> metabolism was significantly higher at 10 mM DTT (0.49 pmol T<sub>4</sub> converted/hr/mg protein) than at 0 mM DTT (0.16 pmol T<sub>4</sub> converted/hr/mg protein;  $F=13.170$ , d.f.=1,  $p=0.001$ ).

For all intestinal regions (PC, MI, or DI), the highest levels of total T<sub>4</sub> metabolism were measured at 0 mM DTT (0.14 pmol T<sub>4</sub> converted/hr/mg protein for PC, 0.11 pmol T<sub>4</sub> converted/hr/mg protein for MI, and 0.20 pmol T<sub>4</sub> converted/hr/mg protein for DI). For the MI, total T<sub>4</sub> metabolism was significantly higher at 0 mM DTT than at 20 mM DTT ( $F=11.615$ , d.f.=4;  $p=0.036$ ). It was unknown, at this point, if the same T<sub>4</sub> metabolism pathways were active at different levels of cofactor. Thus, further assays included cofactor concentrations of both 0 mM and 10 mM DTT. In addition, specific T<sub>4</sub> metabolism pathways and T<sub>4</sub>IP production were measured for liver and intestinal regions.

### **Effects of DTT cofactor concentration on specific T<sub>4</sub> metabolism pathways and T<sub>4</sub>IP production**

DTT concentrations of 0 mM and 10 mM were used to measure specific T<sub>4</sub> metabolism pathways (T<sub>4</sub>cORD, T<sub>4</sub>ORD, and T<sub>4</sub>IRD) and T<sub>4</sub>IP production (Figure 3-6).

In the liver, T<sub>4</sub>ORD at 0 mM DTT was significantly greater than the other specific T<sub>4</sub> metabolism pathways (F=7.542, d.f.=3, p=0.001).

For all regions of the intestine, T<sub>4</sub>cORD did not require DTT and was significantly greater than other specific T<sub>4</sub> metabolism pathways (F=5.307, d.f.=3, p=0.004 for PC; F=1.912, d.f.=3, p=0.035 for MI; F=10.533, d.f.=3, p=0.000 for DI). The PC (0.40 pmol T<sub>4</sub> converted/hr/mg protein) and the DI (0.47 pmol T<sub>4</sub> converted/hr/mg protein) were more active than the MI (0.15 pmol T<sub>4</sub> converted/hr/mg protein).

For all intestinal regions, DTT decreased T<sub>4</sub>cORD activity but increased T<sub>4</sub>ORD activity so that T<sub>4</sub>cORD was no longer significantly greater than the other specific T<sub>4</sub> metabolism pathways (F=0.654, d.f.=3, p=0.632 for PC; F=3.056, d.f.=3, p=0.122 for MI; F=2.691, d.f.=3, p=0.109 for DI). Thus, T<sub>4</sub>ORD functions optimally with cofactor in both liver and intestine.

### **Effects of DTT cofactor concentration on total T<sub>3</sub> metabolism**

Total T<sub>3</sub> metabolism was measured for liver, PC, and DI at 0 mM and 10 mM DTT (Figure 3-7). Liver total T<sub>3</sub> metabolism was low, with little difference between 0 mM and 10 mM DTT (0.04 vs. 0.03 pmol T<sub>3</sub> converted/hr/mg protein).

For intestinal assays, total T<sub>3</sub> metabolism varied with intestinal region and DTT concentration. Only PC total T<sub>3</sub> metabolism was significantly greater at 10 mM DTT than at 0 mM DTT (F=6.324, d.f.=1, p=0.036). However, DI total T<sub>3</sub> metabolism was greater, but not significantly (F=4.090, d.f.=1, p=0.078), without cofactor than with cofactor. Total T<sub>3</sub> metabolism in PC and DI exceeded that of the liver.



### **Effects of DTT cofactor concentration on specific $T_3$ metabolism pathways and $T_3$ IP production**

$T_3$ ORD and  $T_3$ IRD pathways and  $T_3$ IP production were measured with or without DTT (Figure 3-8). All  $T_3$  metabolism pathways were low in liver, with  $T_3$ IRD, which produces  $T_2$  from  $T_3$ , being the most prominent pathway at 10 mM DTT (0.008 pmol  $T_3$  converted/hr/mg protein).

As seen when measuring total  $T_3$  metabolism in intestinal assays, activities of specific TH metabolism pathways varied with intestinal region. Overall, no specific  $T_3$  metabolism pathways were significantly greater than the other for all intestinal regions. For PC,  $T_3$ IRD activity was greatest (0.05 pmol  $T_3$  converted/hr/mg protein). For MI,  $T_3$ ORD activity was greatest (0.05 pmol  $T_3$  converted/hr/mg protein). For DI, both  $T_3$ ORD and  $T_3$ IRD were active without cofactor (0.11 pmol  $T_3$  converted/hr/mg protein and 0.06 pmol  $T_3$  converted/hr/mg protein, respectively). For all intestinal regions,  $T_3$ IP production was consistently low (range: 0.0017-0.0018 pmol  $T_3$  converted/hr/mg protein). Again, DI was more active at metabolizing  $T_3$  than liver or other intestinal regions, and these pathways did not require cofactor.

### **Effects of GSH cofactor concentration on total $T_4$ metabolism**

Since DTT was not required for  $T_4$ cORD, the prominent  $T_4$  metabolism pathway in the intestine, another possible cofactor, GSH, was tested in assays measuring total  $T_4$  metabolism (Figure 3-9). In the liver, total  $T_4$  metabolism was not altered with increases in GSH cofactor concentration.

In the presence of GSH, the total  $T_4$  metabolism in intestinal regions was depressed markedly. Without GSH as a cofactor, PC exhibited the greatest metabolism

(0.62 pmol T<sub>4</sub> converted/hr/mg protein), followed by DI (0.19 pmol T<sub>4</sub> converted/hr/mg protein), and then MI (0.14 pmol T<sub>4</sub> converted/hr/mg protein). Since GSH did not increase total T<sub>4</sub> metabolism, it was not tested further, and both 0 mM and 10 mM DTT were routinely used in subsequent assays.

### **Effects of incubation time on total T<sub>4</sub> metabolism**

The effects of incubation time on total T<sub>4</sub> metabolism (minus the T<sub>4</sub>IP products) were tested for liver, PC, MI, and DI without DTT (Figure 3-10). Maximal total T<sub>4</sub> metabolism was reached in liver by 30 min.

Similar results showing maximal total T<sub>4</sub> metabolism at 30 min were found for the intestinal regions. Again, the distal region exhibited the greatest amount of total T<sub>4</sub> metabolism with 0.61 pmol T<sub>4</sub> converted/hr/mg protein. Thus, a 45-min incubation time was routinely used to allow maximal TH metabolism to occur and to allow time for an adequate number of samples and replicates to be assayed.

### **Effects of pH on T<sub>4</sub> metabolism pathways without DTT**

The effects of pH on T<sub>4</sub> metabolism pathways without DTT were tested for liver, PC, MI, and DI. When measuring total T<sub>4</sub> metabolism, a pH range of 6.5 to 9.5 (specifically 6.5, 7.0, 7.25, 7.5, 8.0, 8.75, and 9.5) was used (Figure 3-11). Specific T<sub>4</sub> metabolism pathways and T<sub>4</sub>IP production were determined over pH values of 7.2, 8.0, 8.8, and 9.4 (Figures 3-12 through 3-15).

For liver, total T<sub>4</sub> metabolism did not differ greatly with changes in assay pH, and activity was highest at pH 8.0 (0.06 pmol T<sub>4</sub> converted/hr/mg protein). Higher total T<sub>4</sub> metabolism at pH 8.0 was due to increased T<sub>4</sub>cORD (0.08 pmol T<sub>4</sub> converted/hr/mg protein), T<sub>4</sub>ORD (0.06 pmol T<sub>4</sub> converted/hr/mg protein), and T<sub>4</sub>IRD (0.02 pmol T<sub>4</sub>

converted/hr/mg protein) (Figure 3-12). However, T<sub>4</sub>IP formation was low, with optimal pH at 8.8 (0.006 pmol T<sub>4</sub> converted/hr/mg protein).

All intestinal regions showed greater total T<sub>4</sub> metabolism with increased pH (Figure 3-11). For example, PC total T<sub>4</sub> metabolism was similar to liver until pH 8.8. PC at higher pH (8.75 and 9.5) showed increased metabolism (0.22 and 0.21 pmol T<sub>4</sub> converted/hr/mg protein, respectively). A similar trend was observed for MI and DI with increased total T<sub>4</sub> metabolism at higher pH.

To investigate the increased total T<sub>4</sub> metabolism at higher pH, specific T<sub>4</sub> metabolism pathways and T<sub>4</sub>IP production were determined at a pH range of 7.2 to 9.4 for all intestinal regions. For PC, pH 8.0 was optimal for T<sub>4</sub>cORD (0.06 pmol T<sub>4</sub> converted/hr/mg protein) (Figure 3-13). T<sub>4</sub>ORD activity was highest at pH 9.4 (0.03 pmol T<sub>4</sub> converted/hr/mg protein). T<sub>4</sub>IRD activity was highest at pH 8.8 (0.025 pmol T<sub>4</sub> converted/hr/mg protein). T<sub>4</sub>IP formation increased with increasing pH, with the highest levels at pH 8.8 and 9.4. Therefore, the increased total T<sub>4</sub> metabolism with increased pH seen in LH-20 column separation was attributed to increased T<sub>4</sub>cORD and T<sub>4</sub>IP production.

For MI, pH 8.8 was optimal for T<sub>4</sub>cORD (0.004 pmol T<sub>4</sub> converted/hr/mg protein), with no activity detectable at lower pH (Figure 3-14). T<sub>4</sub>ORD activity was highest at both pH 7.2 and pH 9.4 (0.02 pmol T<sub>4</sub> converted/hr/mg protein for both). T<sub>4</sub>IRD activity was highest at pH 8.8 (0.02 pmol T<sub>4</sub> converted/hr/mg protein). T<sub>4</sub>IP formation increased with increasing pH, and pH 9.4 produced the greatest T<sub>4</sub>IP (0.04 pmol T<sub>4</sub> converted/hr/mg protein). Besides T<sub>4</sub>IP production, almost all T<sub>4</sub> metabolism pathways in MI were active at higher pH.

For DI, pH 7.2 was the optimal pH for T<sub>4</sub>cORD (0.48 pmol T<sub>4</sub> converted/hr/mg protein), with negligible activity detectable at other pH values (Figure 3-15). T<sub>4</sub>ORD activity was highest at pH 7.2 (0.04 pmol T<sub>4</sub> converted/hr/mg protein), but it was consistently low at other pH. T<sub>4</sub>IRD activity was also consistently low at all pH except pH 9.4, where no rT<sub>3</sub> was detected. T<sub>4</sub>IP production was also low, however, increasing the pH increased IP formation to 0.07 pmol T<sub>4</sub> converted/hr/mg protein. Thus, pH 7.2 was the optimal assay pH for DI, one of the most active regions of the intestine for T<sub>4</sub> metabolism, and T<sub>4</sub>IP was the main active pathway at higher pH.

#### **Effects of pH on T<sub>4</sub> metabolism pathways with DTT**

The assay pH was also determined for total T<sub>4</sub> metabolism with 10 mM DTT by focusing on the liver and the most active intestinal region, DI at pH 7.2, 8.0, and 8.8 (Figure 3-16). Specific T<sub>4</sub> metabolism pathways were measured at pH 7.2 and pH 8.0 (Figures 3-17 and 3-18).

For liver, total T<sub>4</sub> metabolism was highest at pH 7.2 (Figure 3-16). The higher T<sub>4</sub> metabolism at pH 7.2 was due to high T<sub>4</sub>ORD activity (Figure 3-17).

For DI, total T<sub>4</sub> metabolism activity was similar at all pH values, with activity ranging from 0.14 to 0.15 pmol T<sub>4</sub> converted/hr/mg protein (Figure 3-16). The most active pathway was T<sub>4</sub>IRD at pH 7.2 (0.05 pmol T<sub>4</sub> converted/hr/mg protein) (Figure 3-18). At this pH, T<sub>4</sub>ORD and T<sub>4</sub>IP were also active (0.03 pmol T<sub>4</sub> converted/hr/mg protein and 0.01 pmol T<sub>4</sub> converted/hr/mg protein, respectively). As pH increased to 8.8, T<sub>4</sub>IRD was non-detectable, and T<sub>4</sub>ORD increased. T<sub>4</sub>IP production was unaltered by pH. Thus, even though total T<sub>4</sub> metabolism did not change with increased pH, measuring specific T<sub>4</sub>

metabolism indicated a decrease in pathways inactivating  $T_4$  and an increase in pathways activating  $T_4$ .

### **Effects of pH on $T_3$ metabolism pathways without DTT**

To determine assay pH for  $T_3$  metabolism without DTT, specific  $T_3$  metabolism pathways were measured for liver, PC, MI, and DI at pH 7.2, 8.0, and 8.8.

For liver,  $T_3$ ORD activity increased from 0 to 0.005 pmol  $T_3$  converted/hr/mg protein with increased pH (Figure 3-19).  $T_3$ IRD activity was active at pH 8.0 only (0.008 pmol  $T_3$  converted/hr/mg protein).  $T_3$ IP production was present at pH 7.2 only (0.005 pmol  $T_3$  converted/hr/mg protein).

For PC, increasing pH increased  $T_3$ ORD activity only slightly to levels above non-detectable (Figure 3-20).  $T_3$ IRD activity was highest at pH 7.2, decreasing with increased pH (0.05 to 0.003 pmol  $T_3$  converted/hr/mg protein).  $T_3$ IP production was similar at all pH concentrations (0.01 pmol  $T_3$  converted/hr/mg protein).

For MI,  $T_3$ ORD was the most active pathway, increasing with increased pH (0.05 pmol  $T_3$  converted/hr/mg protein to 0.09 pmol  $T_3$  converted/hr/mg protein) (Figure 3-21).  $T_3$ IP production was minimally active and only at pH 8.8 (0.002 pmol  $T_3$  converted/hr/mg protein).

For DI,  $T_3$ ORD was the most active pathway, with highest levels at pH 7.2 (0.12 pmol  $T_3$  converted/hr/mg protein) (Figure 3-22).  $T_3$ IRD was also active at pH 7.2 (0.08 pmol  $T_3$  converted/hr/mg protein), decreasing to non-detectable at pH 8.0 and 0.02 pmol  $T_3$  converted/hr/mg protein at pH 8.8.  $T_3$ IP production was low at all pH values. Overall, DI was the most active intestinal region for  $T_3$  metabolism, even surpassing liver activity; pH 7.2 was optimal for the assay.

### Effects of pH on T<sub>3</sub> metabolism pathways with DTT

To determine optimal assay pH for T<sub>3</sub> metabolism with DTT, specific T<sub>3</sub> metabolism pathways were measured for liver, PC, MI, and DI at pH 7.2, 8.0, and 8.8.

For liver, T<sub>3</sub>IRD was the most active pathway with the highest activity at pH 8.0 (0.04 pmol T<sub>3</sub> converted/hr/mg protein) (Figure 3-23). T<sub>3</sub>IP production fluctuated little with pH (range of 0.01 to 0.02 pmol T<sub>3</sub> converted/hr/mg protein).

For PC, T<sub>3</sub>IRD was the most active pathway, but it was only detectable at pH 7.2 (0.02 pmol T<sub>3</sub> converted/hr/mg protein) (Figure 3-24). T<sub>3</sub>IP production was consistently active (0.02 pmol T<sub>3</sub> converted/hr/mg protein), thus it was insensitive to pH over the range 7.2-8.0.

DI T<sub>3</sub> metabolism was similar to that for PC (Figure 3-25). T<sub>3</sub>IRD activity was highest at pH 7.2 (0.07 pmol T<sub>3</sub> converted/hr/mg protein), decreasing to non-detectable levels at pH 8.8. T<sub>3</sub>IP production did not change with a change in pH (0.03 pmol T<sub>3</sub> converted/hr/mg protein). Again, DI was the most active intestinal region for T<sub>3</sub> metabolism with DTT; pH 7.2 was optimal for the assay. T<sub>3</sub>IRD, whether in liver or intestine, functions optimally with DTT.

### Mechanism of IP formation

Since the pathway for IP production and the actual products formed were unknown, either \*T<sub>4</sub> or \*I<sup>-</sup> substrates were incubated with intestinal microsomes. No IP production occurred with \*I<sup>-</sup> as a substrate (data not shown). Therefore, the production of IP depended upon TH as a substrate, not the \*I<sup>-</sup> released from metabolism.

\*T<sub>4</sub> substrate was incubated with 0.2 mg/mL of BSA as a protein source, instead of microsomal protein, using 0 mM or 20 mM DTT (Figure 3-26). IP production

occurred with BSA, and so was formed regardless of protein source or presence of enzymes. An increase in cofactor decreased TH interaction with proteins.

## Discussion

This chapter set out to describe TH metabolism pathways in specific segments of the intestine (PC, MI, and DI) of the rainbow trout, using liver as a reference standard. Using the microsomal TH metabolism assay, DTT concentration, incubation time, and pH requirements were characterized for the active pathways measured.

Previous studies on the trout liver have optimized conditions for deiodination assays. In the present study, T<sub>4</sub>ORD was the predominant hepatic deiodination pathway that deiodinated T<sub>4</sub> to T<sub>3</sub>, and assay conditions were established as 10 mM DTT, 45 min incubation time, and pH 7.2. Substrate concentrations of 0.16 nM T<sub>4</sub> or 0.19 nM T<sub>3</sub> were used to simulate likely tissue TH levels. This supports previous literature both with regard to optimal T<sub>4</sub>ORD assay conditions and with regard to the liver's role as a main regulator of peripheral TH metabolism and in maintaining T<sub>3</sub> homeostasis (Eales *et al.*, 1993; Eales, 1995).

Intestinal TH metabolism pathways were more complex than those in the liver, and intestinal TH metabolism had different assay requirements than that of the liver. Of all of the intestinal regions studied for TH metabolism, the DI was the most active. The DI did not require cofactor for the most active pathway, T<sub>4</sub>cORD. Hence, assays were run at both 0 mM and 10 mM DTT. Other than cofactor requirements, assay conditions were kept similar to the hepatic TH metabolism assay. Substrate concentrations of 0.16 nM T<sub>4</sub> or 0.19 nM T<sub>3</sub> were used at pH 7.2 with 45 min incubation time.

Besides not requiring cofactor, overall levels of intestinal TH metabolism activity were lower with  $T_4$  substrate but higher with  $T_3$  substrate than in the liver. However, pathways that were low in the liver were more active and predominated in the intestine. Intestinal deiodination in the Atlantic cod (Cyr *et al.*, 1997) and American plaice (Adams *et al.*, 2000) were also low under normal physiological conditions. In sturgeon, intestinal TH metabolism was significant, but it was lower than hepatic deiodination (Plohman *et al.*, 2002). However, in lampreys (Eales *et al.*, 1997, 1999) and hagfish (McLeese *et al.*, 2000), intestinal deiodination ( $T_4$ ORD) predominated over hepatic deiodination. Thus, the intestinal deiodination may represent ancestral TH metabolism pathways that are actively retained in more “primitive” fish lineages but still present in teleost fish.

In summary, in trout under normal physiological conditions, while the liver mainly deiodinated  $T_4$  to form  $T_3$ , the intestine showed a broader array of deiodination and TH metabolism pathways geared toward degradation of  $T_4$  and in particular degradation of  $T_3$ . Thus, the main ways in which the intestine differed from the liver were that  $T_4$ cORD,  $T_4$ IRD, and TH IP production was active, and no DTT was required as a cofactor. These unusual properties of intestinal TH metabolism are discussed below.

#### **$T_4$ cORD**

Complete outer-ring deiodination has not been characterized in other tissues for any species. For this TH metabolism pathway, all of the  $^*I$  was removed without forming other iodothyronines. Thus, this is considered an inactivating pathway.  $T_4$ cORD was, at the very least, removing all of the outer-ring  $I$ . This was shown by using double-labeled  $T_4$ .  $^*I$  production from  $T_4$ cORD doubled with the double-labeled substrate. Since inner-ring  $I$  presence or removal could not be measured without an outer-ring



radioiodine-labeled iodothyronine to follow, it was not known if all of the I<sup>-</sup> (both outer-ring and inner-ring) were removed.

Similar to T<sub>4</sub>cORD, T<sub>3</sub>ORD represents complete outer-ring deiodination. Again, it was not known if T<sub>3</sub>ORD represented the removal of both outer-ring and inner-ring I<sup>-</sup>. Regardless, it was similar in characteristics to T<sub>4</sub>cORD. Both T<sub>4</sub>cORD and T<sub>3</sub>ORD are active without DTT, in fact, they are more active in its absence. Additionally, both are highest in the DI. Intestinal tissue may not contain an endogenous equivalent to the thiol cofactor. Thus, these degradative pathways may be prominent in the DI. They may serve to degrade excess TH potentially entering the intestine through the diet, from the circulation, or from the bile. This would prevent elevated levels of TH from entering or re-entering the circulation. Since activity was higher in the DI, it may serve to salvage I<sup>-</sup> before loss through excretion.

### **IP production**

IP production was further investigated, since its formation was prominent in the intestinal TH metabolism assay. IP production may have been overlooked in tissues such as the liver, since the levels of activity of other TH metabolism pathways were relatively high. IP production would be insignificant, in comparison, and it has probably been disregarded as background. TH metabolism pathways in the intestine were more numerous, however, the products of the pathways were often low in comparison to the liver. Therefore, the "background" of IP production was sufficiently conspicuous to be worthy of measurement.

The identity of the IP, much less the pathway of formation, is poorly understood. Of the TH substrates, T<sub>4</sub> produced more IP than T<sub>3</sub>. However, it was not known if IP

production was dependent upon TH itself as a substrate or I<sup>-</sup> released from the TH. A possible pathway was that <sup>\*</sup>I<sup>-</sup> removed from the TH outer-ring was bound to proteins, just as I<sup>-</sup> is bound to proteins in trout plasma (Leloup, 1970). If this was true, then it would be expected that I<sup>-</sup> alone would serve as a substrate in the assay, resulting in I<sup>-</sup> bound to protein. However, no <sup>\*</sup>IP products were formed with <sup>\*</sup>I<sup>-</sup> as a substrate. This finding was supported by Galton and Ingbar (1961) and Tata (1960) studying IP formation in rats, mice, tadpoles, and frogs. Both agreed that iodide was not the substrate for protein iodination. Thus, IP production required TH, and preferably T<sub>4</sub>, as a substrate.

It was also not known what was the source of protein for IP production. T<sub>4</sub>IP formation was tested using either microsomes or BSA as the protein source in the assay. IP were formed with both protein sources, indicating that TH were spontaneously, covalently bound to protein in the assay. Tata (1960) believed that proteins such as lysozyme and egg albumin could be iodinated during the deiodination of T<sub>4</sub>. The data in this chapter do not support the need for enzymatic deiodination of T<sub>4</sub> to generate IP, since the incubation of T<sub>4</sub> with BSA did not include any source of enzyme. IP production may be a result of spontaneous degradation of TH. However, it may be linked in some way to deiodination as an increase in deiodination in the intestine appeared to increase IP production. Since DTT reduced the production of IP, the cofactor may stabilize TH, reduce spontaneous degradation of TH, and prevent IP formation in the assay. The intestine, with its lack of cofactor requirements may represent a different enzymatic environment which allows greater formation of IP.

Since the pathway for IP production and its identity are not known, it is difficult to speculate on their physiological role. Proteins in the intestinal cells may bind TH for

transport into the circulation. Binding of TH could also promote TH excretion in a manner similar to  $\text{Fe}^{+2}$  excretion in the intestine. Ferritin, an epithelial cell protein, binds excess  $\text{Fe}^{+2}$ , preventing its absorption, while the  $\text{Fe}^{+2}$  that is not bound to ferritin can be absorbed into the circulation. The  $\text{Fe}^{+2}$  that is bound to ferritin is stored intracellularly so that when the epithelial layer is sloughed off, the  $\text{Fe}^{+2}$  is excreted (Vander *et al.*, 1994). IP may serve a similar role as the protein-bound  $\text{Fe}^{+2}$ , but in this case facilitating the excretion of TH.

### **Dependence upon thiol cofactor DTT**

In all regions of the intestine (PC, MI, and DI), 0 mM DTT produced the greatest amount of total  $\text{T}_4$  metabolism. This suggested that enzyme characteristics for TH metabolism pathways in the intestine differed from the liver. After measuring specific  $\text{T}_4$  products, it was shown that varying DTT concentration affected some deiodination pathways, but not others. In all regions,  $\text{T}_4\text{cORD}$  was the prominent pathway without cofactor, with DI  $\text{T}_4\text{cORD}$  activity the highest. With cofactor (10 mM DTT),  $\text{T}_4\text{ORD}$  was the prominent pathway in all regions, except the MI. At this level of cofactor,  $\text{T}_4\text{ORD}$  remained high.

Intestinal  $\text{T}_3$  metabolism also varied with changes in cofactor concentration. In PC, 10 mM, not 0 mM DTT, produced optimal  $\text{T}_3$  metabolism. The opposite was true in DI. Only the DI exhibited activity for both  $\text{T}_3\text{ORD}$  and  $\text{T}_3\text{IRD}$ . Both were active at 0 mM DTT, but only  $\text{T}_3\text{IRD}$  was not inhibited by DTT.

It was shown previously that thiol cofactors such as DTT, dihydrolipoamide, or monogluthathione provide an exogenous thiol that significantly increased trout microsomal deiodination activity in the liver (Pimlott and Eales, 1983; Shields and Eales, 1986).

Sulphydryl groups or selenocysteine residues were found at the deiodinase enzyme catalytic site in mammals (Visser, 1979; Kohrle, 1996). Thiols reduced the deiodinase enzyme, forming a catalytically active enzyme. The exogenous thiol cofactor is believed to replace an endogenous biological equivalent. However, the nature of an endogenous cofactor in fish is not further understood.

Results from the present study using GSH indicated that it is not an effective cofactor for the liver or the intestine. For the liver, adding GSH did not increase activity, as was seen at 10 mM DTT. In mammals, GSH was an effective thiol cofactor for ORD in intestinal tissues (Galton *et al.*, 1991) and hepatic and kidney tissues (Goswami and Rosenberg, 1988). In fact, Galton *et al.*, (1991) suggested that GSH may be an activator of ORD *in vivo*. Yet, the present study showed that GSH was a less effective cofactor than DTT for rainbow trout liver, and it inhibited TH metabolism pathways in the intestine. Thus, GSH is not a likely endogenous cofactor for rainbow trout.

The atypical requirements for thiol cofactor in the intestine suggested a different enzyme or mechanism for intestinal TH metabolism than that found in the liver. Since the intestinal lumen itself is a reduced environment, there may be an abundance of reduced "cofactors" that can enter the intestinal cells, aiding the deiodinase enzyme in metabolism. Hence, intestinal T<sub>4</sub> metabolism pathways may have adapted to a different cofactor. On the other hand, the pathways may have evolved without the need for a thiol cofactor. In fact, it is not known if there is an endogenous cofactor. *In vivo*, deiodinase enzymes may not be regenerated by thiol cofactor (Kohrle *et al.*, 1993). Binding and deiodination may promote enzyme translocation and degradation (St. Germain and

Croteau, 1989). Therefore, the significance of *in vitro* deiodination with and without thiol cofactor is unknown.

Thus, the results confirmed that 0 mM and 10 mM DTT would be required for the microsomal assay to quantify the various TH metabolism pathways in the trout intestine. On one hand, T<sub>4</sub>cORD and T<sub>3</sub>ORD were inhibited by thiol cofactors, but on the other hand, T<sub>4</sub>ORD, T<sub>4</sub>IRD, and T<sub>3</sub>IRD functioned at 10 mM DTT. Therefore, assays were conducted at both 0 and 10 mM DTT in order to measure pathways that required thiol cofactor as well as pathways that were inhibited by thiol cofactor.

### Conclusions

TH metabolism assay conditions were defined for both the liver and the intestine. To standardize the experiments for comparisons in future experiments with these tissues, the microsomal assays were to be run under the following conditions: 0 mM and 10 mM DTT, 45 min incubation time, pH 7.2, and 0.16 nM T<sub>4</sub> substrate or 0.19 nM T<sub>3</sub> substrate.

The differences in TH metabolism between the liver and the intestine indicated different roles in the regulation of thyroid hormones. In the liver, TH metabolism pathways were activating (T<sub>4</sub>ORD) or inactivating (T<sub>3</sub>IRD) based on circulating T<sub>3</sub> levels (Eales *et al.*, 1993; Eales, 1995). Under normal, non-stressful conditions, the predominant pathway for maintaining homeostasis was T<sub>4</sub>ORD, as was seen in this study.

In the intestine, TH metabolism pathways were deactivating. The predominant pathways were T<sub>4</sub>cORD and IP production, leading to degradation of the TH substrate. However, many other pathways were active, such as T<sub>4</sub>ORD, T<sub>4</sub>IRD, T<sub>3</sub>ORD, and T<sub>3</sub>IRD. Together, these would deiodinate T<sub>4</sub> and T<sub>3</sub>, removing a potential source of biologically

active  $T_3$ . Since intestinal TH metabolism was greatest in the DI, this region may salvage  $I^-$  before loss through the excretion.




Figure 3-1. Diagram of regions of intestine sampled, including the pyloric caeca (PC), middle intestine (MI), and distal intestine (DI).




Figure 3-2. Methods for preparing microsomal fractions from liver and regions of the intestine (PC, MI, and DI) used in the *in vitro* TH metabolism assays.






**TH Metabolism Assays****TH Metabolism Analysis**

Figure 3-3. Procedures for TH metabolism assay and analysis of products formed. TH labeled with <sup>125</sup>I on the outer ring (\*T<sub>4</sub> or \*T<sub>3</sub>) allowed measurement of the products formed from various active TH metabolism pathways. The products were analyzed using LH-20 column separation to determine total TH metabolism, followed by protein precipitation with trichloroacetic acid (TCA) to determine TH iodoprotein (IP) production. In addition, the products, after adding methylmercaptoimidazole (MMI) were analyzed using high performance liquid chromatography (HPLC) to separate specific T<sub>4</sub> metabolites to determine active pathways for T<sub>4</sub> metabolism (T<sub>4</sub>ORD, T<sub>4</sub>IRD, T<sub>4</sub>cORD) or to separate specific T<sub>3</sub> metabolites to determine active pathways for T<sub>3</sub> metabolism (T<sub>3</sub>ORD, T<sub>3</sub>IRD).

## PATHWAYS



## HPLC




 $T_4$  SubstrateSpecific  $T_4$  metabolites $T_4$ ORD:  $*T_3$  peak $T_4$ IRD:  $*rT_3$  peak $T_4$ cORD:  $*I^-$  peak- $*T_3$  peak $T_3$  SubstrateSpecific  $T_3$  metabolites $T_3$ ORD:  $*I^-$  peak $T_3$ IRD:  $*T_2$  peak

Figure 3-4. Specific TH metabolism pathways and the representative HPLC radioactivity profiles demonstrating the specific TH metabolites determined from the area under the curve.




Figure 3-5. Rate of total T<sub>4</sub> metabolism (presumed \*I<sup>-</sup> and/or \*IP) at DTT concentrations of 0, 5, 10, 15, or 20 mM as determined by LH-20 column chromatography after \*T<sub>4</sub> incubation with liver (n=12), pyloric caeca (n=22), middle intestine (n=14), or distal intestine (n=25) microsomes. Activities were calculated as pmoles of T<sub>4</sub> converted to product per hour per milligram of microsomal protein ( $\pm$ s.e.). N.A. denotes not assayed. Asterisks indicate significant differences at  $p \leq 0.05$ .




Figure 3-6. T<sub>4</sub>cORD, T<sub>4</sub>ORD, and T<sub>4</sub>IRD activities at DTT concentrations of 0 mM (■) or 10 (□) mM as determined by HPLC separation of \*I<sub>1</sub>, \*T<sub>3</sub>, and \*rT<sub>3</sub> as well as IP production as determined by LH-20 column chromatography followed by TCA precipitation of \*IP after \*T<sub>4</sub> incubation with liver (n=6), pyloric caeca (n=10), middle intestine (n=3), or distal intestine (n=18) microsomes. Activities were calculated as pmoles of T<sub>4</sub> converted to product per hour per milligram of microsomal protein (±s.e.). N.A. denotes not assayed. N.D. denotes non-detectable. Asterisks indicate significant differences at p≤0.05.




Figure 3-7. Rate of total T<sub>3</sub> metabolism (presumed \*I and/or \*IP) at DTT concentrations of 0 or 10 mM as determined by LH-20 column chromatography after \*T<sub>3</sub> incubation with liver (n=21), pyloric caeca (n=7), middle intestine (n=0), or distal intestine (n=4) microsomes. Activities were calculated as pmoles of T<sub>3</sub> converted to product per hour per milligram of microsomal protein ( $\pm$ s.e.). N.A. denotes not assayed. Asterisks indicate significant differences at  $p \leq 0.05$




Figure 3-8. T<sub>3</sub>ORD and T<sub>3</sub>IRD activities at DTT concentrations of 0 (■) or 10 (□) mM as determined by HPLC separation of \*I<sup>-</sup> and \*T<sub>2</sub> as well as IP production as determined by LH-20 column chromatography followed by TCA precipitation of \*IP after \*T<sub>3</sub> incubation with liver (n=7), pyloric caeca (n=3), middle intestine (n=3), or distal intestine (n=4) microsomes. Activities were calculated as pmoles of T<sub>3</sub> converted to product per hour per milligram of microsomal protein (±s.e.). N.A. denotes not assayed. N.D. denotes non-detectable.




Figure 3-9. Rate of total T<sub>4</sub> metabolism (presumed \*I<sup>-</sup> and/or \*IP) at glutathione (GSH) concentrations of 0, 0.5, 1, 2, or 4 mM as determined by LH-20 column chromatography after \*T<sub>4</sub> incubation with liver (n=1), pyloric caeca (n=1), middle intestine (n=1), or distal intestine (n=1) microsomes. Activities were calculated as pmoles of T<sub>4</sub> converted to product per hour per milligram of microsomal protein. N.A. denotes not assayed.




Figure 3-10. Rate of total T<sub>4</sub> metabolism (presumed \*I<sup>-</sup> and/or \*IP) without DTT over a range of incubation times (30, 60, 75, 90, 105, or 120 min) as determined by LH-20 column chromatography followed by TCA precipitation of \*IP after \*T<sub>4</sub> incubation with liver (n=1), pyloric caeca (n=1), middle intestine (n=1), or distal intestine (n=1) microsomes. Activities were calculated as pmoles of T<sub>4</sub> converted to product per hour per milligram of microsomal protein. N.A. denotes not assayed.






Figure 3-11. Rate of total T<sub>4</sub> metabolism (presumed \*I<sup>-</sup> and/or \*IP) without DTT over a range of pH values (6.5, 7.0, 7.2, 7.5, 8.0, 8.8, or 9.5) as determined by LH-20 column chromatography after \*T<sub>4</sub> incubation with liver (n=1-2), pyloric caeca (n=1-6), middle intestine (n=1-5), or distal intestine (n=1-5) microsomes. Activities were calculated as pmoles of T<sub>4</sub> converted to product per hour per milligram of microsomal protein ( $\pm$ s.e.). N.A. denotes not assayed.

## LIVER




Figure 3-12. T<sub>4</sub>cORD, T<sub>4</sub>ORD, and T<sub>4</sub>IRD activities without DTT at pH of 7.2 (n=3), 8.0 (n=1), or 8.8 (n=2) as determined by HPLC separation of \*I<sup>-</sup>, \*T<sub>3</sub>, and \*rT<sub>3</sub> as well as IP production as determined by LH-20 column chromatography followed by TCA precipitation of \*IP after \*T<sub>4</sub> incubation with liver microsomes. Activities were calculated as pmoles of T<sub>4</sub> converted to product per hour per milligram of microsomal protein (±s.e.). N.A. denotes not assayed. N.D. denotes non-detectable.

## PYLORIC CAECA




Figure 3-13. T<sub>4</sub>cORD, T<sub>4</sub>ORD, and T<sub>4</sub>IRD activities without DTT at pH of 7.2 (n=3), 8.0 (n=4), 8.8 (n=4), or 9.4 (n=1) as determined by HPLC separation of \*I<sub>1</sub>, \*T<sub>3</sub>, and \*rT<sub>3</sub> as well as IP production as determined by LH-20 column chromatography followed by TCA precipitation of \*IP after \*T<sub>4</sub> incubation with pyloric caeca microsomes. Activities were calculated as pmoles of T<sub>4</sub> converted to product per hour per milligram of microsomal protein (±s.e.). N.D. denotes non-detectable.

## MIDDLE INTESTINE




Figure 3-14. T<sub>4</sub>cORD, T<sub>4</sub>ORD, and T<sub>4</sub>IRD activities without DTT at pH of 7.2 (n=5), 8.0 (n=4), 8.8 (n=2), or 9.4 (n=1) as determined by HPLC separation of \*I<sub>1</sub>, \*T<sub>3</sub>, and \*rT<sub>3</sub> as well as IP production as determined by LH-20 column chromatography followed by TCA precipitation of \*IP after \*T<sub>4</sub> incubation with middle intestine microsomes. Activities were calculated as pmoles of T<sub>4</sub> converted to product per hour per milligram of microsomal protein ( $\pm$ s.e.). N.D. denotes non-detectable.

## DISTAL INTESTINE




Figure 3-15. T<sub>4</sub>cORD, T<sub>4</sub>ORD, and T<sub>4</sub>IRD activities without DTT at pH of 7.2 (n=5), 8.0 (n=2), 8.8 (n=2), or 9.4 (n=1) as determined by HPLC separation of \*I<sup>-</sup>, \*T<sub>3</sub>, and \*rT<sub>3</sub> as well as IP production as determined by LH-20 column chromatography followed by TCA precipitation of \*IP after \*T<sub>4</sub> incubation with distal intestine microsomes. Activities were calculated as pmoles of T<sub>4</sub> converted to product per hour per milligram of microsomal protein (±s.e.). N.D. denotes non-detectable.




Figure 3-16. Rate of total T<sub>4</sub> metabolism (presumed \*I and/or \*IP) at DTT concentration of 10 mM over a range of pH 7.2, 8.0, or 8.8 as determined by LH-20 column chromatography after \*T<sub>4</sub> incubation with liver (n=1-2) or distal intestine (n=1) microsomes. Activities were calculated as pmoles of T<sub>4</sub> converted to product per hour per milligram of microsomal protein ( $\pm$  s.e.).


**LIVER**

Figure 3-17. T<sub>4</sub>cORD, T<sub>4</sub>ORD, and T<sub>4</sub>IRD activities at DTT concentration of 10 mM at pH of 7.2 (n=4) or 8.0 (n=3) as determined by HPLC separation of \*I<sup>-</sup>, \*T<sub>3</sub>, and \*rT<sub>3</sub> as well as IP production as determined by LH-20 column chromatography followed by TCA precipitation of \*IP after \*T<sub>4</sub> incubation with liver. Activities were calculated as pmoles of T<sub>4</sub> converted to product per hour per milligram of microsomal protein (±s.e.). N.A. denotes not assayed. N.D. denotes non-detectable.

## DISTAL INTESTINE




Figure 3-18. T<sub>4</sub>cORD, T<sub>4</sub>ORD, and T<sub>4</sub>IRD activities at DTT concentration of 10 mM at pH of 7.2 (n=1), 8.0 (n=1), or 8.8 (n=1) as determined by HPLC separation of \*I<sup>-</sup>, \*T<sub>3</sub>, and \*rT<sub>3</sub> as well as IP production as determined by LH-20 column chromatography followed by TCA precipitation of \*IP after \*T<sub>4</sub> incubation with distal intestine microsomes. Activities were calculated as pmoles of T<sub>4</sub> converted to product per hour per milligram of microsomal protein. N.D. denotes non-detectable.



## LIVER




Figure 3-19. T<sub>3</sub>ORD and T<sub>3</sub>IRD activities without DTT at pH of 7.2 (n=1-3), 8.0 (n=1), or 8.8 (n=3) as determined by HPLC separation of \*I<sup>-</sup> and \*T<sub>2</sub>, as well as IP production as determined by LH-20 column chromatography followed by TCA precipitation of \*IP after \*T<sub>3</sub> incubation with liver microsomes. Activities were calculated as pmoles of T<sub>3</sub> converted to product per hour per milligram of microsomal protein ( $\pm$  s.e.). N.D. denotes non-detectable.

## PYLORIC CAECA




Figure 3-20. T<sub>3</sub>ORD and T<sub>3</sub>IRD activities without DTT at pH of 7.2 (n=4), 8.0 (n=1), or 8.8 (n=2) as determined by HPLC separation of \*I<sup>-</sup> and \*T<sub>2</sub>, as well as IP production as determined by LH-20 column chromatography followed by TCA precipitation of \*IP after \*T<sub>3</sub> incubation with pyloric caeca microsomes. Activities were calculated as pmoles of T<sub>3</sub> converted to product per hour per milligram of microsomal protein (±s.e.). N.D. denotes non-detectable.

## MIDDLE INTESTINE




Figure 3-21. T<sub>3</sub>ORD and T<sub>3</sub>IRD activities without DTT at pH of 7.2 (n=1), 8.0 (n=1), or 8.8 (n=1) as determined by HPLC separation of \*I<sup>-</sup> and \*T<sub>2</sub>, as well as IP production as determined by LH-20 column chromatography followed by TCA precipitation of \*IP after \*T<sub>3</sub> incubation with middle intestine microsomes. Activities were calculated as pmoles of T<sub>3</sub> converted to product per hour per milligram of microsomal protein (±s.e.). N.A. denotes not assayed. N.D. denotes non-detectable.

## DISTAL INTESTINE




Figure 3-22. T<sub>3</sub>ORD and T<sub>3</sub>IRD activities without DTT at pH of 7.2 (n=3), 8.0 (n=1), or 8.8 (n=2) as determined by HPLC separation of \*I<sup>-</sup> and \*T<sub>2</sub>, as well as IP production as determined by LH-20 column chromatography followed by TCA precipitation of \*IP after \*T<sub>3</sub> incubation with distal intestine microsomes. Activities were calculated as pmoles of T<sub>3</sub> converted to product per hour per milligram of microsomal protein ( $\pm$ s.e.). N.A. denotes not assayed. N.D. denotes non-detectable.

## LIVER




Figure 3-23. T<sub>3</sub>ORD and T<sub>3</sub>IRD activities at DTT concentration of 10 mM at pH of 7.2 (n=1), 8.0 (n=1), or 8.8 (n=1) as determined by HPLC separation of \*I<sup>-</sup> and \*T<sub>2</sub>, as well as IP production as determined by LH-20 column chromatography followed by TCA precipitation of \*IP after \*T<sub>3</sub> incubation with liver microsomes. Activities were calculated as pmoles of T<sub>3</sub> converted to product per hour per milligram of microsomal protein. N.D. denotes non-detectable.

## PYLORIC CAECA




Figure 3-24. T<sub>3</sub>ORD and T<sub>3</sub>IRD activities at DTT concentration of 10 mM at pH of 7.2 (n=3), 8.0 (n=1), or 8.8 (n=1) as determined by HPLC separation of \*I<sup>-</sup> and \*T<sub>2</sub>, as well as IP production as determined by LH-20 column chromatography followed by TCA precipitation of \*IP after \*T<sub>3</sub> incubation with pyloric caeca microsomes. Activities were calculated as pmoles of T<sub>3</sub> converted to product per hour per milligram of microsomal protein ( $\pm$ s.e.). N.D. denotes non-detectable.

## DISTAL INTESTINE




Figure 3-25. T<sub>3</sub>ORD and T<sub>3</sub>IRD activities at DTT concentration of 10 mM at pH of 7.2 (n=3), 8.0 (n=1), or 8.8 (n=1) as determined by HPLC separation of \*I<sup>-</sup> and \*T<sub>2</sub>, as well as IP production as determined by LH-20 column chromatography followed by TCA precipitation of \*IP after \*T<sub>3</sub> incubation with distal intestine microsomes. Activities were calculated as pmoles of T<sub>3</sub> converted to product per hour per milligram of microsomal protein. N.D. denotes non-detectable.




Figure 3-26. Rate of T<sub>4</sub>IP production at DTT concentrations of 0 (■) or 20 (□) mM as determined by LH-20 column chromatography followed by TCA precipitation of \*IP after \*T<sub>4</sub> incubation with 0.2 mg/mL bovine serum albumin (BSA; n=4). Activities were calculated as pmoles of T<sub>4</sub> converted to IP per hour per milligram of BSA protein (±s.e.).



## Chapter 4

### Effects of Dietary Thyroid Hormone Challenges ( $T_4$ and $T_3$ ) on Intestinal Metabolism of Thyroid Hormones in Rainbow Trout

#### Introduction

The basic pathways for thyroid hormone (TH) metabolism include deiodination, conjugation, deamination, ether-link cleavage, and covalent bonding to proteins (DiStefano, 1988; Hennemann, 1996). Of these, deiodination has been investigated the most due to its role in peripheral regulation of  $T_3$  available to bind to receptors, or thyroidal status, in teleost fish (MacLatchy and Eales, 1993; Eales *et al.*, 1993; Eales, 1995).

*In vitro* liver, kidney, gill, and brain deiodination of TH has been described for rainbow trout (MacLatchy and Eales, 1992; Fines *et al.*, 1999). The liver, which is a main regulator of thyroidal status in rainbow trout, has also been investigated under various physiological states such as when circulating TH have been increased within physiological levels by feeding TH-supplemented food. With the administration of a TH challenge through the diet, the deiodination pathways were altered in the liver, favoring degradation of the hormones into inactive forms (Eales and Finnson, 1991; Sweeting and Eales, 1992; MacLatchy and Eales, 1993). Thus, liver studies have demonstrated autoregulation of  $T_3$  homeostasis in a peripheral tissue.

In the previous chapter, the intestine was shown to metabolize TH. This in itself does not indicate a regulatory role of the intestine, especially if the intestine serves as an excretory pathway only. This study further investigated the phenomenon of peripheral

regulation by considering another tissue, the intestine, that would initially be exposed to the increased levels of TH before the liver. The intestine would be exposed to the heaviest onslaught of TH through direct contact with supplemented food. If intestinal TH metabolism pathways were regulated in response to various levels of TH, the intestine might also control the amounts of TH entering the circulation via the intestine. Thus, the intestine may regulate thyroidal status when faced with a persistent dietary load of TH that could increase plasma TH levels within physiological ranges.

To investigate the potential role of the intestine in regulating thyroidal status, TH metabolism pathways were monitored during dietary TH challenges. This was done by feeding TH ( $T_4$  treatment and  $T_3$  treatment) in the diet over a period of 7 days, and then measuring changes in plasma TH levels. A dietary  $T_3$  challenge is known to increase plasma  $T_3$  levels within physiological ranges (Higgs *et al.*, 1979; Higgs *et al.*, 1982; Cyr and Eales, 1990; Eales *et al.*, 1990; Eales and Finnson, 1991; Sweeting and Eales, 1992b; Fines *et al.*, 1999). In the present study, TH metabolism pathways in the intestinal regions (pyloric caeca, PC; middle intestine, MI; distal intestine, DI) were compared among controls,  $T_4$ -treated, and  $T_3$ -treated fish to see if pathways were modulated under dietary TH challenges. Thus, this chapter reports on investigations of the regulation of intestinal metabolism during a physiological challenge, and its possible role in regulation of thyroidal status in the rainbow trout.

## **Materials and Methods**

### **Fish Maintenance**

Rainbow trout were obtained from Rockwood Hatchery (Gunton, Manitoba) and held at the University of Manitoba in running, aerated, dechlorinated, City of Winnipeg water at 12°C and under a 12L:12D photocycle. Sexually immature trout (160-351 g; mean =  $260.5 \pm 5.7$ ) were placed in 9 tanks (60-cm x 60-cm x 60-cm) with 15 trout per tank and acclimated for 2 weeks while fed commercial trout food diet (3.2 mm, Martin Mills) once daily at 1% of body mass.

### **Dietary T<sub>4</sub> and T<sub>3</sub> challenges**

For the next 7 days, trout were fed either food sprayed with methanol alone (control; 3 tanks), food sprayed with T<sub>4</sub> dissolved in methanol to provide 12 ppm T<sub>4</sub> (T<sub>4</sub> treatment; 3 tanks), or food sprayed with T<sub>3</sub> dissolved in methanol to provide 12 ppm T<sub>3</sub> (T<sub>3</sub> treatment; 3 tanks).

### **Sampling**

At Day 0 (1 day before treatment), Day 2, Day 4, and Day 7, 3 trout per tank were removed for sampling (n=9 per treatment per sampling day). Trout were anesthetized with tricaine methanesulfonate (MS222, 0.067g/L, Syndel Labs), killed by a blow to the head, bled from caudal blood vessels using heparinized syringes, and the liver, PC, MI, and DI were removed. Each tissue was frozen in liquid nitrogen and stored at -76°C. Blood samples were centrifuged at 17,000 g for 5 min, following which the plasma was removed and stored in Eppendorf tubes at -76°C until analysis.

### **Plasma T<sub>4</sub> and T<sub>3</sub> levels**

Plasma T<sub>4</sub> and T<sub>3</sub> levels were determined for control, T<sub>4</sub> treatment, and T<sub>3</sub> treatment for Days 0, 2, and 7 using solid-phase radioimmunoassays (RIA) modified from Brown and Eales (1977), Omeljaniuk *et al.* (1984), and Kohel *et al.* (2001). Separate T<sub>4</sub> and T<sub>3</sub> RIA were performed on G-25 Sephadex columns. The samples were diluted in 100  $\mu$ L buffer (T<sub>4</sub> RIA barbital buffer: 12.15 g barbital per L H<sub>2</sub>O, pH 8.6; T<sub>3</sub> RIA phosphate buffer: 26.81 g Na<sub>2</sub>HPO<sub>4</sub>·7 H<sub>2</sub>O, 11.17 g Na<sub>2</sub>EDTA per 1 L H<sub>2</sub>O, pH 7.2)/8-anilo-1-naphthelene sulfonic acid (ANS; 1 mg ANS/1 mL buffer). 100  $\mu$ L \*T<sub>4</sub> or \*T<sub>3</sub> (approximately 20,000 cpm/100  $\mu$ L buffer) was incubated with the plasma sample overnight. The free iodide (I<sup>-</sup>) was eluted with 3 mL buffer. The TH was eluted with 1 mL T<sub>4</sub> antibody (Sigma; diluted in barbital buffer) or 1 mL T<sub>3</sub> antibody (Sigma; diluted in phosphate buffer) and counted in the gamma counter.

### **Microsomal fraction preparations**

Microsomes were prepared from individual liver, PC, MI, and DI tissues following the procedure of Shields and Eales (1986), as described in Chapter 3.

### **TH metabolism assay**

The TH metabolism assay was performed on samples collected from Days 0, 2, and 7. The assay was based on the microsomal TH deiodinase assay methods of Shields and Eales (1986) and Frith and Eales (1996). Details of the modified procedures were described in Chapter 3. Each TH metabolism assay was run in duplicate under the following conditions: 30 min preincubation in a shaking water bath (12°C, 140 rpm, darkness), 0 mM or 10 mM DTT cofactor, pH 7.2, and 45 min incubation time with either

0.16 nM T<sub>4</sub> or 0.19 nM T<sub>3</sub> substrate and the corresponding radioactive TH (\*TH; approximately 100,000 cpm/sample).

### **TH metabolism analysis**

The incubate was separated into two aliquots. One aliquot was used to determine specific TH metabolism products (T<sub>4</sub>cORD, T<sub>4</sub>ORD, and T<sub>4</sub>IRD; T<sub>3</sub>ORD and T<sub>3</sub>IRD) by using HPLC separation as described in Chapter 3 (Figure 3-3 and 3-4). The other aliquot was used to determine IP production (T<sub>4</sub>IP or T<sub>3</sub>IP) by using LH-20 column separation and protein precipitation as described in Chapter 3 (Figure 3-3). Activities were expressed as picomoles of T<sub>4</sub> or T<sub>3</sub> converted to product per hour per milligram of microsomal protein. Detailed description of TH metabolism products (Figure 1-2) and analyses (Figure 3-4) are found in Chapter 3.

### **Statistics**

Using the SPSS statistics package, univariate analysis of variance (ANOVA) was used to compare plasma T<sub>4</sub> means for the effects of treatments (C, T<sub>4</sub> TRT, and T<sub>3</sub> TRT) and to compare plasma T<sub>3</sub> means for the effects of treatments. Each test was performed for individual days. These were followed by LSD post hoc multiple comparisons to determine significant differences among treatments. Results were determined statistically significant at  $p \leq 0.05$ .

Linear regression analyses were computed to compare TH metabolism activities for the effects of treatments (C, T<sub>4</sub> TRT, and T<sub>3</sub> TRT) and time (Day 0, 2, and 7) for both 0 mM and 10 mM DTT, individually. Tukey's Multiple Comparison was used to compute confidence intervals and determine significant differences among treatments

over time (see Appendix IX for equations used). Results were determined statistically significant at  $p \leq 0.05$ .

## Results

### Effects of dietary $T_4$ and $T_3$ challenges on plasma $T_4$ and $T_3$ levels

Neither dietary  $T_4$  nor  $T_3$  challenges significantly changed plasma  $T_4$  levels by Day 7 (Figure 4-1;  $F=0.462$ , d.f.=2,  $p=0.635$ ).

A dietary  $T_3$  challenge significantly increased plasma  $T_3$  levels from 0.4 ng/mL on Day 0 to 3.1 ng/mL on Day 2 ( $F=8.043$ , d.f.=2,  $p=0.004$ ), with a further increase to 5.1 ng/mL on Day 7 ( $F=25.303$ , d.f.=2,  $p=0.000$ ).  $T_3$  treatment did not, however, influence plasma  $T_4$  levels ( $F=25.303$ , d.f.=2,  $p=0.540$ ).

### Effects of dietary $T_4$ and $T_3$ challenges on TH metabolism pathways

#### *$T_4$ cORD*

At all times and DTT concentrations,  $T_4$ cORD was low or non-detectable in the liver. Without DTT, the highest levels of  $T_4$ cORD activity measured in controls occurred on Day 0 (0.17 pmol  $T_4$  converted/hr/mg protein; Figure 4-2). With DTT,  $T_4$ cORD activity reached 0.24 pmol  $T_4$  converted/hr/mg protein. No significant changes resulted from dietary  $T_4$  or  $T_3$  challenges.

In the intestine, the highest levels of  $T_4$ cORD activity were measured on Day 0. Of the intestinal regions studied, the DI exhibited the highest levels of  $T_4$ cORD activity throughout the time course (up to 2.3 pmol  $T_4$  converted/hr/mg protein). However, only the MI exhibited significant changes in activity at Day 7 due to dietary TH challenges ( $F=1.734$ , d.f.=8  $p \leq 0.05$ ). At this time,  $T_3$  treatment increased  $T_4$ cORD activity to 0.68

pmol T<sub>4</sub> converted/hr/mg protein in comparison to controls (0.09 pmol T<sub>4</sub> converted/hr/mg protein). DI exhibited a similar pattern, however, the changes were not significant.

### ***T<sub>4</sub>ORD***

Liver T<sub>4</sub>ORD activity required DTT (Figure 4-3). By Day 7, a dietary T<sub>3</sub> challenge significantly decreased T<sub>4</sub>ORD activity (0.03 pmol T<sub>4</sub> converted/hr/mg protein) from control levels (0.18 pmol T<sub>4</sub> converted/hr/mg protein;  $F=1.400$ , d.f.=8,  $p\leq 0.05$ ). A dietary T<sub>4</sub> challenge did not affect T<sub>4</sub>ORD activity.

Intestinal levels of T<sub>4</sub>ORD activity were much lower than in the liver. The T<sub>4</sub>ORD activity with DTT was not prominent in the intestine, except in the MI at Day 0. At Day 0, MI T<sub>4</sub>ORD activity was higher with DTT (0.02 pmol T<sub>4</sub> converted/hr/mg protein) than without DTT (non-detectable). Otherwise, T<sub>4</sub>ORD activity levels were low with or without DTT. At Day 7, only activity in the DI was affected by dietary TH challenges. T<sub>4</sub>ORD activity was significantly higher after seven days of either T<sub>4</sub> or T<sub>3</sub> treatment (0.08 and 0.10 pmol T<sub>4</sub> converted/hr/mg protein, respectively;  $F=1.779$ , d.f.=8,  $p\leq 0.05$ ). The increased T<sub>4</sub>ORD activity did not require DTT.

### ***T<sub>4</sub>IRD***

In the liver, highest levels were measured at Day 0 in controls (0.09 pmol T<sub>4</sub> converted/hr/mg protein; Figure 4-4). T<sub>4</sub>IRD activity increased significantly with T<sub>3</sub> treatment after 7 days to 0.04 pmol T<sub>4</sub> converted/hr/mg protein from 0.002 pmol T<sub>4</sub> converted/hr/mg protein in controls ( $F=3.751$ , d.f.=8,  $p\leq 0.05$ ).

A similar pattern of increased T<sub>4</sub>IRD activity with T<sub>3</sub> treatment at Day 7 was seen in the PC (0.03 pmol T<sub>4</sub> converted/hr/mg protein, T<sub>3</sub> treatment; 0.001 pmol T<sub>4</sub>

converted/hr/mg protein, control;  $F=2.564$ , d.f.=8,  $p\leq 0.05$ ) and the MI (0.04 pmol  $T_4$  converted/hr/mg protein,  $T_3$  treatment; 0.01 pmol  $T_4$  converted/hr/mg protein, control;  $F=1.150$ , d.f.=8,  $p\leq 0.05$ ). In these intestinal regions,  $T_4$ IRD activity required DTT. In the DI, however,  $T_4$ IRD activity was elevated for all conditions at Day 7 (range: 0.06-0.10 pmol  $T_4$  converted/hr/mg protein). The increased  $T_4$ IRD activity did not require DTT.

### ***T<sub>4</sub>IP***

For the liver, levels of  $T_4$ IP production were low without and with DTT (range over 7 days: 0.002-0.01 pmol  $T_4$  converted/hr/mg protein), and they did not change significantly at Day 7 with dietary TH challenges (Figure 4-5).

For intestinal regions,  $T_4$ IP production was highest at Day 0, with the highest activity in the DI (0.06 pmol  $T_4$  converted/hr/mg protein). Yet,  $T_4$ IP was low by Day 7.  $T_4$ IP production was greater without DTT for all regions of the intestine. Only the MI significantly increased  $T_4$ IP production to 0.02 pmol  $T_4$  converted/hr/mg protein after a dietary  $T_3$  challenge by Day 7 from control levels of 0.006 pmol  $T_4$  converted/hr/mg protein ( $F=2.354$ , d.f.=8,  $p\leq 0.05$ ). A dietary  $T_4$  challenge had no effect.

### ***T<sub>3</sub>ORD***

In the liver,  $T_3$ ORD activity was low or non-detectable at all days sampled and at all levels of DTT (range over 7 days: 0.002-0.02 pmol  $T_3$  converted/hr/mg protein; Figure 4-6).

In intestinal tissues,  $T_3$ ORD activity was also low, and highest levels were at Day 0 in controls for the PC and the DI (up to 0.6 pmol  $T_3$  converted/hr/mg protein). In the MI, activity significantly increased at Day 7 with  $T_3$  treatment (0.19 pmol  $T_3$



converted/hr/mg protein;  $F=1.238$ , d.f.=8,  $p\leq 0.05$ ).  $T_3$ ORD activity did not require DTT in the intestine.

### ***T<sub>3</sub>IRD***

In the liver,  $T_3$ IRD activity was highest with DTT at Day 0 in controls (0.06 pmol  $T_3$  converted/hr/mg protein; Figure 4-7).  $T_3$ IRD activity was low except for  $T_3$  treatment at Day 2 and 7, where activity increased to 0.02 pmol  $T_3$  converted/hr/mg protein.  $T_3$ IRD activity required DTT.

In the intestine,  $T_3$ IRD activity was also highest at Day 0 in controls (up to 0.09 pmol  $T_3$  converted/hr/mg protein for DI). Otherwise,  $T_3$ IRD activity was low or non-detectable except in the DI. By Day 7, a dietary  $T_3$  challenge significantly increased  $T_3$ IRD activity in the DI to 0.04 pmol  $T_3$  converted/hr/mg protein from 0.004 pmol  $T_3$  converted/hr/mg protein in controls ( $F=2.143$ , d.f.=8,  $p\leq 0.05$ ). The  $T_3$ IRD activity required DTT.

### ***T<sub>3</sub>IP***

In the liver,  $T_3$ IP production was very low to non-detectable (Figure 4-8).

In the intestine,  $T_3$ IP production was highest at Day 0 in controls, especially for the PC and the DI (0.1 pmol  $T_3$  converted/hr/mg protein). After Day 0,  $T_3$ IP production was low or non-detectable, except in the DI at Day 2.  $T_3$ IP production declined to very low or non-detectable levels by Day 7. For all regions of the intestine, DTT was not required for  $T_3$ IP production.

## Discussion

This chapter set out to describe alterations in intestinal TH metabolism under physiological TH challenges. Using the microsomal TH metabolism assay developed in Chapter 3, active TH metabolism pathways were measured during dietary T<sub>4</sub> and T<sub>3</sub> challenges to determine if the intestine could regulate TH metabolism which would possibly control the TH entering into circulation.

### Effects of dietary T<sub>4</sub> and T<sub>3</sub> challenges on plasma T<sub>4</sub> and T<sub>3</sub> levels

A dietary T<sub>4</sub> challenge did not elevate plasma T<sub>4</sub>, yet a dietary T<sub>3</sub> challenge significantly elevated plasma T<sub>3</sub>. The purpose of feeding TH over a period of 7 days was to create physiological T<sub>4</sub> or T<sub>3</sub> challenges and to determine their effects on compensatory TH metabolism in intestinal tissues. A dietary TH challenge can alter the physiological condition of the trout (Higgs *et al.*, 1979), which influences regulation of TH (Eales *et al.*, 1993). For this study, the method of assessing the physiological challenge on the trout thyroidal status was to measure plasma TH levels. It was anticipated that a dietary TH challenge would elevate plasma TH levels. However, only a dietary T<sub>3</sub> challenge affected plasma T<sub>3</sub> levels.

It is possible that a dietary T<sub>4</sub> challenge was not a physiological challenge to the trout thyroidal status, especially if the stable plasma T<sub>4</sub> levels represented a lack of absorption of T<sub>4</sub> from the intestine. Previous studies indicated that T<sub>4</sub>, in comparison to T<sub>3</sub>, is poorly absorbed from the intestine, however these conclusions are based on indirect measurements such as plasma TH levels (Whitaker and Eales, 1993) or by measuring physiological parameters such as growth, food consumption, and food conversion which indicated that dietary T<sub>3</sub> has a greater effect than dietary T<sub>4</sub> (Higgs *et al.*, 1979). The

assessment of TH as a physiological challenge is incomplete without direct measurements of absorption or clearance pathways for TH.

However, the significance of a dietary  $T_4$  challenge as a physiological challenge to thyroidal status should not be dismissed based on plasma  $T_4$  levels. A lack of a significant increase in plasma  $T_4$  may be an indicator of the sensitivity of plasma  $T_4$  control. In trout,  $T_4$  is regulated independently from  $T_3$  (Eales and Himick, 1991; Eales *et al.*, 1993; Eales and Brown, 1993; Eales, 1995).  $T_4$  is the main TH released from the thyroid (Eales and Brown, 1993). Secretion and its resultant plasma  $T_4$  levels are regulated by negative feedback at the hypothalamus (Peter 1971, 1972) and the pituitary (Baker 1965, 1969a, b; Sage 1968; Sage and Bromage, 1970). On the other hand,  $T_3$  availability is peripherally regulated by tissue deiodination, and this is dependent on tissue  $T_3$  demand, not on  $T_4$  availability (MacLachy and Eales, 1993; Eales *et al.*, 1993). Independent regulation of TH was further supported by this experiment. A dietary  $T_4$  challenge did not affect plasma  $T_3$  levels, and likewise, a dietary  $T_3$  challenge did not affect plasma  $T_4$  levels. Thus, an increase in plasma  $T_4$  due to absorption from the intestine could result in a compensatory decrease in thyroidal  $T_4$  output. Unless the rate of absorption from the intestine and uptake into systemic circulation surpasses the thyroid's capacity to reduce  $T_4$  output (along with systemic clearance rates), plasma  $T_4$  levels may not be a reliable indicator of the resulting physiological condition following a dietary, or any,  $T_4$  challenge.

A dietary  $T_3$  challenge resulted in increased plasma  $T_3$  levels. Dietary  $T_3$  challenges have been shown to alter physiological states of coho salmon (Higgs *et al.*, 1979). Fish growth, food consumption, and food conversion were altered with a range of

dietary  $T_3$  challenges (20-500 ppm). In addition, circulating  $T_3$ , regardless of source, altered TH metabolism pathways in the liver to maintain  $T_3$  homeostasis (Eales *et al.*, 1993). Increased  $T_3$  decreased hepatic  $T_4$ ORD (Eales *et al.*, 1990) and increased hepatic  $T_4$ IRD (Sweeting and Eales, 1992b) and  $T_3$ IRD (MacLatchy and Eales, 1993). Thus, a dietary  $T_3$  challenge that increases plasma  $T_3$  levels is a physiological challenge to thyroidal status.

Overall, a dietary  $T_3$  challenge was a physiological challenge to thyroidal status as demonstrated by increased plasma  $T_3$  levels. A dietary  $T_4$  challenge may have resulted in a physiological challenge as well. However, plasma  $T_4$  levels were not a good indicator. The consistent dietary TH challenge of 12 ppm for both  $T_4$  and  $T_3$  allowed the intestine's role in regulating TH through TH metabolism pathways to be compared for each TH.

#### **Effects of dietary $T_4$ and $T_3$ challenges on hepatic TH metabolism**

In liver,  $T_3$  treatment decreased  $T_4$ ORD, increased  $T_4$ IRD, and increased  $T_3$ IRD.  $T_4$  treatment did not affect TH metabolism pathways (Figure 4-9). All pathways in the liver required DTT as a cofactor.

$T_4$ ORD was the main metabolism pathway affected by dietary TH challenges. With  $T_3$  treatment, plasma  $T_3$  levels were elevated. MacLatchy and Eales (1993) have shown that the liver is sensitive to circulating levels of  $T_3$ . With enough biologically active  $T_3$  available in circulation, the liver decreases deiodination pathways converting  $T_4$  to  $T_3$ . Hence in the present experiment, the liver decreased  $T_4$ ORD by Day 7. A dietary  $T_4$  challenge did not affect  $T_4$ ORD, showing that  $T_3$ , not  $T_4$ , influences peripheral regulation of  $T_3$  availability through modulation of peripheral deiodination of  $T_4$  to  $T_3$ .

In addition to reducing production of biologically active TH, this experiment showed that elevated plasma  $T_3$  increased liver  $T_4$ IRD activity. With  $T_3$  treatment, plasma  $T_3$  was elevated, and the liver did not convert more  $T_4$  to biologically active  $T_3$ .  $T_4$ IRD removed the substrate  $T_4$ , preventing the synthesis of more  $T_3$ .

### **Effects of dietary $T_4$ and $T_3$ challenges on intestinal TH metabolism**

All areas of the intestine differed from liver in that DTT as a cofactor was not required, except for  $T_4$ IRD and  $T_3$ IRD in some regions. In addition,  $T_4$ cORD,  $T_4$ IP,  $T_3$ IP production were greater in the intestine than in the liver. Of the regions of the intestine tested, TH metabolism pathways in the MI and the DI were the most active, but different TH metabolism pathways were active for these two sites. The MI and the DI were the main regions of the intestine that responded to dietary TH challenges by altering activity of TH metabolism pathways. The DI was the region of the intestine that exhibited the highest TH metabolism. Thus, TH metabolism pathways in the MI and the DI are discussed further.

### **Middle intestine**

By Day 7, the MI responded to a dietary  $T_3$  challenge by increasing  $T_4$ cORD,  $T_4$ IRD,  $T_4$ IP, and  $T_3$ ORD pathways (Figure 4-10). Only  $T_4$ IRD required DTT.

All of the TH metabolism pathways in the MI increased by  $T_3$  treatment were "inhibitory" or deactivating in that  $T_3$  was not formed as a result of increased activity of the pathways. Thus, the MI responded to a dietary  $T_3$  challenge by removing the  $T_4$  substrate, through  $T_4$ cORD,  $T_4$ IRD, and  $T_4$ IP pathways, or by removing the active hormone  $T_3$ , through  $T_3$ ORD pathways. Except in the cases of  $T_4$ IRD and  $T_3$ ORD, the pathways did not form another iodothyronine which could have biological properties in

the intestine. Thus, the MI was sensitive to dietary  $T_3$  levels, and it prevented the formation of new  $T_3$ .

### **Distal intestine**

The DI increased  $T_4$ ORD in response to a dietary  $T_4$  challenge. The DI increased  $T_4$ ORD, and  $T_3$ IRD in response to a dietary  $T_3$  challenge (Figure 4-11). Only  $T_3$ IRD required DTT.

The main pathways active in the DI, regardless of treatment, were  $T_4$ cORD and  $T_4$ IRD. This and other active TH metabolism pathways deiodinated both  $T_4$  and  $T_3$ . The DI TH metabolism pathways degraded the  $T_4$  substrate, perhaps to salvage iodide before loss through excretion.  $T_4$ cORD and  $T_4$ IRD may explain why less  $T_4$  than  $T_3$  appeared in the plasma, if the hormone was degraded before it could enter circulation. With  $T_3$  treatment,  $T_4$ ORD and  $T_3$ IRD increased.  $T_4$ ORD was also induced with  $T_4$  treatment. This pathway would convert  $T_4$  to active  $T_3$ . However, with  $T_3$ IRD also active, the  $T_3$  produced would be deiodinated. Thus, the process overall would inactivate and degrade TH.

Initially, TH metabolism was greatest in DI, but mainly in the controls. Since this was before treatment began and the fish were acclimated for 2 weeks, all fish should be homogenous, but control fish had higher TH metabolism. It appears that increased TH metabolism in the intestine at Day 0 represented an acute response to initial sampling. Control fish were sampled first. Thus, the stress response of elevated TH metabolism was not evident in subsequent sampling with other groups on Day 0 or on other sampling days. The fish adjusted to the disturbance, and elevated TH metabolism was not observed in controls after Day 0. This suggested that acute responses of TH metabolism pathways

in the intestine can be mediated through a stress response. Another stressor, the physical disturbance of transporting fish, is known to temporarily depress thyroidal status in rainbow trout (Johnston *et al.*, 1996). The stressor decreased hepatic production of biologically active  $T_3$  by decreasing  $T_4$ ORD activity. At the same time, hepatic degradation of  $T_4$  and  $T_3$  was increased by increasing both  $T_4$ IRD and  $T_3$ IRD activity.

For all regions of the intestine under normal conditions, the overall level of TH metabolism was lower than the liver, since  $T_4$ ORD activity in the liver was much more active than in the intestine. Unlike the liver, many different TH metabolisms pathways were active in the intestine, most of which would degrade  $T_4$  and  $T_3$ . With dietary TH challenges, the activities of the degradatory pathways were increased. The only other study on the effects of a dietary  $T_3$  challenge on intestinal metabolism in fish was conducted on sturgeon (Plohman *et al.*, 2002). In the sturgeon, feeding 12 ppm  $T_3$  did not induce  $T_3$  metabolism, and neither hepatic nor intestinal  $T_3$ IRD pathways were increased.

## **Conclusions**

The intestine, specifically the MI and DI, moderated influxes of TH. It responded to increased dietary  $T_3$  by degrading  $T_3$  or preventing the formation of new  $T_3$ , especially in the MI. The DI prevented the increase of  $T_4$  into circulation, despite the high level of this hormone in the diet. The DI, in addition to responding to the presence of  $T_4$ , responded to an increase in dietary  $T_3$  by degrading the hormones, possibly to salvage I before loss through excretion.




Figure 4-1. Plasma T<sub>4</sub> (■) and T<sub>3</sub> (□) levels for control (C, n=9), T<sub>4</sub> treatment (T<sub>4</sub>, n=9), and T<sub>3</sub> treatment (T<sub>3</sub>, n=9) over 0, 2, and 7 days of dietary TH challenges. Bars represent means ( $\pm$  s.e.). Asterisks indicate significant differences at  $p \leq 0.05$  in T<sub>4</sub> or T<sub>3</sub> levels between treated and control fish at that day.






Figure 4-2. Rate of microsomal T<sub>4</sub>cORD activity for control (C), T<sub>4</sub> treatment (T<sub>4</sub>), and T<sub>3</sub> treatment (T<sub>3</sub>) over 0, 2, and 7 days of dietary TH challenge. Activity was determined by HPLC separation of \*T<sub>4</sub> metabolism products after incubation with liver (n=3-9), pyloric caeca (n=3-9), middle intestine (n=3-9), and distal intestine (n=3-9) at DTT concentrations of 0 mM (■) or 10 mM (□). Bars represent means (± s.e.). Asterisks indicate significant differences at  $p \leq 0.05$  in activity between treated and control fish at that day. ND denotes non-detectable.




Figure 4-3. Rate of microsomal T<sub>4</sub>ORD activity for control (C), T<sub>4</sub> treatment (T<sub>4</sub>), and T<sub>3</sub> treatment (T<sub>3</sub>) over 0, 2, and 7 days of dietary TH challenges. Activity was determined by HPLC separation of \*T<sub>4</sub> metabolism products after incubation with liver (n=3-9), pyloric caeca (n=3-9), middle intestine (n=3-9), and distal intestine (n=3-9) at DTT concentrations of 0 mM (■) or 10 mM (□). Bars represent means (± s.e.). Asterisks indicate significant differences at  $p \leq 0.05$  in activity between treated and control fish at that day. ND denotes non-detectable.




Figure 4-4. Rate of microsomal T<sub>4</sub>IRD activity for control (C), T<sub>4</sub> treatment (T<sub>4</sub>), and T<sub>3</sub> treatment (T<sub>3</sub>) over 0, 2, and 7 days of dietary TH challenges. Activity was determined by HPLC separation of \*T<sub>4</sub> metabolism products after incubation with liver (n=3-9), pyloric caeca (n=3-9), middle intestine (n=3-9), and distal intestine (n=3-9) at DTT concentrations of 0 mM (■) or 10 mM (□). Bars represent means (± s.e.). Asterisks indicate significant differences at  $p \leq 0.05$  in activity between treated and control fish at that day. ND denotes non-detectable.




Figure 4-5. Rate of microsomal T<sub>4</sub>IP production for control (C), T<sub>4</sub> treatment (T<sub>4</sub>), and T<sub>3</sub> treatment (T<sub>3</sub>) over 0, 2, and 7 days of dietary TH challenges. Activity was determined by HPLC separation of \*T<sub>4</sub> metabolism products after incubation with liver (n=3-9), pyloric caeca (n=3-9), middle intestine (n=3-9), and distal intestine (n=3-9) at DTT concentrations of 0 mM (■) or 10 mM (□). Bars represent means (± s.e.). Asterisks indicate significant differences at  $p \leq 0.05$  in activity between treated and control fish at that day.




Figure 4-6. Rate of microsomal T<sub>3</sub>ORD activity for control (C), T<sub>4</sub> treatment (T<sub>4</sub>), and T<sub>3</sub> treatment (T<sub>3</sub>) over 0, 2, and 7 days of dietary TH challenges. Activity was determined by HPLC separation of \*T<sub>3</sub> metabolism products after incubation with liver (n=3-9), pyloric caeca (n=3-9), middle intestine (n=3-9), and distal intestine (n=3-9) at DTT concentrations of 0 mM (■) or 10 mM (□). Bars represent means (± s.e.). Asterisks indicate significant differences at  $p \leq 0.05$  in activity between treated and control fish at that day. ND denotes non-detectable.




Figure 4-7. Rate of microsomal T<sub>3</sub>IRD activity for control (C), T<sub>4</sub> treatment (T<sub>4</sub>), and T<sub>3</sub> treatment (T<sub>3</sub>) over 0, 2, and 7 days of dietary TH challenges. Activity was determined by HPLC separation of \*T<sub>3</sub> metabolism products after incubation with liver (n=3-9), pyloric caeca (n=3-9), middle intestine (n=3-9), and distal intestine (n=3-9) at DTT concentrations of 0 mM (■) or 10 mM (□). Bars represent means (± s.e.). Asterisks indicate significant differences at p≤0.05 in activity between treated and control fish at that day. ND denotes non-detectable.




Figure 4-8. Rate of microsomal  $T_3IP$  production for control (C),  $T_4$  treatment ( $T_4$ ), and  $T_3$  treatment ( $T_3$ ) over 0, 2, and 7 days of dietary TH challenges. Activity was determined by HPLC separation of  $^*T_3$  metabolism products after incubation with liver ( $n=3-9$ ), pyloric caeca ( $n=3-9$ ), middle intestine ( $n=3-9$ ), and distal intestine ( $n=3-9$ ) at DTT concentrations of 0 mM (■) or 10 mM (□). Bars represent means ( $\pm$  s.e.). ND denotes non-detectable.

## CONTROL




T<sub>4</sub> TREATMENTT<sub>3</sub> TREATMENT

Figure 4-9. Summary of TH metabolism pathways in the trout liver. For control fish, pathways that were active are designated by black arrows. For  $T_4$ -treated and  $T_3$ -treated fish, pathways that were increased significantly are designated by thick black arrows, and pathways that were decreased significantly are designated by thin black arrows. Pathways that were not measured are designated by thin gray arrows.






**CONTROL** **$T_4$  TREATMENT** **$T_3$  TREATMENT**

Figure 4-10. Summary of TH metabolism pathways in the trout MI. For control fish, pathways that were active are designated by black arrows. For  $T_4$ -treated and  $T_3$ -treated fish, pathways that were increased significantly are designated by thick black arrows. Pathways that were not measured are designated by thin gray arrows.

## CONTROL




T<sub>4</sub> TREATMENTT<sub>3</sub> TREATMENT

Figure 4-11. Summary of TH metabolism pathways in the trout DI. For control fish, pathways that were active are designated by black arrows. For T<sub>4</sub>-treated and T<sub>3</sub>-treated fish, pathways that were increased significantly are designated by thick black arrows. Pathways that were not measured are designated by thin gray arrows.

## Chapter 5

### Development of an *In vivo* Method to Assess the Acute Uptake of Thyroxine and Triiodothyronine by Enterohepatic Tissues of Rainbow Trout

#### Introduction

Enterohepatic circulation (EHC) involves the cycling of substances from the blood to the liver to the bile to the intestine and back to the blood (Figure 1-4). With EHC, the intestine is not considered solely an excretory route, rather it can also provide a dynamic pool of materials from which metabolism, temporary storage, and absorption take place. Thyroid hormones (TH), thyroxine ( $T_4$ ) and triiodothyronine ( $T_3$ ), can follow an EHC, depending on the form of iodothyronine released in bile and the extent of its absorption from the intestine. In mammals, biliary-excreted TH can contribute to the intestinal pool of TH (DiStefano, 1988; DiStefano *et al.*, 1991). From the intestine, unconjugated TH can be absorbed extensively and re-enter the enteric circulation (Briggs *et al.*, 1953; Chung and van Middlesworth, 1964; Sternlicht *et al.*, 1984; Hazenburger *et al.*, 1988; DiStefano, 1988; DiStefano and Harris, 1988; Rutgers *et al.*, 1989; DiStefano *et al.*, 1992). Thus, a TH EHC is created, which may contribute to the regulation of whole-body TH (DiStefano *et al.*, 1993). The same could be true for teleost fish.

There is limited knowledge of TH EHC in teleost fish. Previous studies have investigated individual components of TH EHC, and hence the potential for completion of the EHC, by evaluating intestinal access to TH through biliary supply and by evaluating reentry of TH to plasma through absorption of TH from the intestine. Results reported in Chapter 4 demonstrated the potential of the trout intestine for regulating

metabolic conversion of excess TH. The fish intestine may therefore contribute to the regulation of thyroidal status if TH discharged from bile or obtained through the diet is absorbed from the intestine and contributes to available systemic TH.

In salmonids and other teleost fish, there is abundant evidence for TH uptake by the liver and TH excretion into the bile. After an intraperitoneal injection of  $^*T_4$  into fasted brook trout, over 50% of the radioactivity accumulated in the bile was radiolabeled  $^*T_4$  ( $^*T_4$ ) (Sinclair and Eales, 1972). After an intraperitoneal  $^*T_4$  injection into rainbow trout,  $^*T_4$  and its less absorbable conjugates were also accumulated in the bile after 24 h. After a similar injection of  $^*T_3$ , mainly  $^*T_3$  conjugates, rather than  $^*T_3$ , were accumulated in bile of rainbow trout (Finnson and Eales, 1996). Furthermore, feeding brook trout caused the rapid release of bile into the intestine (Eales and Sinclair, 1974). Thus in salmonid fish studied to date, the biliary route represents a source of TH released to the intestine, with more  $T_4$  than  $T_3$  delivered in its native, unconjugated form.

There is far less information for teleost fish on the completion of EHC with TH uptake from the intestine. Indirect evidence of intestinal absorption of TH has been documented in rainbow trout by measuring increased levels of plasma TH after ingestion of TH-supplemented diets (Higgs *et al.*, 1979; Higgs *et al.*, 1982; Cyr and Eales, 1990; Eales *et al.*, 1990; Eales and Finnson, 1991; Sweeting and Eales, 1992; Fines *et al.*, 1999). There was consistently a greater increase in plasma  $T_3$  than  $T_4$  with the same dietary TH dose.

More direct measurements of TH uptake from the intestine have been made by following radiolabeled TH ( $^*TH$ ) injected into the lumen of a fish intestine. In starved channel catfish, 20-25% of the radioactivity associated with  $^*T_4$  or  $^*T_4$  and its

glucuronidated form ( $*T_4$ -G) were absorbed after 24 h from the lumen of a ligatured middle intestine (Collicutt and Eales, 1974). In brook trout, between 12 and 36% of the radioactivity associated with  $*T_4$  or both  $*T_4$  and  $*T_4$ -G injected into a double-ligatured intestinal loop of middle intestine and distal intestine was lost from the intestinal lumen after 24 h (Eales and Sinclair, 1974). Since the bile is released to the intestine only upon feeding, an experiment compared starved rainbow trout injected with  $*T_4$  and then fed to starved controls injected with  $*T_4$  but not fed. In the fed trout,  $*T_4$  and  $*T_4$ -G accumulated in the bile were released to the intestine, but there was no increase in plasma  $*T_4$  relative to unfed controls (Eales and Sinclair, 1974). This suggested that negligible cycling of TH occurred, since little TH or TH conjugates were absorbed from the intestine in comparison to the amount returning to the intestine. Thus in teleost fish, the intestine is traditionally considered an excretory pathway for TH. Though, considering its mass of tissue, the intestine cannot be ignored as a possible large pool of TH for absorption to the circulation and EHC.

Based on the above, and since a given level of dietary  $T_3$  increased circulating  $T_3$  levels to a greater degree than dietary  $T_4$  increased circulating  $T_4$  levels (Higgs *et al.*, 1979, 1982), it was believed that  $T_4$  was more poorly absorbed than  $T_3$  from the digestive tract. A study by Whitaker and Eales (1993) was conducted to compare  $T_4$  and  $T_3$  absorption from the intestinal lumen of rainbow trout. Large doses of  $*T_4$  or  $*T_3$  were injected into the middle intestine, via an anal catheter, and uptake was measured over a period of 48 h. In agreement with the above studies,  $T_3$  was removed from the intestine and entered blood and tissues more extensively than  $T_4$ .

In summary, there is considerable evidence that high proportions of TH are secreted in fish bile. It has been concluded that significant biliary excretion of unconjugated TH occurs, mainly in the form of  $T_4$ . There is far less information on what appears to be limited uptake from the intestine. However, the existing data suggest that, at least in salmonid fish, a higher proportion of  $T_3$  than  $T_4$  can enter the circulation from the intestinal lumen. At the moment, TH uptake from the intestine to blood, liver and bile has not been addressed in a systemic manner to compare  $T_4$  and  $T_3$ , to identify the region of the intestine involved in absorption of TH, or to describe the mechanisms involved in TH uptake.

The initial objectives of this chapter were to develop an *in vivo* method to describe and quantify the uptake (net loss) of TH from the intestinal lumen and their distribution into systemic blood, liver, and gall bladder of rainbow trout and to determine if TH absorbed from the intestine could complete an enterohepatic cycle. To achieve these various objectives, labeled TH, accompanied by either a low or a high dose of the corresponding unlabeled TH, were injected into a ligatured intestinal section in anesthetized trout, and the luminal and tissue radioactivities were determined one hour later. For each tissue, the form of radioactivity ( $^3H$  or  $^3H$  metabolites) was identified so that the distribution could be followed to a terminal point in the EHC, the gall bladder.

The intent was then to use this procedure to compare the net loss of the two primary TH,  $T_4$  and  $T_3$ , at TH levels that could be encountered normally in the diet. The net loss of TH was used to determine if a saturable intestinal transport system might be involved in their uptake, and to determine for different regions of the intestine if there were differences between  $T_4$  and  $T_3$  net loss from the lumen, uptake to the liver and the

blood, and accumulation in the bile. Other variables that might affect the results were considered. Fundamental to interpretation was the determination of possible degradation of TH in the intestinal lumen prior to TH absorption. Also of interest was the effect of pre-experimental fasting. This chapter, therefore, includes data that address the following hypotheses:

1. Insignificant degradation of  $^*T_4$  or  $^*T_3$  occurs during a one-hour residence in the intestinal lumen.
2. Extended pre-experimental fasting reduces  $T_3$  uptake from the intestinal lumen.
3.  $T_3$  net loss from the intestine is greater than  $T_4$  net loss.
4. The net loss of the radioactive portion of a TH injectate will be reduced in the presence of a high concentration of unlabeled TH in the lumen, demonstrating the involvement of a saturable intestinal transporter.
5. TH net loss from the intestine and uptake into the liver, blood, and gall bladder is greater in ligatured sections that include the distal intestine as opposed to those that include the middle intestine alone.

## **Materials and Methods**

### **Fish maintenance**

Rainbow trout were obtained from the Rockwood Hatchery (Gunton, Manitoba) and held at the University of Manitoba in running, aerated, dechlorinated, Winnipeg city water at 12°C and 12L:12D photoperiod in 60-cm x 60-cm x 60-cm tanks. They were fed once daily with commercial trout food (3.2 mm, Martin Feed Mills) at 1% of body mass.

### **Preparation of intestinal sections**

Food was withheld routinely for three days before injection to allow the intestine to empty. However, in the experiment to test the effects of duration of fasting, food was withheld for up to 14 days prior to injection.

To double-ligature the intestine, fish were anesthetized with tricaine methanesulfonate (MS222, 0.034 g/L, Syndel Labs) and placed on their back in holders with dechlorinated water (12°C) and MS222 (0.034 g/L) pumped over the gills with a Little Giant Pump, Fisher (Figure 5-1). An incision was made on the ventral side beginning anterior to the pectoral fins, cutting laterally around the fins (to avoid severing the abdominal vein), finishing adjacent to the anus, and exposing the length of the intestine. A section of the intestine was ligatured with suture thread in two places. Care was taken to minimize disruption of blood vessels in this region.

In order to compare intestinal regions, two different sections of the intestine, MI section and MI-DI section were double-ligatured. For the MI section, the upper ligature was just posterior to the pyloric caeca and the lower ligature was just anterior to the beginning of the distal intestine at the pyloric sphincter (trout mean weight 898.1; range 660-1290 g). For the MI-DI loop, the upper ligature was just posterior to the pyloric caeca and the lower ligature was just anterior to the anus (trout mean weight 572.4; range 295-1064 g). The middle intestine was included with the distal section to ensure adequate blood supply and to simulate the site of entry if TH were in the biliary discharge.



***In vivo* injection of labeled substances into double-ligated MI or MI-DI sections**

Intestinal injectate composed of radioactive TH ( $^*T_4$  or  $^*T_3$ ,  $>800 \mu\text{Ci}/\mu\text{g}$  New England Nuclear) followed immediately by a non-radioactive TH dose ( $T_4$  or  $T_3$ ) was consistently injected into the MI lumen of both MI and MI-DI sections. Purified  $^*T_4$  ( $^*I^-$  contamination 7.8%) or  $^*T_3$  ( $^*I^-$  contamination 5.0%) was reconstituted in 0.1 N NaOH to provide approximately 4,000,000 cpm/mL. Non-radioactive TH doses ( $T_4$  or  $T_3$ ) at pre-determined molar concentrations of 200 fmoles (low dose) or 100 pmoles (high dose) were prepared in osmotically balanced Tris-HEPES buffer (0.50 g Tris, 1.39 g HEPES, and 3.64 g mannitol per 1 L  $\text{H}_2\text{O}$ ; pH 7.4). 50  $\mu\text{L}$  of either  $^*T_4$  or  $^*T_3$  was injected into the double-ligated section, followed immediately by 50  $\mu\text{L}$  of either  $T_4$  or  $T_3$  dose, to make a total of 100  $\mu\text{L}$  of intestinal injectate.

To test the mechanism of TH uptake for saturability, the effects of the low TH dose of 200 fmoles and a high TH dose of 100 pmoles were compared for net loss of  $T_4$  or  $T_3$ . The lower concentration of TH was at a level that the fish could normally be encountered in diets (MacKenzie *et al.*, 1993). The net loss of TH were measured for both MI and MI-DI sections.

**Sampling**

One hour after injection into the intestinal section, the already anesthetized fish were killed by a blow to the head, and the cardiac whole blood, liver, bile, and intestinal section (tissue and contents) were collected and weighed. Sampling was done at one hour to provide sufficient time for measurable uptake while minimizing the possibility of TH metabolism in the intestinal tissue. For all tissues, except for bile, 2 mL of a protease

(0.025 g/mL of buffer, Pronase, Sigma) was added, and radioactivity was measured in the gamma counter against the injected dose.

### **Tissue extractions**

After 24 h of protease digestion at 25°C, 2 mL of methanolic ammonia (MeOH:NH<sub>4</sub>OH; 99:1; v/v) containing methylmercaptoimidazole (MMI, 0.115 g/mL) as a reducing agent was added to all but bile, vortexed, and centrifuged at 1420 g for 20 min. The supernatant was saved, and extraction of the pellet with MeOH:NH<sub>4</sub>OH was repeated two more times. The pooled supernatants for individual tissue extracts were dried at 37°C under an airstream.

### **Identification of radioactive substances**

The evaporated tissue extracts were reconstituted in 0.05 N NaOH and added to LH-20 Sephadex mini-columns (5 mL Quick Sep Column, Isolab), each containing 0.25 g of LH-20 Sephadex and equilibrated with 750 µL of 0.1 N HCl. Bile was added directly to the LH-20 column. The TH metabolites (such as \*TH conjugates and \*I) were eluted with 3 mL of H<sub>2</sub>O, and then the total TH fraction (\*TH) was eluted with 3 mL of ethanolic ammonia (EtOH:NH<sub>4</sub>OH, 99:1, v/v). The fractions were counted in the gamma counter.

Column recovery of TH for each tissue was tested by adding a known amount of \*T<sub>4</sub> or \*T<sub>3</sub> to a tissue (approximately 5,000 cpm), digesting with protease, extracting with MeOH:NH<sub>4</sub>OH, and separating the \*TH metabolism products and \*TH on LH-20 columns. By measuring both the amount of TH recovered from \*T<sub>4</sub> or \*T<sub>3</sub> alone and the amount of TH recovered from \*T<sub>4</sub> or \*T<sub>3</sub> in the tissues, a correction factor for column recovery could be determined for each tissue processed (Appendices VII and VIII).

## Calculations

Several calculations were made to evaluate the EHC of  $T_4$  and  $T_3$  through determinations of loss of the injectate from the intestinal section, uptake of radioactivity to blood and liver, accumulation of radioactivity in bile, and the forms of radioactivity in these tissues. These determined whether TH could cycle to and from the intestine.

### 1. Net loss of total injected radioactivity from the intestinal section (%)

$$= (\text{cpm radioactivity lost from section} / \text{cpm radioactivity injected}) \times 100$$

Initial attempts were made to separate the intestinal contents from the intestinal tissue itself. However, washing the intestinal tissue with ethanol to remove residual luminal contents may have extracted intracellular hormone from the intestinal tissue or removed the mucosal layer. Thus, the percent of the total injected radioactivity removed from the entire intestinal section (tissue and contents) was used to determine loss of the radioactive injectate. This calculation represented the percent of total radioactivity (\*TH or \*TH metabolites) absorbed from the intestinal section that could potentially enter the EHC one hour after injection of  $^*T_4$  or  $^*T_3$ .

### 2. Percent \*TH in the injectate, intestinal section, liver, blood, or bile (%)

$$= (\text{cpm } ^*TH \text{ from the column fraction} / \text{cpm total tissue radioactivity}) / 100$$

The fraction of total radioactivity represented by \*TH was determined for the injectate, intestinal section, liver, blood, or bile, respectively. This was determined by separating the \*TH from possible \*TH metabolites (such as \*TH conjugates and \*I) on LH-20 mini-columns. Thus, \*TH in the injectate or tissues was calculated as the percent of the total radioactivity in the tissue that was eluted as \*TH.

The percent \*TH in the injectate and intestinal sections was used to determine metabolic breakdown of \*TH and \*I contamination after processing samples, thus evaluating the degradation of \*TH during a one-hour residence in the intestinal lumen.

The percent \*TH was also used in later calculations to determine \*TH uptake by the liver or blood and to determine accumulation of \*TH in the bile.

### **3. Uptake by the liver or blood**

#### **a. Total radioactivity uptake by the liver or blood (%/mg)**

$$= [(cpm \text{ tissue}/cpm \text{ injectate}) \times 100/mg \text{ tissue}] \times (\text{body weight}/500)$$

Uptake of total radioactivity into the liver or the blood was calculated as the percent of the total radioactive injectate taken up by a milligram of tissue, and this was then corrected for isotope dilution due to body weight by normalizing to a 500-g fish. This calculation was used to further calculate \*TH uptake by the liver or blood and \*TH metabolite uptake by the liver or blood.

#### **b. \*TH uptake by the liver or blood (%/mg)**

$$= (\text{Total radioactivity uptake into tissue}) \times (\text{Percent *TH in tissue}/100)$$

By using calculations 2 and 3a, the amount of total radioactivity taken up by the liver or blood was adjusted to represent only the amount of radioactivity remaining as \*TH. \*TH uptake to the liver represented the amount of TH from the intestine entering the liver, a main peripheral regulator of available systemic TH and the source of biliary TH. \*TH uptake to the blood represented the amount of TH the intestine could make available to the tissues through systemic circulation.

**c.      \*TH metabolite uptake by the liver or blood (%/mg)**

$$= (\text{Total radioactivity uptake into tissue}) - (*\text{TH uptake into tissue})$$

\*TH uptake by the liver or blood (calculation 3b) was subtracted from the total radioactivity uptake by the liver or blood (calculation 3a). This represented the radioactivity in the tissue that was no longer in the form of the \*TH injected, rather it was \*TH metabolites such as \*TH conjugates and \*I.

**4.      Accumulation in the bile**

**a.      Total radioactivity accumulation in the bile (%)**

$$= (\text{cpm total radioactivity in bile/cpm injectate}) \times 100$$

Net accumulation of total radioactivity in the bile was determined as a percent of injected dose. The bile represented the contents of a terminal sac that could be emptied into the intestine. It would contain the stored \*TH and \*TH metabolites that would be released to the intestine upon feeding. Thus, neither the amount of bile nor the isotope dilution due to body size were factors in calculating uptake, only the amount of radioactivity accumulated. This calculation was further used to calculate accumulation of \*TH in the bile and accumulation of \*TH metabolites in the bile.

**b.      \*TH accumulation in the bile (%)**

$$= (\text{Accumulation total radioactivity in bile}) \times (\text{Percent *TH bile}/100)$$

From calculations 2 and 4a, accumulation of unconjugated \*TH in the bile was determined. This calculated the portion of the radioactivity in the bile that remained in the form of the \*TH injected, potentially returning to the intestine in the EHC.

**c. \*TH metabolite accumulation in the bile (%)**

$$= (\text{Accumulation total radioactivity in bile}) - (\text{Accumulation of *TH in bile})$$

The accumulation of \*TH in the bile was subtracted from the accumulation of total radioactivity in the bile. This represented the radioactivity in the bile that was no longer in the form of the \*TH injected, rather it was \*TH metabolites such as \*TH conjugates and \*I.

**Protocol**

The above parameters were measured under various conditions to address previously stated hypotheses:

**1. Degradation of TH during one-hour residence in the intestinal lumen**

The proportion of \*TH in the injectate standard was compared to the proportion of \*TH remaining in the injected intestinal section after an hour. A significant difference between these values would indicate that TH metabolism occurred in the intestinal lumen.

**2. Length of fasting prior to injection**

Because intestinal digesta can bind TH and restrict their reabsorption, and because this variable was difficult to control, all studies were conducted on fish fasted at least 3 days, which is the time required to clear the distal intestine. This led to a preliminary study to determine if extended fasting (3-5 days, 6-10 days, 11-14 days) prior to injection of T<sub>3</sub> (low dose of 200 fmoles) reduced T<sub>3</sub> net loss from the intestinal lumen. T<sub>3</sub> was chosen as the test hormone, since previous studies (see Introduction) suggested that T<sub>3</sub> was the main TH likely to be absorbed from the intestinal lumen.

### **3. Form of TH injected**

The net loss of  $T_3$  from the intestinal section was compared to net loss of  $T_4$ . In all cases, the injection of a consistent dose of \*TH (\* $T_4$  or \* $T_3$ ) was followed immediately by an injection of the corresponding non-radioactive TH.

### **4. Dose of TH injected**

The uptake of the \*TH injected was compared in the presence of a low (200 fmoles) or a high (100 pmoles) level of unlabeled TH in the lumen in order to determine involvement of a saturable intestinal transporter.

### **5. Region of intestine used to form the double-ligated intestinal section**

The middle region of the intestine alone (MI section) and the middle and distal regions of the intestine together (MI-DI section) were compared for differences in net loss of TH from the intestinal lumen, uptake by the liver or blood, and accumulation in the bile. The injection of \*TH was consistently into the middle section (site of bile discharge), downstream from the upper ligature. The lower ligature was tied either at the junction of the middle and distal intestine to create the MI section, or close to the anus to create the MI-DI section. The sites for ligatures were chosen to simulate biliary discharge with the injection site, and to ensure adequate blood supply to and from the intestinal sections. In addition, TH metabolism occurred in the middle and distal intestine, with greater activity in the distal region (Chapters 3 and 4).

### **Statistics**

Using the SPSS statistics package, univariate analysis of variance (ANOVA) was used to compare means of either net loss of total radioactivity from the intestine, total uptake by the liver, total uptake by the blood, or total accumulation in the bile for effects

of the length of pre-experimental fasting. Univariate ANOVA was used to compare means for net loss of TH from the intestinal section for effects of TH injectate (T<sub>4</sub> low dose, T<sub>4</sub> high dose, T<sub>3</sub> low dose, and T<sub>3</sub> high dose). Each test was performed individually for MI or MI-DI sections. These tests were followed by LSD post hoc multiple comparisons to determine significant differences among TH injectates. For each analyzed (either net loss of TH from the intestinal section, TH uptake by the liver, TH uptake by the blood, or TH accumulation in the bile), independent t-tests were used to compare means between MI section and MI-DI section. Each test was performed individually for TH injectate doses. Statistics were not performed on percent \*TH (that was used to determine degradation of TH during one-hour residence in the intestinal section) due to low and variable sample sizes. Results were determined statistically significant at  $p \leq 0.05$ .

## **Results**

### **Degradation of TH during one-hour residence in the intestinal lumen**

The comparisons of percent \*TH in the injectate vs. percent \*TH in the intestinal section were made several days after processing, and some non-biological degradation of \*TH would be expected (Table 5-1). Thus, the percent \*TH in the injectate was lower than when measured at injection (> 92% TH with less than 8% \*I contamination). However, it was assumed that non-biological degradation would occur at the same rate in injectate and samples.

In all instances, the percent \*TH in the standard injectate fell within the range of variation of the percent \*TH in the intestinal section, indicating that negligible intestinal



TH metabolism occurred after one hour. Thus, it was assumed that net loss of radioactivity from the intestinal section represented absorption of the intact \*TH injected.

### **Length of fasting prior to injection of \*T<sub>3</sub>**

Fasting before injection of \*T<sub>3</sub> (low dose) did not significantly affect net loss of injectate from the MI-DI section ( $F=0.100$ , d.f.=2,  $p=0.909$ ), total uptake to the blood ( $F=2.405$ , d.f.=2,  $p=0.206$ ), total uptake to the liver ( $F=2.588$ , d.f.=2  $p=0.169$ ), or total accumulation of injectate in the bile ( $F=0.7488$ , d.f.=2,  $p=0.496$ ; Table 5-2).

### **Form of TH injected**

For the MI section, there was a significant difference in net loss among injectates ( $F=7.200$ , d.f.=2,  $p=0.034$ ) such that net loss of T<sub>3</sub> high dose from the intestine was significantly greater than net loss of T<sub>4</sub> high dose (Table 5-3). The greatest net loss from the intestine was T<sub>3</sub> high dose, followed by T<sub>4</sub> high dose, and then T<sub>3</sub> low dose.

For the MI-DI section, there was no significant difference in net loss among injectates ( $F=1.399$ , d.f.=2,  $p=0.342$ ). Though, net loss of T<sub>4</sub> high dose (17%) was greater than net loss of T<sub>3</sub> at either high (6.1%) or low (6.0%) doses. Thus, in the MI section, T<sub>3</sub> was absorbed more than T<sub>4</sub>, but in the MI-DI section, T<sub>4</sub> was absorbed more than T<sub>3</sub>.

### **Dose of T<sub>3</sub> injected**

For the MI section, net loss of T<sub>3</sub> from the intestine increased significantly with an increase in unlabeled TH injected ( $F=7.200$ , d.f.=2,  $p=0.013$ ; Table 5-3).

For the MI-DI section, net loss of T<sub>3</sub> low dose was comparable to that for the T<sub>3</sub> high dose, and there was no change in net loss of T<sub>3</sub> with an increase in unlabeled T<sub>3</sub>

injected. Thus, for both sections, there was no decrease in net loss of  $T_3$  from the intestinal lumen with the use of a potentially saturating dose of unlabeled  $T_3$ .

### **Region of intestine used to form the double-ligated intestinal section**

#### ***Fate of $T_4$ injected into intestinal sections***

The fate of the  $T_4$  low dose was examined for the MI-DI section only (Table 5-4). Its net loss was not measured. The liver had a significant level of \*TH metabolites (11.1%/mg), and it appeared that some of these entered the systemic circulation. The majority of the injectate present in the systemic circulation was in the form of \*TH metabolites (0.0315%/g). From the liver, 0.0013% of the total injectate was accumulated as \*TH in the bile, however, the majority of the radioactivity was in the form of \*TH metabolites (0.0087%).

For the MI section, the net loss of  $T_4$  high dose was 10.7%. The intestine's contribution to \*TH available to tissues (via liver) was mainly in the form of \*TH metabolites (0.0133%/g). \*TH uptake by the liver was comparable to the amount of \*TH metabolite uptake by the liver. Little of the \*TH injected remained as \*TH when it was taken up by the systemic blood; most of it was in the form of \*TH metabolites. No \*TH was accumulated in the bile, even though 0.0028% of the total injectate was accumulated in the bile as \*TH metabolites.

Net loss of  $T_4$  high dose from the MI-DI section was 17.3%. The majority of the injectate taken up into the liver and the blood was in the form of \*TH metabolites. However, only \*TH was accumulated in the bile (0.0210%). Overall, injection of  $T_4$  into the MI-DI section, rather than the MI section alone, resulted in significantly greater TH uptake by the liver ( $t=3.323$ , d.f.=9,  $p=0.010$ ), uptake by the blood ( $t=2.237$ , d.f.=9,

$p=0.054$ ), but not significantly greater net loss from the intestine ( $t=0.685$ , d.f.=3,  $p=0.542$ ) or accumulation in the bile ( $t=0.886$ , d.f.=14,  $p=0.087$ ).

### ***Fate of $T_3$ injected into intestinal sections***

Net loss of  $T_3$  low dose from the MI section was 5.4% (Table 5-5). All of the injectate taken up by the liver remained in the form of \*TH. This was also true for uptake by the systemic circulation. The form of radioactivity accumulated in the bile was not assayed.

Net loss of  $T_3$  low dose from MI-DI section was 6.1%. This was not significantly different than net loss of  $T_3$  low dose from the MI ( $t=0.317$ , d.f.=2,  $p=0.782$ ). Not all of the original injectate remained in the form of \*TH. This contrasts with results from the MI section. The majority of the injectate taken up by the liver remained in the form of \*TH, and this amount was significantly greater than for the MI section ( $t=2.789$ , d.f.=4,  $p=0.049$ ). However, the majority of the injectate entering the systemic circulation was in the form of \*TH metabolites. Thus, the amount of \*TH in the blood was not significantly different than the amount of \*TH in the blood for the MI section ( $t=2.239$ , d.f.=4,  $p=0.089$ ). The form of radioactivity accumulated in the bile was unknown, but the total radioactivity accumulated in the bile was greater than for the MI section. Thus, net loss of  $T_3$  low dose was similar for both intestinal sections, however, greater amounts of \*TH circulated from the intestine to tissues in EHC after absorption from the MI-DI section in comparison to the MI section.

Net loss of  $T_3$  high dose from the MI section was 15.4%. Despite this high net loss, none of the radioactivity in the systemic circulation remained in the form of \*TH. The form of radioactivity in the liver was not assayed. From the liver, no \*TH was

accumulated in the bile, but 0.0073% of the total injectate was accumulated in the bile as \*TH metabolites.

Net loss of T<sub>3</sub> high dose from the MI-DI section was 6.0%. The levels of \*TH and \*TH metabolites present in the liver were comparable, yet the majority of the injectate from the intestine entering systemic circulation via the liver remained as \*TH. Uptake to blood was greater for the MI-DI section. Only \*TH was accumulated in bile. Even though net loss of T<sub>3</sub> high dose from the MI-DI section was significantly less than from the MI section ( $t=3.644$ , d.f.=4,  $p=0.022$ ), a greater amount of T<sub>3</sub> from the MI-DI section entered tissues in EHC and was accumulated in the bile ( $t=1.806$ , d.f.=6,  $p=0.012$ ), allowing for greater \*TH return to the intestine.

## Discussion

In rainbow trout, there are no previous studies on the role of specific regions of the intestine in acute, *in vivo* EHC of T<sub>4</sub> or T<sub>3</sub>. The present goal was to establish an *in vivo* technique to measure net loss of T<sub>4</sub> and T<sub>3</sub> from double-ligated intestinal sections, their uptake to blood and liver, and their accumulation in bile in anesthetized, fasted trout. Had the trout been fed, the release of bile back to the intestine would have completed the cycle. Based on the results obtained, the hypotheses presented in the Introduction are addressed here in the Discussion.

### 1. **Insignificant degradation of T<sub>4</sub> or T<sub>3</sub> occurs during a one-hour residence in the intestinal lumen**

Insignificant degradation of T<sub>4</sub> or T<sub>3</sub> occurred during the one-hour residence in the intestinal lumen of the MI section or the MI-DI section. In addition, comparable percent

TH found in the injectate standard and the injected intestinal section indicated that \*TH metabolites (most likely \*I) were not preferentially absorbed over \*TH from either intestinal section, thus not altering the percent \*TH in the intestinal section.

This information was fundamental to the interpretation of the data. In the study by Whitaker and Eales (1993), \*T<sub>3</sub> injected into the MI remained in its parent form after 24 hours. After \*T<sub>4</sub> injection, however, radioactivity in the lumen was predominantly \*I, and the majority of the radioactivity absorbed to plasma was also \*I. Since experiments described in Chapters 3 and 4 demonstrated the ability of the intestine, especially the MI and DI, to metabolize TH after one hour, the concern was that significant loss of TH through degradation would be interpreted as net loss of TH through absorption. Also a concern was that \*I contamination could mask the uptake of \*TH. When measuring net loss, uptake, and accumulation of the injectate, it was unknown whether \*I entered from contamination of the injectate, TH metabolism in the intestine, or TH metabolism in other tissues, and each source of \*I would require a separate adjustment. Hence, a correction was not feasible. However, insignificant degradation of \*TH occurred, so it was assumed that net loss from the intestinal section represented TH absorption.

## **2. Extended pre-experimental fasting did not reduce T<sub>3</sub> uptake from the intestinal lumen.**

Duration of pre-experimental fasting did not significantly affect net loss of T<sub>3</sub> from the MI-DI section, total radioactivity uptake to blood and liver, or accumulation of total radioactivity in bile. Even though it appeared that T<sub>3</sub> net loss increased with pre-experimental fasting, the changes were not significant, probably due to low sample size and animal variation. However, subsequent studies were performed consistently within

3-5 days of fasting, which provided enough time for intestinal contents to be cleared. In mammals, intestinal contents were shown to reduce absorption of TH from the intestine (Cottle, 1964; Chung and van Middlesworth, 1967; Ruegamer *et al.*, 1967; Heroux and Petrovic, 1969). However, prolonged fasting in fish changed intestinal intracellular structure (McLeese and Bergeron, 1990) decreased microvillar length (Hossain and Dutta, 1991; McLeese and Bergeron, 1990), altered enzymatic activities (Mommensen *et al.*, 2003) and decreased absorption of nutrients such as amino acids (Collie, 1985; Avella *et al.*, 1992). Prolonged fasting can also alter physiological state, such as thyroidal status, in rainbow trout. A decrease in nutrient intake leads to inhibition of thyroidal function and peripheral production of  $T_3$  (Eales, 1988; Leatherland, 1994). This could alter the intestine's response to luminal TH. With short-term fasting of 3-5 days, influences of both digesta binding the injectate and confounding effects of nutritional status on intestine were minimized. In addition, radioactivity from all tissues was separated using columns to determine the form of radioactivity counted.

Even though short-term fasting may have altered the physiological state of the fish, all studies were conducted under the same conditions. The TH that was delivered to the bile from the liver was not released to the intestine, and this was advantageous. The amount of  $^*TH$  and  $^*TH$  metabolites that would cycle to the intestine could be collected. They did not confound the calculations of original injectate net loss and distribution to EHC tissues.

### **3. $T_3$ net loss from the intestine is greater than $T_4$ net loss.**

For the MI section, greatest net loss from the intestine was measured for the  $T_3$  high dose, followed by the  $T_4$  high dose, and then the  $T_3$  low dose. This only partially

supports previous data suggesting that  $T_3$  is more readily absorbed than  $T_4$ . Furthermore, for the MI-DI section the greatest net loss from intestine was measured for the  $T_4$  high dose.

Previous data supporting greater  $T_3$  absorption than  $T_4$  were based on feeding TH in the diet and then measuring physiological markers such as growth (Higgs *et al.*, 1979) or measuring plasma TH levels (Sweeting and Eales, 1992b). However, these indirect measurements of TH absorption may instead reflect physiological mechanisms other than intestinal absorption that regulate plasma TH levels, since this study indicated that both TH were absorbed from the intestine, with  $T_4$  absorbed to a greater extent than  $T_3$  from the MI-DI section.

The entry of an "excess" of TH into circulation may induce mechanisms to maintain TH homeostasis despite TH uptake from the intestine. For  $T_4$ , regulation by feedback at the level of the hypothalamus and pituitary could reduce  $T_4$  production from the thyroid. For both  $T_4$  and  $T_3$ , peripheral TH metabolism such as deiodination and conjugation could maintain static plasma TH levels.

Plasma  $T_4$  levels may be affected by negative feedback at the hypothalamic-pituitary level so that  $T_4$  absorbed from the intestine is offset by reduced thyroidal  $T_4$  secretion.  $T_4$ , which is the main hormone released by the thyroid, exerts a strong negative feedback on the hypothalamo-pituitary-thyroid axis, but  $T_3$  exerts little influence at this level (Eales and Himick, 1991). Thus, a decrease in thyroidal production of  $T_4$ , in conjunction with liver metabolism and accumulation in the bile, may effectively reduce circulating  $T_4$  levels as a result of  $T_4$  absorption from the intestine.

As shown earlier in this chapter, the data on percent TH in the injectate standard vs. the injected intestinal section supported the view that the form of TH injected was the same as that absorbed from the intestine. This was not the case in a previous study in which the TH injected resided for 24 hours in the intestine (Whitaker and Eales, 1993). In that study, the  $^*T_4$  injected into the MI was mainly in the form of  $^*T$  after 24 hours. It is possible that other studies that support greater  $T_3$  absorption than  $T_4$  were biased by a greater propensity for  $T_4$  metabolism in the intestine than  $T_3$ .

For the MI-DI section in particular, greater absorption of  $T_4$  than  $T_3$  may not be evident by measuring plasma levels, especially in experiments extending longer than one hour. In the present study, TH injected at the site of bile entry were able to move to the DI, and a small proportion was absorbed within one hour. Higher doses of  $T_4$  (and  $T_3$ ) in the MI-DI section resulted in unmetabolized  $^*TH$  accumulated in the bile.

The liver is the site where TH are discharged to the gall bladder. An increase in TH can lead to greater biliary excretion. For both  $^*T_4$  and  $^*T_3$  injected into the MI section at a high dose, the liver accumulated  $^*TH$  metabolites in the bile. However,  $T_4$  was not preferentially metabolized over  $T_3$ , suggesting that peripheral metabolism did not reduce plasma  $T_4$  to a greater extent than  $T_3$ .

For experiments of longer duration,  $T_4$  may not be available for absorption, since it can be degraded in the intestinal tissue. If it does get absorbed from the intestine, it can be accumulated in the bile. Finally, if it enters systemic circulation, it can inhibit thyroidal secretion of  $T_4$ .



4. **Net loss of the radioactive portion of  $T_3$  injectate was not reduced in the presence of a high concentration of unlabeled TH in the lumen, not supporting the involvement of a saturable intestinal transporter.**

After  $*T_3$  injection,  $*TH$  net loss was not reduced by a 500-fold increase of unlabeled TH. This suggests that a saturable TH transporter is not involved. However, a  $T_3$  carrier system that is very abundant or saturable at a higher dose cannot be excluded. The difference in net loss of  $T_3$  at low and high doses for the MI section and the MI-DI section suggest that there are regional differences in the mechanism of absorption of  $T_3$ . The transport systems for absorption of TH from the intestine have not been studied in any animal, to date. However in fish, the transport of TH into hepatocytes and red blood cells (RBC) have been characterized for rainbow trout.

In the liver, various  $T_4$  and  $T_3$  uptake and inhibition properties suggested that  $T_4$  and  $T_3$  were transported to a small extent by diffusion, but that  $T_4$  and  $T_3$  had separate binding sites for transport (Riley and Eales, 1994). Yet, both transporters shared characteristics in that transport into hepatocytes was an energy-dependent,  $Na^+$ -independent, carrier-mediated and possibly an endocytotic process. Transport was not inhibited by tyrosine and phenylalanine. Thus, TH were not transported into hepatocytes by the same system used by structurally similar aromatic amino acids.

Transport of TH into RBC differed from hepatocyte uptake.  $T_4$  and  $T_3$  were taken up into RBC by both nonsaturable and saturable systems (McLeese and Eales, 1996a, 1996b). In addition to simple diffusion, separate transport systems were characterized for  $T_4$  and  $T_3$ . Rapid  $T_3$  transport was energy-independent and  $Na^+$ -independent, which

resembled the T system for aromatic amino acid transport. Slower T<sub>4</sub> uptake did not involve the amino acid transporter.

All tissues may not necessarily have the same mechanism for TH transport across cell membranes. Different tissues appear to have different TH uptake mechanisms, most likely based on their varying roles in regulating thyroidal status. For example, separate hepatic T<sub>4</sub> and T<sub>3</sub> uptake may allow independent regulation of peripheral metabolism. Separate, rapid uptake of T<sub>3</sub> by RBC may allow stable levels of plasma T<sub>3</sub> for autoregulation. In future studies, uptake by enterocytes should be characterized to determine differences in T<sub>4</sub> and T<sub>3</sub> transport properties and to determine regional differences in the intestine. Energy requirements, Na<sup>+</sup> requirements, and inhibition by amino acid concentrations should be tested. This would elucidate whether aromatic amino acid transporters were used for TH uptake or if separate transporters have evolved for intestinal TH absorption. Since uptake of various nutrients is regionally distributed, the differential uptake of TH may be determined by different transporters that are regionally distributed.

**5. TH net loss from the intestine and uptake by the liver, blood, and gall bladder is greater in ligatured sections that include the distal intestine as opposed to those that include the middle intestine alone.**

Overall, the enterohepatic parameters of TH net loss from the intestine and uptake into the liver, blood and gall bladder were greater in ligatured sections that included the distal intestine as opposed to those that included the middle intestine alone. These parameters were evaluated together to determine the potential for TH EHC and what tissues were involved in regulating the potential TH EHC. The intestine and the liver are

the main enterohepatic tissues with the ability to regulate the amount of TH cycling. The intestine serves as a source of TH entering the EHC. From intestinal saturation studies with  $T_3$ , the intestine does not appear to regulate acute doses of TH entering the EHC, since an increased TH dose injected into the lumen results in increased net loss from the intestinal loop. The liver is the pivotal tissue that determines what returns to the intestine via biliary route. It has the ability to regulate the amount and form of TH entering the bile, since it is the main peripheral tissue involved in TH metabolism through deiodination or conjugation. Thus, the liver may regulate the amount of TH cycling.

### ***MI section***

The MI section did not appear to contribute to  $T_4$  or  $T_3$  EHC. For  $T_4$ ,  $^*TH$  were taken up by the liver, however little  $^*T_4$  was measured in the blood and no  $^*T_4$  was measured in the bile. Thus,  $T_4$  could not return to the intestine upon refeeding, completing the  $T_4$  EHC. Radioactivity accumulated in the bile was represented by  $^*T_4$  metabolites such as  $^*TH$  conjugates or  $^*I$ . Conjugates are more water soluble (Visser, 1990) and do not appear to lead to deiodination in trout (Finnson and Eales, 1996), representing an excreted form of TH. The biliary route was an excretory pathway for a high dose of  $T_4$  which was peripherally metabolized, maintaining low levels of  $T_4$  in systemic circulation.

$T_3$  EHC was negligible or non-existent for the MI section.  $T_3$  was taken up by the blood at low dose, maintaining circulating  $T_3$  available to systemic tissues. However, it was not determined what percent of the radioactivity accumulated in the bile was  $^*T_3$ . Even if only  $T_3$  was accumulated in the bile, the amount of radioactive injectate potentially returning to the intestine was minimal. For the  $T_3$  high dose, no  $T_3$  uptake was

measured in the blood, and no  $^*T_3$ , only  $^*T_3$  metabolites, were accumulated in the bile. Thus  $T_3$  could not cycle to and from the MI section. With an increase in  $T_3$ , peripheral tissues quickly metabolized and cleared  $^*T_3$  via the biliary route, preventing a systemic increase in biologically active  $T_3$ .

### ***MI-DI section***

In the MI-DI section, EHC of  $T_4$  was most likely to occur, since net loss from the intestine, TH uptake to the liver and the blood, and accumulation in the bile were the greatest. At a low  $T_4$  dose, little  $^*T_4$ , mainly  $^*T_4$  metabolites, were accumulated in the bile after peripheral metabolism. Thus, at the low levels of  $T_4$ , little  $^*T_4$  remained in circulation, and it would return to the intestine as  $^*T_4$  metabolites. At the high levels of  $T_4$ , absorption from the MI-DI section increased, and only unmetabolized  $^*T_4$  was accumulated in the bile. Together, these indicated an increased potential for  $T_4$  EHC at a high dose of  $T_4$  injected. As with the high  $T_4$  dose, the liver responded to a high dose of  $T_3$  by accumulating only  $^*T_3$  in the bile. Thus, the potential for  $T_3$  EHC also existed, but it was less than for  $T_4$ .

For both  $T_4$  and  $T_3$ , an acute increase in intestinal injectate dose altered TH cycling for the MI-DI section. At high doses, the amount of TH accumulated in the bile was 100% TH. This was different from the metabolism of TH seen in the MI section. The increased percent TH in bile may be a result of saturation of the enzymes in the liver that conjugate excess TH for excretion and removal from the system. Glucuronidation by uridine diphosphoglucuronosyl transferase (UDPGT) and sulfation by phenol sulfotransferases (PST) are significant TH metabolism pathways in rainbow trout, especially for  $T_4$  (Finnson and Eales, 1996, 1997). Such conjugation modifies TH into a

more water-soluble, less absorbable form (Visser, 1990). Hence, this metabolism of TH is considered an excretory pathway. Previous experiments on various teleost fish have shown that up to 50% of TH is conjugated in the liver and excreted to the bile (Sinclair and Eales, 1972; Eales and Collicutt, 1974; Finnson and Eales, 1996). Finnson and Eales (1997) have shown that the UDPGT enzyme is sensitive to various iodothyronines. For example,  $T_4$  can inhibit  $T_3$  glucuronidation. Thus, an increased percent TH in the bile may be a result of saturation or inhibition of enzymes in the liver.

Whereas a greater percent \*TH in the bile could be considered excretion of excess hormone through the gastrointestinal tract, this would not necessarily be a loss of TH from the system. The intestine is a large mass of tissue, and TH in bile entering the intestine could be bound by digesta, temporarily stored, and later transported back into circulation. Overall, the presence of  $T_4$  or  $T_3$  in the MI section resulted in absorption, degradation, and excretion of TH through the biliary pathway. This may be to prevent fluctuations of TH, especially  $T_3$  which is the biologically active form that is more readily absorbed from this region. The presence of  $T_4$  or  $T_3$  in the MI-DI section resulted in greater absorption but also accumulation in the bile as the parent form of TH injected. This represented differential regulation by the liver, allowing TH EHC for TH absorbed from the distal intestine. The presence of TH in different regions of the intestine may activate control of the liver through hormones or the nervous system. This may allow salvaging of TH from the distal region before loss through excretion.

## Conclusions


From these experiments, several specific points were concluded. In regards to measuring net loss of TH from the intestine, insignificant degradation of  $T_4$  or  $T_3$

occurred within a one-hour residence in the intestinal lumen of the MI or the MI-DI section. Thus, net loss from the ligatured intestinal section represented TH absorption. Another concern was that the duration of pre-experimental fasting would affect net loss from the intestine. By performing experiments within 3-5 days of withholding food, TH could not bind to digesta, and the TH cycling to and from the intestine could be measured with insignificant alterations to the physiological state of the fish. Net loss of TH from the intestine depended on the form of TH injected and the region of the intestine investigated. From the MI,  $T_3$  was absorbed to a greater extent.  $T_4$  was absorbed more readily from the DI. However, the duration of TH residence in the intestinal lumen would affect results, as negative feedback at the hypothalamus and pituitary, degradation, and biliary excretion can influence the availability of systemic TH. There was no evidence for saturable TH transporters for TH intestinal absorption. However, a carrier system that is very abundant or saturable at a higher dose cannot be excluded. Since absorption of TH was dependent on the form of TH and the region of the intestine, there may be different transporters for  $T_4$  and  $T_3$  distributed regionally.

With TH absorption from the intestine and accumulation in the bile, the potential for TH EHC was evaluated. The MI did not appear to contribute to  $T_4$  or  $T_3$  EHC. This may be to prevent fluctuations of TH, especially  $T_3$  which is the biologically active form that is more readily absorbed from this region. The MI and DI together can potentially cycle TH to and from the intestine, with  $T_4$  returning to a greater extent than  $T_3$ . This may allow salvaging of TH from the distal region before loss through excretion. Therefore the intestine, through absorption and EHC, could serve as an extrathyroidal source of TH for tissues.

This study established an *in vivo* method to evaluate the complete TH EHC from the intestine to blood to liver to bile. Using the *in vivo* method established, it was shown that the intestine served as a source of TH. However the intestine itself did not regulate increases of TH within one hour. Neither TH metabolism nor saturation at high TH doses occurred in the intestinal lumen. Rather, the liver moderated TH EHC through TH metabolism and accumulation of \*TH and \*TH metabolites in the bile. Previously, the intestine was shown to regulate TH metabolism under TH challenges, so the question was asked whether the intestine could regulate TH EHC with similar TH challenges. In the next chapter, the effects of chronic dietary TH challenges on potential TH EHC were examined. This was to determine if and how the availability of TH in EHC may be regulated by the intestine, hence the role of the intestine in regulating thyroidal status.

## Set-up



## Double-ligatured intestinal sections




Figure 5-1. Methods used for characterization of *in vivo* absorption of TH from a double-ligatured intestinal section. The set-up demonstrates the flow of water and anesthesia over the gills while the intestine was exposed. The double-ligatured intestinal sections demonstrate where ligatures were tied to make MI sections and MI-DI sections. The site of injection in the MI, as indicated, was consistent for both sections.



Table 5-1. Comparisons of the injectate standard (STANDARD) and the injected intestinal section (INTESTINE) when analyzed for the percent of the radioactivity remaining as labeled hormone (%\*TH) after one hour. Injectate was \*T<sub>4</sub> or \*T<sub>3</sub> with a low dose (200 fmoles) or high dose (100 pmoles) of the corresponding unlabeled TH. Intestine includes luminal contents and tissue from the double-ligatured MI or MI-DI section that was injected with \*TH. N.A. denotes not assayed.

PERCENT *TH REMAINING (%*TH)				
	T <sub>4</sub> LOW	T <sub>4</sub> HIGH	T <sub>3</sub> LOW	T <sub>3</sub> HIGH
<b>MI</b>				
STANDARD (n=1)	N.A.	72.3	77.7	65.8
INTESTINE (n=3)	N.A.	71.1 ± 11.9	77.7 ± 7.6	69.4 ± 9.3
<b>MI-DI</b>				
STANDARD (n=1)	56.1	77.6	93.4	78.7
INTESTINE (n=3)	69.9 ± 7.2	78.9 ± 4.1	N.A.	66.2 ± 7.1

Table 5-2. Effects of duration of pre-experimental fasting on the fate of  $^*T_3$  injected one hour previously into the lumen of the double-ligated MI-DI section.

LENGTH OF PRE-EXPERIMENTAL FASTING (days)			
	3-5 (n=4)	6-10 (n=3)	11-14 (n=3)
NET LOSS (%)*	6.1 $\pm$ 6.1	11.0 $\pm$ 5.6	13.3 $\pm$ 12.2
TOTAL UPTAKE			
LIVER (%/mg)	68.3 $\pm$ 24.3	20.7 $\pm$ 11.5	16.0 $\pm$ 8.0
BLOOD (%/mg)	23.0 $\pm$ 9.6	3.7 $\pm$ 1.9	2.5 $\pm$ 1.5
BILE (%)*	0.0670 $\pm$ 0.0195	0.0530 $\pm$ 0.0189	0.0136 $\pm$ 0.0023

\* units in percent of total injectate (%),  
instead of percent of total injectate/mg tissue \* g of body weight/500g (%/mg)

Table 5-3. Net loss of  $^*T_4$  and  $^*T_3$  injected one hour previously into the lumen of the double-ligatured MI section and MI-DI section, accompanied by either a low dose (200 fmoles) or a high dose (100 pmoles) of the corresponding unlabeled TH. N.A. denotes not assayed. Letters indicate significant differences at  $p \leq 0.050$ .

NET LOSS FROM INTESTINAL SECTION (%)				
	<b>T<sub>4</sub> LOW</b>	<b>T<sub>4</sub> HIGH (n=9)</b>	<b>T<sub>3</sub> LOW (n=4)</b>	<b>T<sub>3</sub> HIGH (n=9)</b>
<b>MI<sup>a</sup></b>	N.A.	10.7 ± 2.9	5.4 ± 1.1	15.4 ± 2.2
<b>MI-DI</b>	N.A.	17.3 ± 6.2	6.1 ± 0	6.0 ± 1.4
<sup>a</sup> p=0.034	among injectates			

Table 5-4. Fate of  $^*T_4$  injected one hour previously into the lumen of the double-ligated MI section, accompanied by either a low dose (200 fmoles) or a high dose (100 pmoles) of the corresponding unlabeled TH. N.A. denotes not assayed. Letters indicate significant differences at  $p \leq 0.050$ .

		<b>T<sub>4</sub> LOW</b>		<b>T<sub>4</sub> HIGH</b>	
		<b>MI</b>	<b>MI-DI (n=3)</b>	<b>MI (n=3)</b>	<b>MI-DI (n=9)</b>
<b>NET LOSS (%)*</b>					
		N.A.	N.A.	$10.7 \pm 2.9$	$17.3 \pm 6.2$
<b>UPTAKE BY LIVER (%/mg)</b>					
<b>TH</b>	N.A.		$1.9 \pm 0.3$	$5.7 \pm 1.5$	$23.2 \pm 7.7^a$
<b>TH MET</b>	N.A.		$11.1 \pm 1.7$	$5.3 \pm 1.5$	$72.8 \pm 24.3$
<b>UPTAKE BY BLOOD (%/mg)</b>					
<b>TH</b>	N.A.		$0.5 \pm 0.1$	$0.2 \pm 0.2$	$24.7 \pm 7.3^b$
<b>TH MET</b>	N.A.		$31.5 \pm 8.9$	$13.3 \pm 2.3$	$63.3 \pm 18.7$
<b>ACCUMULATION IN BILE (%)*</b>					
<b>TH</b>	N.A.		$0.0013 \pm 0.0003$	0	$0.0210 \pm 0.0120$
<b>TH MET</b>	N.A.		$0.0087 \pm 0.0037$	$0.0028 \pm 0.0020$	0

<sup>a</sup> $p=0.010$  MI vs. MI-DI

<sup>b</sup> $p=0.054$  MI vs. MI-DI

\*units in percent of total injectate (%),

instead of percent total injectate/mg of tissue \* g of body weight/500g (%/mg)

Table 5-5. Fate of  $^*T_3$  injected one hour previously into the lumen of the double-ligated MI section, accompanied by either a low dose (200 fmoles) or a high dose (100 pmoles) of the corresponding unlabeled TH. N.A. denotes not assayed. Letters indicate significant differences at  $p \leq 0.050$ .

		<b>T<sub>3</sub> LOW</b>		<b>T<sub>3</sub> HIGH</b>	
		<b>MI (n=3)</b>	<b>MI-DI (n=4)</b>	<b>MI (n=3)</b>	<b>MI-DI (n=5)</b>
<b>NET LOSS (%)*</b>					
		5.4 ± 1.1	6.1 ± 0	15.4 ± 2.2	6.0 ± 1.4 <sup>a</sup>
<b>UPTAKE TO LIVER (%/mg)</b>					
<b>TOTAL†</b>				0.0017 ± 0.0007	
<b>TH</b>	0.3 ± 0.3	45.1 ± 16.1 <sup>b</sup>	N.A.	0.7 ± 0.1	
<b>TH MET</b>	0	22.9 ± 7.9	N.A.	0.3 ± 0.9	
<b>UPTAKE TO BLOOD (%/mg)</b>					
<b>TH</b>	0.3 ± 0.3	5.9 ± 2.5	0	4.7 ± 1.6 <sup>c</sup>	
<b>TH MET</b>	0	17.1 ± 7.5	2.7 ± 1.5	0.3 ± 0.4	
<b>ACCUMULATION IN BILE (%)*</b>					
<b>TOTAL†</b>	0.0003 ± 0.0002	0.0670 ± 0.0390			
<b>TH</b>	N.A.	N.A.	0	0.0070 ± 0.0002 <sup>d</sup>	
<b>TH MET</b>	N.A.	N.A.	0.0073 ± 0.0048	0	

<sup>a</sup>  $p=0.022$  MI vs. MI-DI

<sup>b</sup>  $p=0.040$  MI vs. MI-DI

<sup>c</sup>  $p=0.044$  MI vs. MI-DI

<sup>d</sup>  $p=0.012$  MI vs. MI-DI

† total radioactivity uptake or accumulation reported,  
when  $^*TH$  uptake and  $^*TH$  metabolite uptake were not assayed.

\* units in percent of total injectate (%),  
instead of percent total injectate/mg of tissue \* g of body weight/500g (%/g).

## Chapter 6

### Effects of Chronic Dietary Thyroid Hormone Challenges on *In vivo* Uptake of Thyroxine and Triiodothyronine by Enterohepatic Tissues of Rainbow Trout

#### Introduction

In mammals, the intestine provides a dynamic pool of thyroid hormones (TH), thyroxine ( $T_4$ ) and triiodothyronine ( $T_3$ ), where metabolism, storage, and absorption take place (DiStefano, 1988). Under induced hypothyroidism, rats excrete less  $T_3$  and absorb more  $T_3$  and  $T_4$  from the intestine, compensating for low available  $T_3$  (DiStefano *et al.*, 1993). Thus, the intestinal pool is utilized under physiological changes to maintain thyroidal status.

In rainbow trout and other teleost fish, negligible work has been done on the role of the intestine in regulating TH. In trout, peripheral tissues contribute to the regulation of thyroidal status (Eales, 1995). Hence, the intestine, with access to TH, may contribute to TH availability through enterohepatic circulation (EHC) of TH from the intestine to the blood to the liver to the bile and back to the intestine. Rainbow trout intestine has access to TH through the diet, the systemic blood circulation, intestinal metabolism, and the biliary supply (Figure 1-4). TH enter through the diet (MacKenzie *et al.*, 1993). Dietary TH challenges (Sweeting and Eales, 1992b) or injections of TH into the intestine (Whitaker and Eales, 1993) have shown that TH can be absorbed from the intestine, resulting in plasma  $T_3$  circulating at higher levels than plasma  $T_4$  levels. TH may be excreted into the bile as TH or TH conjugates, with  $T_4$  conjugated to a greater extent than  $T_3$  (Finnsen and Eales, 1997). Yet, previous studies ultimately conclude that negligible

T<sub>4</sub> and limited T<sub>3</sub> recycling occurs through enterohepatic routes for channel catfish (Collicutt and Eales, 1974), brook trout (Eales and Sinclair, 1974) and rainbow trout (Whitaker and Eales, 1993).

Despite these conclusions, findings reported in Chapter 4 suggest a role of the intestine in regulating fluctuating levels of dietary TH available for absorption by modulating TH metabolism. In Chapter 5, it was shown that loss of TH from the intestinal lumen and uptake into EHC tissues could be measured one hour after injection of \*TH into the lumen. These results also showed that the potential for T<sub>4</sub> EHC was greater than that for T<sub>3</sub> EHC, and that the middle and distal intestinal section (MI-DI section), not the middle intestinal section alone (MI section), were involved in TH EHC. Furthermore, acute increases in injectate dose resulted in increased potential TH EHC. Therefore, the intestine, through TH EHC, could serve as an extrathyroidal source of TH.

In this chapter, investigations of the role of the intestine in contributing to the regulation of thyroidal status following dietary T<sub>4</sub> or T<sub>3</sub> challenges are described. This was evaluated by determining the loss from the lumen and uptake into EHC tissues of labeled T<sub>4</sub> (\*T<sub>4</sub>) or labeled T<sub>3</sub> (\*T<sub>3</sub>) injected with the corresponding unlabeled TH at low (200 fmoles) or high (100 pmoles) doses into the MI-DI section after trout were fed T<sub>4</sub>- or T<sub>3</sub>-supplemented food for 7 days. Owing to the need to clear the intestine of digesta before these measurements could be made, all trout were fasted for 3-4 days following dietary T<sub>4</sub> or T<sub>3</sub> challenges, immediately prior to injection of \*TH. Both T<sub>4</sub> and T<sub>3</sub> were used in the experiments based on the assumption that T<sub>4</sub> and T<sub>3</sub> metabolism are to a considerable degree independently regulated (Eales and Brown, 1993). Consequently, experimental conditions were designed to investigate the following hypotheses:

1. Dietary  $T_4$  or  $T_3$  challenges 3-4 days previously will elevate plasma  $T_3$  but not plasma  $T_4$  levels.
2. Net loss of  $T_4$  from the MI-DI section is greater than net loss of  $T_3$ .
3.  $T_4$  and  $T_3$  uptake across the wall of the intestinal lumen do not involve saturable transport systems.
4. A prior dietary  $T_4$  challenge, not a dietary  $T_3$  challenge, will modify aspects of  $T_4$  metabolism by the enterohepatic tissues.
5. A prior dietary  $T_3$  challenge, not a dietary  $T_4$  challenge, will modify aspects of  $T_3$  metabolism by the enterohepatic tissues.

## **Materials and Methods**

### **Fish maintenance**

Rainbow trout were obtained from Rockwood Hatchery (Gunton, Manitoba) and held at the University of Manitoba in running, aerated, dechlorinated, City of Winnipeg water at 12°C and 12L:12D photoperiod. Trout (mean weight 1116.5 g; range 409-2033 g) were acclimated in 3 tanks (60-cm x 60-cm x 60-cm) for 7 days with 6 fish per tank and fed once daily with commercial trout food (3.2 mm, Martin Feed Mills) at 1% of body mass.

### **Experimental protocol**

To address the various hypotheses stated in the introduction, three groups of trout ( $n=3$  per group) were used to test the effects of dietary TH challenges. Following acclimation, each group was fed either trout food sprayed with  $T_4$  dissolved in methanol to provide 12 ppm  $T_4$  ( $T_4$  TRT), food sprayed with  $T_3$  dissolved in methanol to provide



12 ppm  $T_3$  ( $T_3$  TRT), or food sprayed with methanol alone (control). In order to generate the final sample sizes ( $n=3-9$ ), this was repeated six times during August 30, 2000 to November 10, 2000. After 7 days of experimental feeding, trout were fasted for 3-4 days to allow the intestine to empty. They were then injected with intestinal perfusate consisting of  $^*T_4$  or  $^*T_3$  ( $>800 \mu\text{Ci}/\mu\text{g}$ , New England Nuclear) accompanied by the corresponding unlabeled TH at a low dose (200 fmoles) or a high dose (100 pmoles) consistently injected into the lumen of the middle intestine of a double-ligated MI-DI section. Trout were sampled one hour later.

### **Preparation of intestinal sections**

Trout were anesthetized, the body cavity opened, and a section of the intestine that contained the middle and distal regions was double-ligated to form the MI-DI section, as described in Chapter 5. The placement of the ligatures ensured adequate blood supply to and from the intestine by keeping large vessels intact. The intestinal section included the site of entry if TH were in biliary discharge. In addition, the MI-DI section included regions of the intestine where deiodination was known to occur, as measured in Chapters 3 and 4.

### **Sampling**

The trout tissues (intestinal section and contents, liver, cardiac whole blood, and bile) were sampled one hour after injection into the MI-DI section, as described in Chapter 5. An additional 3 mL of blood was centrifuged at 17,000 g for 5 min to separate the plasma, with 0.5 mL frozen at  $-76^\circ\text{C}$  for later analysis of plasma TH levels using radioimmunoassays.

### **Tissue extractions**

For all tissues, except for bile, the radioactivity was extracted with methanolic ammonia after 24 hours of protease digestion, as described in Chapter 5.

### **Identification of radioactive substances**

Radioactive substances were identified as \*TH or \*TH metabolites for tissue extracts and bile after separation on LH-20 columns, as described in Chapter 5. The correction factor for column recovery can be found in Appendices VII and VIII.

### **Plasma T<sub>4</sub> and T<sub>3</sub> levels**

Using solid-phase radioimmunoassay (RIA) modified from Brown and Eales (1977), Omeljaniuk *et al.* (1984) and Kohel *et al.* (2001), separate T<sub>4</sub> and T<sub>3</sub> RIA were performed on G-25 Sephadex columns, as described in Chapter 4.

### **Calculations**

Several calculations were made to evaluate the EHC of T<sub>4</sub> and T<sub>3</sub> through determinations of loss of injectate from the intestinal section, uptake of radioactivity by the liver or blood, accumulation of radioactivity in the bile, and the forms of radioactivity in these tissues. Details on the following calculations are described in Chapter 5.

1. Net loss of total injected radioactivity from the intestinal section (%).
2. Percent \*TH in the intestinal section, liver, blood, or bile (%).
3. Uptake by the liver or blood
  - a. Total radioactivity uptake by the liver or blood (%/mg).
  - b. \*TH uptake by the liver or blood (%/mg).
  - c. \*TH metabolite uptake by the liver or blood (%/mg).

4. Accumulation in the bile
  - a. Total radioactivity accumulation in the bile (%).
  - b. \*TH accumulation in the bile (%).
  - c. \*TH metabolite accumulation in the bile (%).

### **Experimental tests**

The above parameters were measured under various conditions to test the previously stated hypotheses.

#### **1. Effects of dietary T<sub>4</sub> and T<sub>3</sub> challenges on plasma TH levels.**

Plasma T<sub>4</sub> and T<sub>3</sub> levels were measured to determine whether dietary TH challenges resulted in physiological increases in TH. This prediction was based on data from Chapter 4 in which trout were fed TH until one day before sampling and plasma T<sub>3</sub>, but not plasma T<sub>4</sub>, was significantly elevated. This was assessed by comparing plasma T<sub>4</sub> and T<sub>3</sub> levels among controls, T<sub>4</sub> TRT, and T<sub>3</sub> TRT.

#### **2. Comparisons of T<sub>4</sub> and T<sub>3</sub> net loss from the intestinal lumen.**

Net loss of T<sub>4</sub> from the intestinal lumen was compared to net loss of T<sub>3</sub>. This was in part a re-examination of a hypothesis tested in Chapter 5 by repeating the techniques with, in most cases, a larger sample size, but this was further investigated by following net loss of TH from the intestine after dietary T<sub>4</sub> and T<sub>3</sub> challenges. This was accomplished by comparing net loss of T<sub>4</sub> and T<sub>3</sub> for control fish. This was repeated separately for T<sub>4</sub>-treated fish and T<sub>3</sub>-treated fish.

**3. Effects of a high dose of  $T_4$  or  $T_3$  on  $T_4$  or  $T_3$  net loss from the intestinal lumen.**

The uptake of the radioactive portion of TH injected was measured to see if there was a reduction in the presence of a high concentration of unlabeled TH in the lumen, demonstrating the involvement of a saturable intestinal transporter. To measure this, the non-radioactive dose was varied to include a low TH dose of 200 fmoles and a high TH dose of 100 pmoles. This was a re-examination of a hypothesis in Chapter 5 by repeating the techniques with larger sample sizes, but this was further investigated by measuring net loss of TH high dose from the intestine after dietary  $T_4$  and  $T_3$  challenges. This was accomplished by comparing  $T_4$  low and high dose net loss for controls and by comparing  $T_3$  low and high dose net loss for controls. This was repeated separately for  $T_4$ -treated fish and  $T_3$ -treated fish.

**4. Effects of dietary  $T_4$  or  $T_3$  challenges on  $^*T_4$  metabolism in fish also injected with a low dose of unlabeled  $T_4$ .**

This looked at the effects of chronic physiological TH challenges on how a low dose of TH in the intestine, which could be encountered in the diet, were handled by the enterohepatic tissues. The  $T_4$  net loss, uptake to the liver or blood, and accumulation in the bile were measured to see if there were alterations in  $^*T_4$  or  $^*T_4$  metabolites in EHC tissues. The prediction was that  $T_4$  and  $T_3$  were to a large degree independently regulated. Thus, a dietary  $T_3$  challenge was not expected to alter  $^*T_4$  metabolism in EHC tissues. This was surmised by comparing amounts of  $^*T_4$  or  $^*T_4$  metabolites in each EHC tissue among controls,  $T_4$  TRT, and  $T_3$  TRT.

**5. Effects of dietary T<sub>4</sub> or T<sub>3</sub> challenges on \*T<sub>4</sub> metabolism in fish also injected with a high dose of unlabeled T<sub>4</sub>.**

The same methods, predictions and tests were used as above, however a high dose of T<sub>4</sub>, not a low dose of T<sub>4</sub>, accompanied the \*T<sub>4</sub> injected into the lumen.

**6. Effects of dietary T<sub>4</sub> or T<sub>3</sub> challenges on \*T<sub>3</sub> metabolism in fish also injected with a low dose of unlabeled T<sub>3</sub>.**

The T<sub>3</sub> net loss, uptake to the liver and the blood, and accumulation in the bile were measured to see if there was an alteration in \*T<sub>3</sub> or \*T<sub>3</sub> metabolites in EHC tissues. The prediction was that T<sub>4</sub> and T<sub>3</sub> were to a large degree independently regulated. Thus, a dietary T<sub>4</sub> challenge was not expected to alter \*T<sub>3</sub> metabolism in EHC tissues. This was surmised by comparing amounts of \*T<sub>3</sub> or \*T<sub>3</sub> metabolites in each EHC tissue among controls, T<sub>4</sub> TRT, and T<sub>3</sub> TRT.

**7. Effects of dietary T<sub>4</sub> or T<sub>3</sub> challenges on \*T<sub>4</sub> metabolism in fish also injected with a low dose of unlabeled T<sub>4</sub>.**

The same methods, predictions, and tests were used as above, however a high dose of T<sub>3</sub>, not a low dose of T<sub>3</sub>, accompanied the \*T<sub>3</sub> injected into the lumen.

### **Statistics**

Using the SPSS statistical package, univariate analysis of variance (ANOVA) was used to compare plasma T<sub>4</sub> means or plasma T<sub>3</sub> means for the effects of treatments (C, T<sub>4</sub> TRT, and T<sub>3</sub> TRT) at Day 7. This was followed by LSD post hoc multiple comparisons to determine significant differences among treatments. Independent t-tests were used to compare means for net loss of TH from the intestinal section between T<sub>4</sub> low dose and T<sub>3</sub> low dose or T<sub>4</sub> high dose and T<sub>3</sub> high dose. Independent t-tests were also used to

compare means for net loss of TH from the intestinal section between T<sub>4</sub> low dose and T<sub>4</sub> high dose or T<sub>3</sub> low dose or T<sub>3</sub> high dose. For each component of TH EHC studied (net loss of TH from the intestinal section, uptake by the liver, uptake by the blood, and accumulation in the bile), means were compared for the effects of treatments. Each TH injectate (T<sub>4</sub> low dose, T<sub>4</sub> high dose, T<sub>3</sub> low dose, or T<sub>3</sub> high dose) was analyzed separately. This was followed by LSD post hoc multiple comparisons to determine significant differences among treatments from controls. Results were significantly different at  $p \leq 0.05$ .

## Results

### Effects of dietary T<sub>4</sub> and T<sub>3</sub> challenges on plasma TH levels

A dietary T<sub>4</sub> challenge did not significantly change plasma T<sub>4</sub> levels from controls (Figure 6-1). A dietary T<sub>3</sub> challenge increased plasma T<sub>3</sub> (1.58 ng/mL) from controls (0.13 ng/mL), however, the 10-fold increase was not significant ( $F=1.026$ , d.f.=2,  $p=0.362$ ). This may be largely due to the very high standard error of the T<sub>3</sub>-treated fish.

### Comparisons of T<sub>4</sub> and T<sub>3</sub> net loss from the intestinal lumen

In control fish, net loss of T<sub>4</sub> low dose from the intestinal section was not significantly different from net loss of T<sub>3</sub> low dose in control fish ( $t=1.140$ , d.f.=10,  $p=0.281$ ; Tables 6-1 and 6-2). This trend remained the same with dietary TH challenges.

In control fish, net loss of T<sub>4</sub> high dose from the intestinal section was significantly greater than net loss of T<sub>3</sub> high dose ( $t=6.949$ , d.f.=4,  $p=0.002$ ). This difference in absorption between T<sub>4</sub> and T<sub>3</sub> was abolished with T<sub>3</sub> TRT because a dietary T<sub>3</sub> challenge increased net loss of T<sub>3</sub> high dose.

### **Effects of a high dose of T<sub>4</sub> or T<sub>3</sub> on T<sub>4</sub> or T<sub>3</sub> net loss from the intestinal lumen**

Net loss of \*T<sub>4</sub> from the intestine did not change significantly with an increase in unlabeled T<sub>4</sub> injected simultaneously ( $t=0.122$ , d.f.=6,  $p=0.907$ ; Table 6-1). Dietary TH challenges of T<sub>4</sub> and T<sub>3</sub> did not affect net loss of T<sub>4</sub> low or high doses ( $F=0.500$ , d.f.=2,  $p=0.617$  or  $F=0.138$ , d.f.=2,  $p=0.873$ , respectively).

Net loss of \*T<sub>3</sub> from the intestine decreased significantly with an increase in unlabeled T<sub>3</sub> injected simultaneously ( $t=4.504$ , d.f.=9,  $p=0.001$ ; Table 6-2), indicating the presence of a saturable intestinal transport mechanism for T<sub>3</sub> absorption from the intestine. Unlike \*T<sub>4</sub> net loss, dietary T<sub>4</sub> and T<sub>3</sub> challenges significantly increased \*T<sub>3</sub> net loss. T<sub>4</sub> TRT increased both net loss of T<sub>3</sub> low dose ( $F=3.546$ , d.f.=2,  $p=0.031$ ) and net loss of T<sub>3</sub> high dose ( $F=21.325$ , d.f.=2,  $p=0.038$ ). Therefore, chronic T<sub>4</sub> did not affect saturability of the T<sub>3</sub> transporter. T<sub>3</sub> TRT did not significantly alter net loss of T<sub>3</sub> low dose ( $F=3.546$ , d.f.=2,  $p=0.349$ ), yet it increased net loss of T<sub>3</sub> high dose ( $F=21.325$ , d.f.=2,  $p=0.000$ ). Therefore, chronic T<sub>3</sub> altered characteristics of T<sub>3</sub> absorption such that net loss of \*T<sub>3</sub> was not saturable.

### **Effects of dietary T<sub>4</sub> or T<sub>3</sub> challenges on \*T<sub>4</sub> metabolism in fish also injected with a low dose of unlabeled T<sub>4</sub>**

In control fish, 13.2% of the total T<sub>4</sub> low dose injected was lost from the intestinal section (Table 6-1). From the liver, mainly \*T<sub>4</sub> metabolites entered systemic circulation, while mainly \*T<sub>4</sub> was excreted to the bile (0.0042%).

With a dietary T<sub>4</sub> challenge, \*T<sub>4</sub> net loss from the intestine, \*T<sub>4</sub> uptake to the liver and the blood, and \*T<sub>4</sub> accumulation in the bile were not altered significantly. However, the amount of \*T<sub>4</sub> metabolites accumulated in the bile increased significantly to 0.0063%

of the total  $T_4$  injected ( $F=9.657$ , d.f.=2,  $p=0.001$ ), which was comparable to the amount of  $*T_4$  accumulated in the bile (0.0062%).

With a dietary  $T_3$  challenge, only  $*T_4$  uptake to the blood increased significantly ( $F=4.148$ , d.f.=2,  $p=0.031$ ).

#### **Effects of dietary $T_4$ or $T_3$ challenges on $*T_4$ metabolism in fish also injected with a high dose of unlabeled $T_4$**

In control fish, 13.9% of the total  $T_4$  high dose injected was lost from the intestinal section (Table 6-1). A larger portion of  $*T_4$  than  $*T_4$  metabolites were measured in the liver. From the liver, comparable amounts of  $*T_4$  and  $*T_4$  metabolites entered the systemic circulation, while mainly  $*T_4$  was accumulated in the bile (0.0009%).

With a dietary  $T_4$  challenge,  $*T_4$  net loss from the intestine and  $*T_4$  uptake to the liver and the blood did not change significantly. Both  $*T_4$  (0.0073%) and  $*T_4$  metabolite (0.0024%) accumulation in bile increased, but not significantly ( $F=1.203$ , d.f.=2,  $p=0.179$  and  $F=1.209$ , d.f.=2,  $p=0.314$ ).

With a dietary  $T_3$  challenge,  $*T_4$  net loss from the intestine and  $*T_4$  uptake to the liver and the blood, and  $*T_4$  accumulation in the bile were unaltered.

#### **Effects of dietary $T_4$ or $T_3$ challenges on $*T_3$ metabolism in fish also injected with a low dose of unlabeled $T_3$**

Without dietary TH challenges, 9.7% of total  $T_3$  low dose injected was lost from the intestine (Table 6-2). Comparable amounts of  $*T_3$  and  $*T_3$  metabolites were measured in the liver. From the liver, less  $*T_3$  than  $*T_3$  metabolites entered the systemic



circulation. Also from the liver, only  $^*T_3$  metabolites were accumulated in the bile (0.0089%).

With a dietary  $T_4$  challenge,  $^*T_3$  net loss increased significantly to 16.5% of the total  $T_3$  injected ( $F=3.546$ , d.f.=2,  $p=0.031$ ).  $^*T_3$  uptake to liver did not increase significantly. However,  $^*T_3$  uptake to blood ( $F=4.144$ , d.f.=2,  $p=0.029$ ) and  $^*T_3$  accumulation in bile (0.0025%;  $F=2.613$ , d.f.=2,  $p=0.036$ ) increased significantly.

With a dietary  $T_3$  challenge,  $^*T_3$  net loss did not change significantly (9.4%).  $^*T_3$  uptake to the liver and blood were not altered significantly.  $^*T_3$  accumulated in the bile (0.0017%) increased, but not significantly ( $F=2.613$ , d.f.=2,  $p=0.136$ ). However,  $^*T_3$  metabolites accumulated in the bile (0.0009%) decreased significantly ( $F=2.696$ , d.f.=2,  $p=0.030$ ).

#### **Effects of dietary $T_4$ or $T_3$ challenges on $^*T_3$ metabolism in fish also injected with a high dose of unlabeled $T_3$**

Without dietary TH challenges, 0.1% of the total  $^*T_3$  high dose injected was lost from the intestine (Table 6-2). All of the radioactivity measured in the liver was in the form of  $^*T_3$ . From the liver, no  $^*T_3$  was measured in the blood, only  $^*T_3$  metabolites. No radioactivity,  $^*T_3$  or  $^*T_3$  metabolites, was accumulated in the bile.

With a dietary  $T_4$  challenge,  $^*T_3$  net loss from the intestine increased significantly to 8.9% of the total  $^*T_3$  injectate ( $F=21.325$ , d.f.=2,  $p=0.038$ ). Both  $^*T_3$  and  $^*T_3$  metabolites measured in the liver increased, but not significantly.  $^*T_3$  uptake to the blood increased significantly ( $F=4.107$ , d.f.=2,  $p=0.015$ ). Radioactivity accumulated in the bile was detected (0.0284%), but the form of radioactivity,  $^*T_3$  and/or  $^*T_3$  metabolites, was not assayed.

With a dietary  $T_3$  challenge,  $*T_3$  net loss from the intestine increased significantly to 22.3% of the total  $T_3$  injectate ( $F=21.325$ , d.f.=2,  $p=0.000$ ).  $*T_3$  measured in the liver was not significantly altered. The amount of  $*T_3$  and  $*T_3$  metabolites taken up by the blood increased, but not significantly. No  $*T_3$  was accumulated in the bile, but  $*T_3$  metabolites accumulated in the bile increased significantly to 0.0295% of the total injectate ( $F=5.290$ , d.f.=2,  $p=0.050$ ).

### Discussion

In rainbow trout, the role of the intestine in contributing to the regulation of thyroidal status is unknown. The goal of the present study was to evaluate the potential for TH EHC and the effects of chronic dietary TH challenges on the TH EHC. The Discussion is organized according to the hypotheses presented in the Introduction.

#### 1. **Dietary $T_4$ or $T_3$ challenges 3-4 days previously did not significantly elevate plasma $T_3$ nor plasma $T_4$ levels.**

A prior dietary  $T_3$  challenge elevated plasma  $T_3$  levels, though not significantly. A prior dietary  $T_4$  challenge did not elevate plasma  $T_4$  levels. The purpose of feeding TH over a period of 7 days was to create physiological  $T_4$  or  $T_3$  challenges and to determine their effects on the compensatory TH metabolism in the enterohepatic tissues, with the underlying assumption that the effects would persist after 3-4 days of fasting. Based on the results of a similar feeding protocol in Experiment 4, but which was continued until the day before sampling, it was anticipated that there would be no change in plasma  $T_4$  based on a dietary  $T_4$  challenge, but there might be an elevation in plasma  $T_3$  based on a dietary  $T_3$  challenge. In the present experiment, there was indeed no change in plasma  $T_4$ .

Although the  $T_3$  challenge that was terminated 3 days prior to sampling did not produce a statistically significant elevation in plasma  $T_3$ , it did result in some high plasma  $T_3$  values such that the mean plasma  $T_3$  was over 10-fold that of controls. Therefore, it is clear that even 3 days after the end of feeding, at least some of the  $T_3$ -treated fish were still in a period of adjustment to the dietary  $T_3$  challenge. There are no previous studies in trout on the short-term time-course of readjustment in plasma  $T_3$  levels following withdrawal of a chronic dietary  $T_3$  challenge. However,  $T_3$  dependency was found following removal of the dietary  $T_3$  challenge (Eales and Finnson, 1991). Plasma  $T_3$  levels fell to subnormal levels, and enzyme pathways, such as  $T_4$ ORD, required at least 6 weeks to return to normal activity levels. Hence, the lack of significant change in plasma levels may represent a rapid regulation of plasma TH levels. Even though trout exhibited this stability of plasma TH levels, other physiological changes, such as enzyme pathways for TH metabolism would still be affected.

A prior dietary TH challenge can alter the physiological state of the trout (Higgs *et al.*, 1979), which influences regulation of TH (Eales *et al.*, 1993), as was addressed in Chapter 4. The main regulation of plasma  $T_4$  is the central control mechanism involving the release of  $T_4$  from the thyroid tissue and its regulation via negative feedback at the hypothalamus and pituitary (Eales *et al.*, 1990; Eales and Himick, 1991). Central control of plasma  $T_4$  levels can occur very quickly, but it will only be as effective as long as the  $T_4$  absorption from the intestine does not exceed the normal rate of  $T_4$  secretion by the thyroid. Beyond this point, the central control cannot compensate for the increase in plasma  $T_4$ . Other mechanisms of  $T_4$  regulation may include, but are not limited to, the induced conversion of hepatic  $T_4$ IRD which degrades  $T_4$  to  $rT_3$ , the deiodination

pathways in the intestinal tissue itself (pathways described in Chapters 3 and 4 which mainly degrade  $T_4$ ), and increased biliary excretion of  $T_4$  and  $T_4$  metabolites (described in Chapter 5 and a focus of this chapter to be discussed later).

The mechanisms of  $T_3$  autoregulation, which were discussed in Chapter 4, differed from  $T_4$  regulation. Since thyroidal  $T_3$  secretion is not thought to be extensive, the main control of  $T_3$  availability involves peripheral mechanisms of regulation. These include the reduction of hepatic  $T_4$ ORD activity which reduces  $T_3$  formation (Eales and Finnson, 1991), possible uptake into muscles, changes in intestinal deiodination (as described in Chapter 4), and increased biliary excretion of  $T_3$  and  $T_3$  metabolites (initially investigated in Chapter 5 and a focus of this chapter to be discussed later).

Thus, the dietary  $T_4$  challenge may have increased compensatory mechanisms and prevented increased plasma  $T_4$  levels. Feeding trout  $T_3$  increased plasma  $T_3$  levels and resulted in a physiological challenge, supporting the hypothesis. After a 3-day cessation of the challenge, many fish compensated, as was detected by some plasma  $T_3$  levels reverting to control levels.

## **2. Net loss of $T_4$ from the MI-DI section is greater than net loss of $T_3$ .**

When TH net loss was measured, it was assumed that all radioactivity lost from the intestinal section was the intact TH initially injected. This was based on Chapter 5's comparisons of percent TH in the injectate and percent TH remaining in the intestinal section one hour after TH injection into the lumen. Since there was no difference between the two percentages, preferential net loss of  $^*I^-$  contamination over  $^*TH$  or intestinal metabolism of  $^*TH$  did not occur. Thus, TH net loss represented TH absorption from the lumen of the intestinal section.

\*T<sub>4</sub> was more readily absorbed from the intestine than \*T<sub>3</sub>, with a net loss of \*T<sub>4</sub> high dose significantly greater than \*T<sub>3</sub> high dose. Interestingly, if only plasma TH levels had been measured, then it would have appeared that T<sub>3</sub> was absorbed to a greater extent than T<sub>4</sub>. As discussed in Chapter 5, it was previously believed that T<sub>3</sub> was absorbed from the intestine more effectively than T<sub>4</sub>. However, measurements of net loss of \*TH from the intestinal loop in Chapter 5 and data from this chapter do not support this conclusion. The difference in plasma levels may represent negative feedback of T<sub>4</sub> at the hypothalamo-pituitary level, decreasing thyroidal output of T<sub>4</sub>. T<sub>4</sub> exerts a strong negative feedback on the hypothalamo-pituitary-thyroid axis, but T<sub>3</sub> exerts little influence (Eales and Himick, 1991). There may be a difference in plasma TH levels due to clearance pathways that are more sensitive to T<sub>4</sub> than T<sub>3</sub>. For example, greater amounts of T<sub>4</sub> are conjugated for excretion to the bile than T<sub>3</sub> (Finnson and Eales, 1997). Together, these regulatory pathways would preferentially reduce plasma T<sub>4</sub> over T<sub>3</sub>.

The net loss of \*T<sub>3</sub> from the intestine was more sensitive to dietary TH fluctuations than the net loss of \*T<sub>4</sub>. Dietary TH challenges increased \*T<sub>3</sub> net loss to levels of \*T<sub>4</sub> net loss. This indicated that the mechanisms of T<sub>4</sub> and T<sub>3</sub> absorption from the intestine differed in sensitivities to the chronic presence of intestinal TH.

Thus, T<sub>4</sub> net loss from the MI-DI section was at least as great as T<sub>3</sub> net loss in all experiments conducted. In fact, T<sub>4</sub> net loss from the intestinal section exceeded T<sub>3</sub> net loss in the majority of the experiments.

**3.  $T_4$  and  $T_3$  uptake across the wall of the intestinal lumen do not involve saturable transport systems.**

The net loss of  $^*T_4$  from the intestinal section was not reduced in the presence of a high concentration of  $T_4$ , indicating that the mechanism for  $^*T_4$  net loss was not saturated with 100 pmoles of  $T_4$  injected.  $^*T_4$  net loss from the intestinal section may be solely by diffusion. However, these data do not exclude a transporter that is saturable at a higher dose of  $T_4$ .

In contrast, the net loss of  $^*T_3$  was reduced in the presence of a 500-fold increase in non-radioactive  $T_3$ , indicating that the transport mechanism was saturable at 100 pmoles of  $T_3$  injected.  $T_3$  TRT, but not  $T_4$  TRT, altered the characteristics of  $T_3$  absorption such that net loss of  $^*T_3$  was no longer saturable. Thus, chronic intestinal exposure to  $T_3$  did not saturate the mechanism of  $T_3$  absorption, rather, it increased the mechanism's ability to transport  $T_3$  from the intestine.

In other tissues, such as hepatocytes and red blood cells,  $T_4$  uptake was described as having non-saturable and saturable components (Riley and Eales, 1994; McLeese and Eales, 1996a, b). Even though characteristics of each tissue's transporters differed, both studies concluded that binding sites for  $T_4$  and  $T_3$  transport differed. The present data also support two separate mechanisms for intestinal  $T_4$  and  $T_3$  net loss. Only  $^*T_3$  net loss from the intestine responded to chronic influxes of TH, and  $^*T_4$  net loss from the intestinal lumen was often greater than  $^*T_3$  net loss. Chronic dietary TH challenges may increase the mass of intestinal tissue, hence its surface area for uptake, and increase the  $T_3$  intestinal transporter itself. However, it is more likely that TH only altered the characteristics of the intestinal transporter, since an increase in intestinal tissue surface

area would inherently alter net loss of  $T_4$  from the intestine, whether it was based on free diffusion or if it was transport-mediated. TH would be increasing the mucosal layer, and increasing the overall absorptive layer. The TH treatments only increased  $T_3$  net loss from the intestine. Therefore,  $T_3$  net loss from the intestine, not  $T_4$  net loss, was sensitive to prolonged exposure to dietary TH.

Besides having two separate mechanisms for  $T_4$  and  $T_3$  net loss from the intestine,  $T_3$  net loss itself may employ two separate mechanisms. Both dietary  $T_4$  and  $T_3$  challenges increased  $T_3$  net loss. However, a dietary  $T_4$  challenge increased  $T_3$  net loss without altering the transporter's saturability. A dietary  $T_3$  challenge increased  $T_3$  net loss, but the mechanism for absorption was no longer saturable. Chronic  $T_4$  may have up-regulated the  $T_3$  transporter, increasing transport capabilities. Chronic  $T_3$  either increased a non-saturable component of  $T_3$  net loss from the intestine, or the hormone altered the characteristics of the existing transporter, or it induced a transporter that has higher saturability capabilities.

Further information was found for mammals on membrane transport of TH for several tissues, but not for intestinal cells. Two binding sites for each of  $T_4$  and  $T_3$  have been detected in cell membranes and intact cells such as hepatocytes, erythrocytes, kidney, testis, spleen, placenta, and neuroblasts (Hennemann *et al.*, 2001). The mean apparent dissociation constant values ( $K_d$ ) for high-affinity, low-capacity binding sites for  $T_4$  and  $T_3$  were in the nanomolar range. These transporters bound and translocated TH over membranes. They were often energy- and  $Na^+$ -dependent. In contrast, the mean apparent  $K_d$  values for low-affinity, high-capacity binding sites for  $T_4$  and  $T_3$  were in the micromolar range. These represented TH binding to membrane proteins, and the process

was energy- and  $\text{Na}^+$ -independent. Different types of transporters include organic anion transport proteins and amino acid transporters (reviewed in Hennemann *et al.*, 2001; Abe *et al.*, 2002). There are many possible transport mechanisms. The characteristics of transport are determined not only by the type of transport and the efficacy of its translocation but also by variations in the free TH concentrations. Thus, intestinal transport of TH may be determined by various transporters that are sensitive to the fluctuating levels of TH that would be present in the intestinal lumen.

**4. A prior dietary  $T_4$  challenge, not a  $T_3$  challenge, will modify aspects of  $T_4$  metabolism by the enterohepatic tissues.**

Without dietary TH challenges, the potential for  $T_4$  EHC existed with both a low and a high dose of  $T_4$  injected.  $^*T_4$  was absorbed from the intestine, and  $^*T_4$  was accumulated in the bile that would return to the intestine upon refeeding the trout.

A prior dietary  $T_4$  challenge modified aspects of  $^*T_4$  metabolism by enterohepatic tissues. Chronic  $T_4$  TRT altered  $T_4$  EHC by increasing  $^*T_4$  metabolites accumulated in the bile after a low dose of  $T_4$  was injected into the intestinal lumen. These changes to  $T_4$  metabolism by enterohepatic tissues were not due to intestinal regulation of  $T_4$  because entry of  $^*T_4$  into EHC from the intestine was not altered by a chronic influx of  $T_4$  from the diet in the intestine. Presumably the liver regulated the amount of  $^*T_4$  and  $^*T_4$  metabolites returning to the intestine through excretion to the biliary pathway, thus altering  $T_4$  EHC. This would decrease the circulating  $T_4$  substrate available for conversion to  $T_3$ .

In contrast, a prior dietary  $T_3$  challenge did not modify aspects of  $^*T_4$  metabolism by enterohepatic tissues. Chronic  $T_3$  TRT did not alter  $^*T_4$  entry into EHC or  $^*T_4$  or  $^*T_4$



metabolites accumulated in the bile. Thus,  $T_4$  regulation was independent from influence by  $T_3$ .

In teleost fish, a main control of plasma  $T_4$  levels is through the hypothalamo-pituitary-thyroid axis.  $T_4$  negative feedback occurs at the hypothalamus (Peter, 1971; 1972) and the pituitary (Baker, 1965, 1969a,b; Sage, 1968; Sage and Bromage, 1970). Plasma  $T_3$  does not influence the control of  $T_4$  at any level of the hypothalamo-pituitary-thyroid axis (Eales, *et al.*, 1990; Eales and Himick, 1991). Thus, it is not surprising that the intestine, as a source of  $T_4$ , was also insensitive to  $T_3$  control of  $T_4$  net loss.

Overall, a consistent net loss of  $T_4$  from the intestine and supply of  $T_4$  to the intestinal pool occurred. Hence a constant  $T_4$  EHC was maintained, regardless of dietary TH challenges. The ability to maintain a constant  $T_4$  EHC may allow the fish to advantageously utilize a dietary source of TH that would fluctuate greatly. Since  $T_4$  is not the biologically active hormone, an influx of  $T_4$  would not necessarily elicit actions at a target. Peripheral metabolism of  $T_4$  to  $T_3$  and/or  $T_4$  degradation and clearance would be regulated separately.

However,  $T_4$  EHC one hour after injecting  $T_4$  into the intestinal lumen represents an on-going process. A longer residence of the TH within the intestinal lumen may alter the overall results of  $T_4$  EHC. Intestinal metabolism may occur, preventing  $T_4$  net loss from the intestine and entry into  $T_4$  EHC. In studies encompassing longer residence of the injectate in the intestinal lumen,  $T_4$  was metabolized to iodide, and  $T_4$  itself did not enter systemic circulation (Whitaker and Eales, 1993). In Chapter 4, dietary TH challenges increased intestinal metabolism. The intestinal  $T_4$  metabolism pathways ( $T_4$ cORD,  $T_4$ ORD,  $T_4$ IRD, and  $T_4$ IP) were characterized as mainly degradative,

supporting findings in other studies that  $T_4$  may be poorly absorbed from the intestine. Thus, comparisons to other experiments should consider the context of time and methodology. Again, for this experiment,  $T_4$  EHC existed within one hour after injection of  $T_4$  into the intestinal lumen.

**5. A prior dietary  $T_3$  challenge, not a dietary  $T_4$  challenge, will modify aspects of  $T_3$  metabolism by the enterohepatic tissues.**

Without dietary TH challenges, there was no  $T_3$  EHC with both a low and a high dose of  $T_3$  injected.  $^*T_3$  was absorbed from the intestine, but no  $^*T_3$ , only  $^*T_3$  metabolites, were accumulated in the bile. Both dietary  $T_3$  and  $T_4$  challenges modified aspects of  $T_3$  metabolism by the enterohepatic tissues.

A prior dietary  $T_3$  challenge modified aspects of  $^*T_3$  metabolism by enterohepatic tissues. Chronic  $T_3$  TRT increased  $^*T_3$  entry into EHC by increasing  $^*T_3$  net loss from the intestinal section. Chronic  $T_3$  TRT increased  $^*T_3$  metabolites accumulated in the bile after a low dose of  $T_3$  injected into the intestinal lumen. However, this did not create  $T_3$  EHC with at a high  $T_3$  dose, since no intact  $T_3$  returned to the intestine. Thus, a prior dietary  $T_3$  challenge created  $T_3$  EHC at the low dose only. Otherwise, the intestine increased disposal of  $^*T_3$  metabolites.

Regulation of  $T_3$  EHC may be more sensitive to acute changes in  $T_3$  levels for several reasons. First,  $T_3$  supply in trout occurs through tissue demand and not through thyroidal supply (Eales and Brown, 1993).  $T_3$  is the biologically active hormone, and its availability is regulated by  $T_4$  to  $T_3$  conversion at peripheral tissues. Thus, a continual supply of  $T_3$  through  $T_3$  EHC would represent a source of  $T_3$  not driven by tissue demand. Second, this would be a situation encountered in the wild that the trout would be adapted

to: variable influxes of TH when trout eat other fish, including their TH. Since  $T_3$  is the biologically active hormone, its availability to the whole system would be an immediate concern that would not allow time for enzyme synthesis necessary for TH metabolism. Hence, the present study indicated that  $T_3$  transport was saturable. Increased  $T_3$  was not free to diffuse in and increase circulating levels. After injecting a high dose of  $T_3$ , the  $T_3$  that entered was not retained in blood to distribute to the whole body, and  $T_3$  was not accumulated in the bile. These suggest that other excretory routes (branchial or urinary systems) may be stimulated to increase plasma clearance rates, handling influxes of  $*T_3$  and  $*T_3$  metabolites.

For trout, up to 15% of injected  $*T_4$  and 12.3% of injected  $*T_3$  can be excreted into urine, while up to 41.4% of  $*T_4$  and 25.7% of  $*T_3$  can be excreted into the gall bladder (Parry *et al.*, 1994). Thus, urine is a significant route for excretion of TH and TH conjugates. Yet, renal excretion was not regulated to compensate for TH challenge. In addition, up to 25% of TH was not accounted for by excretion into urine or gall bladder.

Other excretory routes or storage pools include gills and muscle. Rapid uptake of TH by gills from water (Eales, 1974; Omeljaniuk and Eales, 1985) also suggested that exchange across the gills can occur. Skeletal muscle, a possible storage site, comprised the largest tissue pool for  $T_3$ , and it was also responsive to altered physiological states such as low pH and increased aluminum exposure (Fok *et al.*, 1990). These excretory routes and storage sites together may regulate an acute  $T_3$  high dose.

Unexpectedly, a prior dietary  $T_4$  challenge also modified aspects of  $*T_3$  metabolism by enterohepatic tissues. Chronic  $T_4$  TRT increased  $T_3$  entry into EHC by increasing  $*T_3$  absorption from the intestine. Chronic  $T_4$  TRT also altered the potential

T<sub>3</sub> EHC by increasing \*T<sub>3</sub> accumulated in the bile after a low dose of T<sub>3</sub> was injected into the intestinal lumen. Overall, T<sub>4</sub> TRT stimulated T<sub>3</sub> EHC, and the changes to T<sub>3</sub> EHC included both intestinal and hepatic regulation of T<sub>3</sub> metabolism in response to chronic influxes of intestinal T<sub>4</sub>.

The increase in T<sub>3</sub> accumulated in the bile may be due to the effects of increased T<sub>4</sub> on the liver. Finnson and Eales (1997) have shown that T<sub>4</sub> can inhibit T<sub>3</sub> glucuronidation. In the present experiment, \*T<sub>3</sub> metabolites accumulated decreased slightly with T<sub>4</sub> treatment, yet it was enough to significantly increase \*T<sub>3</sub> accumulation. Any excess \*T<sub>3</sub> not accumulated in the bile would appear in the blood, hence the increased \*T<sub>3</sub> blood uptake was measured.

### Overview

Overall, chronic dietary TH challenges, both T<sub>4</sub> and T<sub>3</sub>, increased T<sub>3</sub> EHC. However, dietary TH challenges increase intestinal metabolism (Chapter 4). Specifically, a dietary T<sub>3</sub> challenge increased T<sub>4</sub>cORD, T<sub>4</sub>IRD, T<sub>4</sub>IP, and T<sub>3</sub>ORD in the MI, decreased T<sub>4</sub>ORD in the MI, and increased T<sub>4</sub>ORD and T<sub>3</sub>IRD in the DI. All of these pathways together were degradative pathways, preventing the formation of T<sub>3</sub>. Thus, increased return of T<sub>3</sub> to the intestine would not necessarily supply the intestinal pool for T<sub>3</sub> EHC. Rather, it would be an increased T<sub>3</sub> excretory route through the intestine. Since T<sub>4</sub> treatment provided excess T<sub>4</sub> substrate for conversion to T<sub>3</sub>, and T<sub>3</sub> treatment provided biologically active T<sub>3</sub>, an increase in T<sub>3</sub> return to the intestine for excretion would regulate thyroidal status by preventing excess T<sub>3</sub>.

In the previous chapter, high TH doses, both T<sub>4</sub> and T<sub>3</sub>, resulted in only TH accumulated in the bile. Yet, this pattern of TH return to the intestine was not seen here,

especially for  $T_3$ . In these experiments, the fish are larger, reproductively mature, and they tend to have lower circulating levels of TH, lower metabolism, and lower demands for TH. This situation may create a lower need for TH EHC, especially  $T_3$ , to regulate thyroidal status in larger trout.

## Conclusions

From examination of the above hypotheses, several conclusions may be drawn. Prior dietary TH challenges may have increased compensatory mechanisms. After a 3-day cessation of the dietary  $T_4$  challenge, plasma  $T_4$  levels were not elevated. A prior dietary  $T_3$  challenge elevated plasma  $T_3$  levels, but it was not statically significant. After a 3-day cessation of the prior dietary  $T_3$  challenge, many fish compensated, as was detected by some plasma  $T_3$  levels reverting to control levels.

$T_4$  net loss from the intestinal section was greater than that for  $T_3$ . However, dietary TH challenges increased  $T_3$  net loss from the intestine to amounts of net loss measured for  $T_4$ . There was no evidence for a saturable  $T_4$  transporter for  $T_4$  net loss from the intestine. This did not change with dietary TH challenges. However, there was evidence for a saturable  $T_3$  transporter for  $T_3$  net loss from the intestine. Dietary  $T_4$  challenges and dietary  $T_3$  challenges, to a greater extent, increased  $T_3$  net loss and changed transport characteristics so that  $T_3$  net loss was no longer saturable. Both differential  $T_4$  and  $T_3$  net loss from the intestine and differential  $T_4$  and  $T_3$  net loss resulting from dietary TH challenges suggested separate transport mechanisms (if a transporter is involved for  $T_4$ ) for  $T_4$  and  $T_3$  in the intestine.

With TH absorption from the intestine and accumulation in the bile, the potential for TH EHC and the effects of chronic dietary TH challenges on the potential TH EHC

were evaluated. For controls,  $T_4$  EHC existed. A prior dietary  $T_4$  challenge, but not a  $T_3$  challenge, modified aspects of  $T_4$  metabolism. The liver regulated the increase in  $T_4$  metabolites returning to the intestine for  $T_4$  low dose injected. Thus, excess  $T_4$  was metabolized, removing the substrate for conversion to biologically active  $T_3$ . This would work in conjunction with negative feedback to prevent fluctuations in plasma  $T_4$  levels. For controls,  $T_3$  EHC did not exist. A prior dietary  $T_3$  challenge modified aspects of  $T_3$  metabolism through intestinal and hepatic regulation. However,  $T_3$  EHC existed only for a low dose of  $T_3$  injected into the intestine after dietary  $T_4$  or  $T_3$  challenges. The intestine and the liver increased the  $T_3$  EHC.




Figure 6-1. Plasma T<sub>4</sub> levels (■) and plasma T<sub>3</sub> levels (□) after 7 days of dietary TH challenges for control fish (C, n=32), fish fed 12 ppm T<sub>4</sub> (T<sub>4</sub> TRT, n=33), and fish fed 12 ppm T<sub>3</sub> (T<sub>3</sub> TRT, n=36). Bars represent means ( $\pm$  s.e.).

Table 6-1. Effects of 7 days of dietary T<sub>4</sub> challenge (T<sub>4</sub> TRT) or dietary T<sub>3</sub> challenge (T<sub>3</sub> TRT) on the fate of \*T<sub>4</sub> injected one hour previously into the lumen of the intestinal section, accompanied by either a low dose (200 fmoles) or a high dose (100 pmoles) of unlabeled T<sub>4</sub>. Numbers represent percent total injectate/mg of tissue x g of body weight/500 g (%/mg)  $\pm$  s.e. Letters indicate significant differences at  $p \leq 0.050$ .

		T <sub>4</sub> LOW	T <sub>4</sub> HIGH
<b>NET LOSS (%)*</b>			
	<b>Control</b>	13.2 $\pm$ 3.7 (n=9)	13.9 $\pm$ 5.3 (n=6)
	<b>T<sub>4</sub> TRT</b>	11.8 $\pm$ 1.0 (n=9)	11.2 $\pm$ 1.3 (n=5)
	<b>T<sub>3</sub> TRT</b>	10.1 $\pm$ 2.0 (n=9)	14.6 $\pm$ 7.7 (n=6)
<b>UPTAKE TO LIVER (%/mg)</b>			
<b>TH</b>	<b>Control</b>	3.1 $\pm$ 0.8	8.9 $\pm$ 5.4
	<b>T<sub>4</sub> TRT</b>	2.2 $\pm$ 0.7	15.2 $\pm$ 10.3
	<b>T<sub>3</sub> TRT</b>	4.0 $\pm$ 1.0	12.3 $\pm$ 5.6
<b>TH METABOLITES</b>	<b>Control</b>	4.5 $\pm$ 1.1	1.9 $\pm$ 1.2
	<b>T<sub>4</sub> TRT</b>	6.5 $\pm$ 2.1	7.8 $\pm$ 5.3
	<b>T<sub>3</sub> TRT</b>	2.3 $\pm$ 0.6	5.4 $\pm$ 2.5
<b>UPTAKE TO BLOOD (%/mg)</b>			
<b>TH</b>	<b>Control</b>	1.1 $\pm$ 0.2	1.1 $\pm$ 1.0
	<b>T<sub>4</sub> TRT</b>	0.6 $\pm$ 0.1	4.0 $\pm$ 2.1
	<b>T<sub>3</sub> TRT</b>	4.7 $\pm$ 1.9 <sup>b</sup>	4.6 $\pm$ 2.7
<b>TH METABOLITES</b>	<b>Control</b>	10.5 $\pm$ 2.2	1.7 $\pm$ 1.5
	<b>T<sub>4</sub> TRT</b>	11.4 $\pm$ 2.7	13.2 $\pm$ 7.0
	<b>T<sub>3</sub> TRT</b>	9.3 $\pm$ 3.7	9.0 $\pm$ 5.2
<b>ACCUMULATION IN BILE (%)*</b>			
<b>TH</b>	<b>Control</b>	0.0042 $\pm$ 0.0016	0.0009 $\pm$ 0.0009
	<b>T<sub>4</sub> TRT</b>	0.0062 $\pm$ 0.0017	0.0073 $\pm$ 0.0062
	<b>T<sub>3</sub> TRT</b>	0.0029 $\pm$ 0.0018	0.0016 $\pm$ 0.0010
<b>TH METABOLITES</b>	<b>Control</b>	0.0004 $\pm$ 0.0001	0.0001 $\pm$ 0.0001
	<b>T<sub>4</sub> TRT</b>	0.0063 $\pm$ 0.0017 <sup>a</sup>	0.0024 $\pm$ 0.0020
	<b>T<sub>3</sub> TRT</b>	0.0003 $\pm$ 0.0002	0.0008 $\pm$ 0.0004

<sup>a</sup>  $p=0.001$  C vs. T<sub>4</sub> TRT

<sup>b</sup>  $p=0.031$  C vs. T<sub>3</sub> TRT

\* units in percent of total injectate (%), instead of %/mg



Table 6-2. Effects of 7 days of dietary T<sub>4</sub> challenge (T<sub>4</sub> TRT) or dietary T<sub>3</sub> challenge (T<sub>3</sub> TRT) on the fate of \*T<sub>3</sub> injected one hour previously into the lumen of the intestinal section, accompanied by either a low dose (200 fmoles) or high dose (100 pmoles) of unlabeled T<sub>3</sub>. Numbers represent percent total injectate/mg of tissue x g of body weight/500 g (%/mg) ± s.e. N.A. denotes not assayed. Letters indicate significant differences at p≤0.050.

		T <sub>3</sub> LOW	T <sub>3</sub> HIGH
<b>NET LOSS (%)*</b>			
	<b>Control</b>	9.7 ± 1.3 (n=9)	0.1 ± 0.1 <sup>a</sup> (n=3)
	<b>T<sub>4</sub> TRT</b>	16.5 ± 2.1 <sup>b</sup> (n=8)	8.9 ± 1.4 <sup>c</sup> (n=5)
	<b>T<sub>3</sub> TRT</b>	9.4 ± 3.3 (n=9)	22.3 ± 2.9 <sup>d</sup> (n=6)
<b>UPTAKE TO LIVER (%/mg)</b>			
<b>TH</b>	<b>Control</b>	9.6 ± 4.3	7.5 ± 7.5
	<b>T<sub>4</sub> TRT</b>	7.9 ± 2.5	21.7 ± 11.1
	<b>T<sub>3</sub> TRT</b>	2.5 ± 0.9	3.2 ± 0.9
<b>TH METABOLITES</b>	<b>Control</b>	11.2 ± 5.0	0
	<b>T<sub>4</sub> TRT</b>	5.1 ± 1.6	3.5 ± 1.8
	<b>T<sub>3</sub> TRT</b>	1.7 ± 0.6	1.2 ± 0.3
<b>UPTAKE TO BLOOD (%/mg)</b>			
<b>TH</b>	<b>Control</b>	2.4 ± 1.0	0
	<b>T<sub>4</sub> TRT</b>	7.0 ± 2.2 <sup>e</sup>	13.4 ± 3.8 <sup>h</sup>
	<b>T<sub>3</sub> TRT</b>	1.8 ± 0.7	8.0 ± 2.3
<b>TH METABOLITES</b>	<b>Control</b>	12.1 ± 4.8	6.3 ± 6.3
	<b>T<sub>4</sub> TRT</b>	8.9 ± 2.8	20.0 ± 5.7
	<b>T<sub>3</sub> TRT</b>	2.9 ± 1.1	5.1 ± 1.5
<b>ACCUMULATION IN BILE (%)*</b>			
<b>TH</b>	<b>Control</b>	0	0
	<b>T<sub>4</sub> TRT</b>	0.0025 ± 0.0010 <sup>f</sup>	0.0284 ± 0.0271 <sup>†</sup>
	<b>T<sub>3</sub> TRT</b>	0.0017 ± 0.0010	0
<b>TH METABOLITES</b>	<b>Control</b>	0.0089 ± 0.0039	0
	<b>T<sub>4</sub> TRT</b>	0.0042 ± 0.0016	N.A.
	<b>T<sub>3</sub> TRT</b>	0.0009 ± 0.0005 <sup>g</sup>	0.0295 ± 0.0088 <sup>i</sup>

<sup>a</sup>p=0.001 T<sub>3</sub> low vs. high

<sup>b</sup>p=0.031 C vs. T<sub>4</sub> TRT

<sup>c</sup>p=0.038 C vs. T<sub>4</sub> TRT

<sup>d</sup>p=0.000 C vs. T<sub>3</sub> TRT

<sup>e</sup>p=0.029 C vs. T<sub>4</sub> TRT

<sup>f</sup>p=0.036 C vs. T<sub>4</sub> TRT

<sup>g</sup>p=0.030 C vs. T<sub>3</sub> TRT

<sup>h</sup>p=0.015 C vs. T<sub>3</sub> TRT

<sup>i</sup>p=0.050 C vs. T<sub>3</sub> TRT

<sup>†</sup> total radioactivity accumulated since \*TH and \*TH metabolites were not assayed

\* units in percent of total injectate (%), instead of %/mg.

## Chapter 7

### General Discussion

This study was performed to determine the properties and capacities of the various regions of the rainbow trout intestine to metabolize TH, absorb TH from the lumen, complete the TH EHC through TH uptake to the liver, systemic blood, and gall bladder, and regulate the above pathways following physiological challenges with dietary  $T_4$  and  $T_3$ .

Intestinal TH metabolism pathways were more complex than those in the liver, and the intestine showed a broader array of TH deiodination and metabolism pathways geared toward degradation of  $T_4$  and  $T_3$ . The active intestinal TH metabolism pathways were  $T_4$ cORD which completely deiodinated  $T_4$  on the outer ring,  $T_4$ ORD which monodeiodinated  $T_4$  on the outer ring to  $T_3$ ,  $T_4$ IRD which monodeiodinated  $T_4$  on the inner ring to  $rT_3$ ,  $T_3$ ORD which monodeiodinated  $T_3$  on the outer ring to 3,5- $T_2$ ,  $T_3$ IRD which monodeiodinated  $T_3$  on the inner ring to 3,3'- $T_2$ , and IP production which formed iodinated proteins from  $T_4$  or  $T_3$ . In the PC, few TH metabolism pathways were active, except for  $T_4$ cORD. In the MI, mainly  $T_4$  metabolism pathways were active. The DI was the most active region of the intestine. The predominant pathways were  $T_4$ cORD and  $T_3$ ORD, however, all of the TH metabolism pathways were active. Together, these pathways would deiodinate  $T_4$  and  $T_3$ , removing a potential source of biologically active  $T_3$  and salvaging I<sup>-</sup> before loss through excretion.

Besides exhibiting a broader array of active TH metabolism pathways than the liver, the assay cofactor requirements for the intestine also differed from those of the liver. The

intestinal TH metabolism pathways were active without DTT, and in fact, T<sub>4</sub>cORD, T<sub>3</sub>ORD, and TH IP were more active in its absence. Since the cofactor requirements for the intestine were different than for the liver, and since different TH metabolism pathways were active, the intestine may have evolved different enzyme characteristics along with different roles in regulating TH metabolism.

The difference between the liver and the intestine under physiological challenges of T<sub>4</sub> and T<sub>3</sub> indicated their different roles in the regulation of TH. Under normal, non-stressful conditions, the liver is a main peripheral regulator of thyroidal status. The predominant pathway for maintaining available T<sub>3</sub> is T<sub>4</sub>ORD (Eales, *et al.*, 1993), as was seen in this study. To maintain T<sub>3</sub> homeostasis in response to a dietary T<sub>3</sub> challenge, the liver decreased T<sub>4</sub>ORD and increased T<sub>4</sub>IRD. The pathways reduced production of T<sub>3</sub> and removed the substrate T<sub>4</sub>.

In contrast, the intestine, specifically the MI and DI, moderated influxes of TH from the intestinal lumen. A dietary T<sub>4</sub> challenge did not result in increased plasma T<sub>4</sub> levels. This can be accounted for by both central regulation and also by peripheral changes in TH metabolism by the intestine. The DI responded by increasing T<sub>4</sub>ORD. However, T<sub>4</sub>cORD and T<sub>4</sub>IRD were consistently active with or without physiological challenges. Thus, the plasma pool of T<sub>4</sub> available to tissues was strictly maintained by negative feedback controlling thyroidal output and by TH metabolism controlling intestinal uptake.

A dietary T<sub>3</sub> challenge resulted in increased plasma T<sub>3</sub> levels. T<sub>3</sub> would not be regulated centrally but rather by peripheral mechanisms. Both MI and DI regions responded to increased dietary T<sub>3</sub> by degrading T<sub>3</sub> or preventing the formation of new T<sub>3</sub>. In the MI, T<sub>4</sub>cORD, T<sub>4</sub>IRD, T<sub>4</sub>IP, and T<sub>3</sub>ORD increased. In the DI, T<sub>4</sub>ORD and T<sub>3</sub>IRD

increased. Thus, the MI and DI regions of the intestine that would have access to both increased TH from the diet and biliary discharge were sensitive to the presence of chronic  $T_3$ , and the regions increased their metabolism of TH. The intestine contributed to the autoregulation of  $T_3$  by preventing potential surges of TH to the systemic circulation. Since intestinal TH metabolism was greatest in the DI, this region may salvage I before loss through excretion.

In the MI section, the greatest net loss from the intestine was measured for  $T_3$ . However, the MI section did not contribute to  $T_4$  EHC or  $T_3$  EHC. With an increase in  $T_4$  or  $T_3$  injected into the intestinal lumen, both TH were absorbed, however, peripheral tissues quickly metabolized and cleared TH via the biliary route, maintaining low levels of  $T_4$  and  $T_3$  in systemic circulation. The MI and other peripheral tissues together prevent fluctuations of TH in the circulation, especially  $T_3$ , that may enter from the MI from both dietary and biliary sources.

In the MI-DI section, the greatest net loss from the intestine was measured for  $T_4$ . In addition,  $T_4$  EHC was greater than  $T_3$  EHC, due to more unconjugated  $T_4$  than  $T_3$  returning to the intestine in the bile. An acute increase in  $T_4$  and  $T_3$  injected increased the proportion of TH accumulated in the bile to 100% TH, increasing both  $T_4$  and  $T_3$  EHC. Thus, the MI and DI regions of the intestine together may cycle TH either to provide an extrathyroidal source of TH or to allow the intestine to salvage I before loss through excretion.

The MI-DI section was further investigated. The net loss of  $T_4$  from the intestine was greater than net loss of  $T_3$ , and it was not saturable at 100 pmoles of  $T_4$  injected. In addition, dietary challenges of  $T_4$  and  $T_3$  did not alter the net loss of  $T_4$ . Thus, potentially

large, unregulated amounts of  $T_4$  can enter into circulation from the intestine. Previous speculations on the absorption of TH from the intestine focused on the greater entry of  $T_3$  into systemic circulation than  $T_4$ . However, the present study supports greater net loss of  $T_4$  from the intestine than  $T_3$ , at least within one hour. The previous conclusions on poor  $T_4$  uptake from the intestine may be invalid, since the method of measuring absorption was based on measuring plasma TH levels. As discussed earlier, central control mechanisms are sensitive to plasma  $T_4$  levels, and they compensate for increases in circulating  $T_4$ , regardless of its source.

Unlike  $T_4$  net loss from the intestine,  $T_3$  net loss was saturable at 100 pmoles of  $T_3$  injected. This indicates that there are separate mechanisms for  $T_4$  and  $T_3$  absorption, and that the amount of  $T_3$  entering the intestine into circulation is regulated. With a dietary  $T_3$  challenge,  $T_3$  net loss appears to be non-saturable at a high  $T_3$  dose injected. However, the transport mechanism for absorption may have been saturated with the chronic  $T_3$  challenge. Since intestinal TH metabolism pathways are activated with a dietary  $T_3$  challenge, and only net loss of total radioactivity can be measured, increased absorption may be  $^*I$  released from TH metabolism, not the  $^*T_3$  injected.

Dietary TH challenges, even 3 days previously, modified aspects of TH metabolism and altered TH EHC. A prior dietary  $T_4$  challenge increased the proportion of  $T_4$  in the bile returning to the intestine as  $T_4$  metabolites. Thus, the  $T_4$  EHC was altered through peripheral metabolism to decrease the circulating  $T_4$  substrate available for conversion to  $T_3$ . A prior dietary  $T_4$  challenge also altered  $T_3$  EHC but by increasing the amount of TH in the bile returning to the intestine. Without TH treatments,  $T_3$  EHC was non-existent. The effects of  $T_4$  on  $T_3$  regulation may actually be from an increase in  $T_4$  substrate

causing an increase in  $T_3$  production. Thus, some effects on  $T_3$  EHC would be expected as  $T_3$  increases. This was confirmed with a prior dietary  $T_3$  challenge which also increased  $T_3$  EHC by increasing TH in the bile returning to the intestine.

Intestinal TH metabolism, enteric absorption of TH, and TH EHC may represent a large store of endogenous and exogenous TH available to the fish, or they may represent salvaging of  $I^-$  from this large store of TH. Thyroid function depends on  $I^-$ , which could be limiting in the freshwater environment of the rainbow trout. Thus, the DI may have evolved as the region of the intestine to recycle TH and salvage  $I^-$  before loss through excretion. This would contribute to other adaptations of the rainbow trout in obtaining and retaining  $I^-$  at high levels in the plasma (Gregory and Eales, 1975; Eales and Brown, 1993).

Overall, the intestine is more sensitive to increases in  $T_3$ , and it has mechanisms to prevent large increases in systemic  $T_3$ : TH metabolism pathways increase;  $T_3$  absorption is saturable; and  $T_3$  EHC increases. It appears that central control is a main control for  $T_4$  availability. However, intestinal TH metabolism and other peripheral metabolism aid in reducing the amount of  $T_4$  absorbed from the intestine and also returning to the intestine. This differential regulation of  $T_4$  and  $T_3$  may reflect a primitive control of  $T_3$  that was retained in teleost fish. Peripheral control, with the intestine playing a major role in  $T_3$  availability, evolved early on in primitive fish (Eales, 1997). In lampreys, no central control of thyroid hormones has been discovered, and peripheral control may be the main regulator of thyroidal status (Dickoff and Darling, 1983). In fact, intestinal TH metabolism is greater than hepatic TH metabolism in more primitive fish, possibly due to this emphasis on peripheral control of  $T_3$  by the intestine (Eales *et al.*, 1997, 1999;

McLeese *et al.*, 2000). A more recently evolved central control of  $T_4$  is seen in more advanced fish, and this trend of further evolving central control can be followed through the vertebrate classes to mammals. Thus in rainbow trout, the intestinal control of TH metabolism and the regulation of thyroidal status represents both a primitive intestinal control of  $T_3$  and  $T_4$  metabolism and absorption with a more derived central control of  $T_4$ .

To further elucidate the role of the intestine in TH metabolism and the regulation of thyroidal status, future studies should focus on the differential regulation of  $T_4$  and  $T_3$ , especially the entry of TH into circulation. This could be studied by using enterocytes to determine mechanisms for  $T_4$  and  $T_3$  transport and the conditions altering this transport.

## References

- Abe, T., Suzuki, T., Unno, M., Tokui, T., and Ito, S. 2002. Thyroid hormone transporters: recent advances. *TRENDS Endocrinol. Met.* 13: 215-220.
- Adams, B. A., Cyr, D. G., and Eales, J. G. 2000. Thyroid hormone deiodination in tissues of American plaice, *Hippoglossoides platessoides*: characterization and short-term responses to polychlorinated biphenyls (PCBs) 77 and 126. *Comp. Biochem. Physiol. C* 127: 367-378.
- Albert, A., and Keating, F. R. 1952. The role of the gastrointestinal tract, including the liver, in the metabolism of radiothyroxine. *Endocrinol.* 51: 427.
- Albert, A., Tenney, A., and Lorenz, N. 1952. The absorption of thyroxine from the gastrointestinal tract of the rat. *Endocrinol.* 50: 374-376.
- Avella, M., Blaise, O., and Berhaut, J. 1992. Effects of starvation on valine and alanine transport across the intestinal mucosal border in sea bass, *Dicentrarchus labrax*. *J. Comp. Physiol. B* 162: 430-435.
- Baker, B. I. 1965. Direct action of thyroxine on the trout pituitary *in vitro*. *Nature, Lon.* 208: 1234-1235.
- Baker, B. I. 1969a. Uptake of uridine by teleost thyrotrophs *in vitro*. *Gen. Comp. Endocrinol.* 12: 322-325.
- Baker, B. I. 1969b. The response of teleost pituitary thyrotrophs to thyroxine *in vitro* – a histological study. *Gen. Comp. Endocrinol.* 12: 427-437.
- Briggs, F. N., Taurog, A., Chaikoff, I. L. 1953. The enterohepatic circulation of thyroxine in the rat. *Endocrinol.* 52: 559-567.
- Bromage, N. R., Whitehead, C., and Brown, T. J. 1976. Thyroxine secretion in teleosts and effects of TSH, TRH, and other peptides. *Gen. Comp. Endocrinol.* 29: 246.
- Brown, S. B. and Eales, J. G. 1977. Measurement of L-thyroxine and 3,5,3'-triiodothyronine levels in fish plasma by radioimmunoassay. *Can. J. Zool.* 55: 293-299.
- Brown, S. B., Fedoruk, K., and Eales, J. G. 1978. Physical injury due to injection or blood removal causes transitory elevations of plasma thyroxine in rainbow trout, *Salmo gairdneri*. *Can. J. Zool.* 56: 1998-2003.



- Burger, A. G. 1986. Nondeiodinative pathways of thyroid hormone metabolism. In *Thyroid hormone metabolism*, ed., G. Hennemann, pp. 255-276. New York: Marcel Dekker Inc.
- Byamungu, N., Mol, K., and Kuhn, E. R. 1992. Evidence for the kidney as an important source of 5'-monodeiodination activity and stimulation by somatostatin in *Oreochromis niloticus* L. *Gen. Comp. Endocrinol.* 88: 199-208.
- Chan, H. H. and Eales, J. G. 1975. Identification of iodoamino acids in the plasma and bile of brook trout, *Salvelinus fontinalis* (Mitchill). *Can. J. Zool.* 53: 97-101.
- Chung, S. J., and van Middlesworth, L. 1964. Absorption of thyroxine from the small intestine of rats. *Endocrinol.* 74: 694-700.
- Chung, S. J. and van Middlesworth, L. 1967. Thyroxine-binding glycoproteins in intestinal contents of rats. *Proc. Fed. Amer. Soc. Exp. Biol.* 26: 644.
- Collicutt, J. M. and Eales, J. G. 1974. Excretion and enterohepatic cycling of  $^{125}\text{I}$ -L-thyroxine in channel catfish, *Ictalurus punctatus* Rafinesque. *Gen. Comp. Endocrinol.* 23: 390-402.
- Collie, N. L. 1985. Intestinal nutrient transport in coho salmon (*Oncorhynchus kisutch*) and the effects of development, starvation, and seawater adaptation. *J. Comp. Physiol. B* 156: 163-174.
- Cottle, W. H. 1964. Biliary and fecal clearance of endogenous thyroid hormone in cold-acclimated rats. *Am. J. Physiol.* 207: 1063-1066.
- Cottle, W. H., and Veress, A. T. 1965. Absorption of biliary thyroxine from loops of small intestine. *Can. J. Physiol.* 43: 801-807.
- Crantz, F. R., Silva, J. E., and Larsen, P. R. 1982. An analysis of the sources and quantity of 3,5,3'-triiodothyronine specifically bound to nuclear receptors in rat cerebral cortex and cerebellum. *Endocrinol.* 110: 367-375.
- Cyr, D. G. and Eales, J. G. 1990. Influence of short-term oestradiol treatment on plasma thyroid hormone kinetics in rainbow trout, *Salmo gairdneri*. *J. Fish Biol.* 36: 391-400.
- Darras, V. M., Visser, T. J., Berghman, L. R., and Kuhn, E. R. 1992. Ontogeny of type I and type III deiodinase activities in embryonic and posthatch chicks: relationship with changes in plasma triiodothyronine and growth hormone levels. *Comp. Biochem. Physiol.* 103A: 131-136.

- DeGroot, L. J. and Stanbury, J. B. 1975. The thyroid and its diseases. New York: Wiley and Sons.
- de Herder, W. W., Hazenburg, M. P., Pennock-Schroder, A. M., Hennemann, G., and Visser, T. J. 1985. Hydrolysis of iodothyronine sulfates by sulfatase activity of anaerobic bacteria from rat intestinal flora. *Fed. Eur. Microbiol. Sci. Microbiol. Letters* 27: 79-83.
- de Herder, W. W., Hazenburg, M. P., Pennock-Schroder, A. M., Hennemann, G., and Visser, T. J. 1986. Rapid and bacteria-dependent in vitro hydrolysis of iodothyronine conjugates by intestinal contents of humans and rats. *Med. Biol.* 64: 31-35.
- Dickhoff, W. W. and Darling, D. A. 1983. Evolution of thyroid function and its control in lower vertebrates. *Am Zool.* 23: 697-707.
- DiStefano, J. J. 1988. Excretion, metabolism and enterohepatic circulation pathways and their role in overall thyroid hormone regulation in the rat. *Am. Zool.* 28: 373-388.
- DiStefano, J. J., Sternlicht, M., and Harris, D. 1988. Rat enterohepatic circulation and intestinal distribution of externally-infused thyroid hormones. *Endocrinol.* 123: 2526-2539.
- DiStefano, J. J., Nguyen, T. T., and Yen, Y.-M. 1992. Sites and patterns of absorption of 3,5,3'-triiodothyronine and thyroxine along rat small and large intestines. *Endocrinol.* 131: 275-280.
- DiStefano, J. J., DeLuze, A., and Nguyen, T. T. 1993a. Binding and degradation of 3,5,3'-triiodothyronine and thyroxine by rat intestinal bacteria. *Am. J. Physiol.* 264: E966-E972.
- DiStefano, J. J., Nguyen, T. T., and Yen, Y.-M. 1993b. Transfer kinetics of 3,5,3'-triiodothyronine (T<sub>3</sub>) and thyroxine (T<sub>4</sub>) from rat blood to large and small intestines, liver and kidneys *in vivo*. *Endocrinol.* 132: 1735-1744.
- DiStefano, J. J., Morris, W. L., Nguyen, T. T., Van Herle, A. J., and Florsheim, W. 1993c. Enterohepatic regulation and metabolism of 3,5,3'-triiodothyronine in hypothyroid rats. *Endocrinol.* 132: 1665-1670.
- Eales, J. G. 1969. Bile excretion of radiothyroxine by the brook trout, *Salvelinus fontinalis* (Mitchill). *Gen. Comp. Endocrinol.* 13: 502.
- Eales, J. G. 1970. Biliary excretion of radiothyroxine by the brook trout, *Salvelinus fontinalis* (Mitchill). *Gen. Comp. Endocrinol.* 14: 385-395.

- Eales, J. G. 1974. Creation of chronic physiologic elevations of plasma thyroxine in brook trout, *Salvelinus fontinalis* (Mitchill) and other teleosts. Gen. Comp. Endocrinol. 22: 209-217.
- Eales, J. G. 1972. Influence of injection site on radiothyroxine metabolism in brook trout, *Salvelinus fontinalis* (Mitchill). Can. J. Zool. 50: 1337-1341.
- Eales, J. G. 1979. Thyroid functions in cyclostomes and fishes. In Hormones and Evolution, Vol. I., ed., E. J. W. Barrington, pp. 341-436. London: Academic Press.
- Eales, J. G. 1985. The peripheral metabolism of thyroid hormones and regulation of thyroidal status in poikilotherms. Can. J. Zool. 63: 1217-1231.
- Eales, J. G. 1988. Thyroid function and nutritional status in various vertebrates. Am. Zool. 28: 351-362.
- Eales, J. G. 1995. Regulation and measurement of thyroidal status in fish. Neth. J. Zool. 45: 175-180.
- Eales, J. G. 1997. Iodine metabolism and thyroid-related functions in organisms lacking thyroid follicles: Are thyroid hormones also vitamins? P. S. E. B. M. 214: 302-317.
- Eales, J. G. and Brown, S. B. 1993. Measurement and regulation of thyroidal status in teleost fish. Rev. Fish Biol. Fisheries 3: 299-347.
- Eales, J. G. and Collicutt, J. M. 1974. Uptake of ambient radioactive L-thyroxine and 3,5,3'-triiodo-L-thyronine by rainbow trout, *Salmo gairdneri* Richardson. Gen. Comp. Endocrinol. 24: 347-351.
- Eales, J. G., Cyr, D. G., and Cook, R. F. 1986. Effect of excess iodide on thyroid function of rainbow trout, *Salmo gairdneri*. Fish Physiol. Biochem. 1: 171-177.
- Eales, J. G. and Finnson, K. W. 1991. Response of hepatic thyroxine 5'-deiodinase of rainbow trout, *Oncorhynchus mykiss*, to chronic ingestion of 3,5,3'-triiodo-L-thyronine. J. Exp. Zool. 257: 230-235.
- Eales, J. G., Higgs, D. A., Uin, L.A., MacLatchy, D. L., Bres, O., McBride, J. R. and Dosanje, B. S. 1990. Influence of dietary and carbohydrate levels and chronic 3,5,3'-triiodo-L-thyronine treatment on thyroid function in immature rainbow trout, *Oncorhynchus mykiss*. Gen. Comp. Endocrinol. 80: 146-154.
- Eales, J. G. and Himick, B. A. 1991. Regulation of hormone release from the thyroid of teleost fish. Adv. Comp. Endocrinol. 1: 33-43.

- Eales, J. G., Holmes, J. A., McLeese, J. M., and Youson, J. H. 1997. Thyroid hormone deiodination in various tissues of larval and upstream-migrant sea lampreys, *Petromyzon marinus*. Gen. Comp. Endocrinol. 106: 202-210.
- Eales, J. G., MacLatchy, D. L., and Sweeting, R. M. 1993. Thyroid hormone deiodinase systems in salmonids, and their involvement in the regulation of thyroidal status. Fish Physiol. Biochem. 11: 313-321.
- Eales, J. G. and Sinclair, D. A. R. 1974. Enterohepatic cycling of thyroxine in starved and fed brook trout, *Salvelinus fontinalis* (Mitchill). Comp. Biochem. Physiol. 49A: 661-672.
- Eales, J. G., Wesh, L. A., and Chan H. H. 1971. Biliary excretion of 3,5,3'-triiodo-L-thyronine  $^{125}\text{I}$  by the brook trout, *Salvelinus fontinalis* (Mitchill). Gen. Comp. Endocrinol. 16: 169-175.
- Fines, G. A., Plohman, J., and Eales, J. G. 1999. Effect of experimental 3,5,3'-triiodothyronine hyperthyroidism on thyroid hormone deiodination in brain regions and liver of rainbow trout, *Oncorhynchus mykiss*. Can. J. Zool. 77: 1185-1191.
- Finnson, K. W. and Eales, J. G. 1996. Identification of thyroid hormone conjugates produced by isolated hepatocytes and excreted in bile of rainbow trout, *Oncorhynchus mykiss*. Gen. Comp. Endocrinol. 101: 145-154.
- Finnson, K. W. and Eales, J. G. 1997. Glucuronidation of thyroxine and 3,5,3'-triiodothyronine by hepatic microsomes in rainbow trout, *Oncorhynchus mykiss*. Comp. Biochem. Physiol. 117C: 193-199.
- Finnson, K. W. and Eales, J. G. 1998. Sulfation of thyroid hormones by liver of rainbow trout, *Oncorhynchus mykiss*. Comp. Biochem. Physiol. 120: 415-420.
- Finnson, K. W., McLeese, J. M., and Eales, J. G. 1999. Deiodination and deconjugation of thyroid hormone conjugates and type I deiodination in liver of rainbow trout, *Oncorhynchus mykiss*. Gen. Comp. Endocrinol. 115: 387-397.
- Flett, P. A. and Leatherland, J. F. 1989. Dose-related effects of  $17\beta$ -oestradiol ( $\text{E}_2$ ) on liver weight, plasma  $\text{E}_2$ , protein, calcium and thyroid hormone levels, and measurement of the binding of thyroid hormones to vitellogenin in rainbow trout, *Salmo gairdneri* Richardson. J. Fish Biol. 34: 515-527.
- Fok, P. and Eales, J. G. 1984. Regulation of plasma  $\text{T}_3$  levels in  $\text{T}_4$ -challenged rainbow trout, *Salmo gairdneri*. Gen. Comp. Endocrinol. 53: 197-202.

- Freeman, T. B. and McNabb, F. M. A. 1991. Hepatic 5'-deiodinase activity of Japanese quail using reverse-T<sub>3</sub> substrate: Assay validation, characterization, and developmental studies. *J. Exp. Zool.* 258: 212-220.
- Frith, S. D. and Eales, J. G. 1996. Thyroid hormone deiodination pathways in brain and liver of rainbow trout, *Oncorhynchus mykiss*. *Gen. Comp. Endocrinol.* 101: 323-332.
- Galton, V. A., and Hiebert, A. 1987. Iodothyronine 5'-deiodinase activity in the amphibian *Rana catesbeiana* at different stages of the life cycle. *Endocrinol.* 122: 1746-1750.
- Galton, V. A. and Ingbar, S. H. 1961. The mechanism of protein iodination during the metabolism of thyroid hormone by peripheral tissues. *Endocrinol.* 69: 30-38.
- Galton, V. A., McCarthy, P. T., and St. Germain, D. L. 1991. The ontogeny of iodothyronine deiodinase systems in liver and intestine of the rat. *Endocrinol.* 128: 1717-1722.
- Goswami, A. and Rosenberg, I. N. 1988. Effects of glutathione on iodothyronine 5'-deiodinase activity. *Endocrinol.* 123: 192-202.
- Grau, E. G., Helms, L. M., Shimoda, S. K., Ford, C.-A., LeGrand, J., and Yamauchi, K. 1986. The thyroid gland of the Hawaiian parrot-fish and its use as an in vitro model system. *Gen. Comp. Endocrinol.* 61: 100-108.
- Gregory, L. A. and Eales, J. G. 1975. Factors contributing to high levels of plasma iodide in brook trout, *Salvelinus fontinalis* (Mitchill). *Can. J. Zool.* 53: 267-277.
- Hazenburger, M. P., de Herder, W. W., and Visser, T. J. 1988. Hydrolysis of iodothyronine conjugates by intestinal bacteria. *Fed. Eur. Microbiol. Sci. Microbiol. Rev.* 54: 9-16.
- Hennemann, G., Docter, R., Friesema, E. C. H., de Jong, M., Krenning, E. P., and Visser, T. J. 2001. Plasma membrane transport of thyroid hormones and its role in thyroid hormone metabolism and bioavailability. *Endocrine Rev.* 22: 451-476.
- Heroux, O. and Petrovich, V. M. 1969. Effect of high- and low- bulk diets on the thyroxine turnover rate in rats with acute and chronic exposure to different temperatures. *Can. J. Physiol. Pharmacol.* 47: 963-968.
- Hesch, R.-D. and Kohle, J. 1986. Intracellular pathways of iodothyronine metabolism. In Werner's *The thyroid. A fundamental and clinical text*, 5<sup>th</sup> ed., eds., S. H. Ingbar and L. E. Braverman, pp. 154-200. Philadelphia: J. B. Lippincott Co.

- Higgs, D. A. and Eales, J. G. 1971. Iodide and throxine metabolism in the brook trout, *Salvelinus fontinalis* (Mitchill) during sustained exercise. *Can. J. Zool.* 49: 1255-1269.
- Higgs, D. A., Fagerlund, U. H. M., McBride, J. R., and Eales, J. G. 1979. Influence of orally administered L-thyroxine or 3,4,3'-triiodo-L-thyronine on growth, food consumption, and food conversion of the underyearling coho salmon (*Oncorhynchus kisutch*). *Can. J. Zool.* 57: 1974-1979.
- Higgs, D. A., Fagerlund, U. H., Eales, J. G., and McBride, J. R. 1982. Application of thyroid and steroid hormones as anabolic agents in fish culture. *Comp. Biochem. Physiol.* 73B: 143-176.
- Hossain, A. M. and Dutta, H. M. 1991. Food deprivation induces differential changes in contents and microstructures of digestive tract and appendages in bluegill fish, *Lepomis macrochirus*. *Comp. Biochem. Physiol.* 100A: 769-772.
- Huan, T. S., Chopra, I. J., Boado, R., Solomon, D. H., Chua Teco, G. N. 1988. Thyroxine inner ring monodeiodinating activity in fetal tissues of the rat. *Ped. Res.* 23: 196-199.
- Hunn, J. B. and From, P. O. 1966. *In vivo* uptake of radioiodide by rainbow trout. *J. Water Poll. Contr. Fed.* 38: 1981-1985.
- Inui, Y., Tagawa, M., Miwa, S., and Hirano, T. 1989. Effects of bovine TSH on the tissue thyroxine level and metamorphosis in the prometamorphic flounder larvae. *Gen. Comp. Endocrinol.* 74: 68-76.
- Johnston, C. E. and Eales, J. G. 1995. Effects of acclimation and assay temperature on outer- and inner-ring thyroxine and 3,5,3'-triiodothyronine deiodination by liver microsomes of rainbow trout, *Oncorhynchus mykiss*. *J. Exp. Zool.* 272: 426-434.
- Kohel, K. A., MacKenzie, D. S., Rostal, D. C., Grumbles, J. S., and Lance, V. A. 2001. Seasonality in plasma thyroxine in the desert tortoise, *Gopherus agassizii*. *Gen. Comp. Endocrinol.* 121: 214-222.
- Kohrle, J. 1996. Thyroid hormone deidinases – a selenoenzyme family acting as gate keepers to thyroid hormone action. *Acta Med. Austriaca* 23: 17-30.
- Kohrle, J., Oertel, M., Hoang-Vu, C., Schnieders, F., and Brabant, G. 1993. Type I 5'-deiodinase – a marker for differentiated thyroid carcinoma? *Exp. Clin. Endocrinol.* 101: 60-72.

- Kuhn, E. R. 1993. Role of growth hormone in thyroid function in vertebrates. Mededelingen van de Koninklijke Academie voor Wetenschappen, Letteren en Schone Kunsten van België, klasse der Wetenschappen, Jaargang 5S, no. 4, Paleis der Academein, Brussels, pp. 1-3.
- Law, Y. M. C. and Eales, J. G. 1973. Deiodination of radiothyroxine by tissue homogenates of brook trout, *Salvelinus fontinalis* (Mitchill). Comp. Biochem. Physiol. 44B: 1175-1183.
- Leatherland, J. F. 1981. Conversion of L-thyroxine to triiodo-L-thyronine in rainbow trout (*Salmo gairdneri*) liver and kidney homogenates. Comp. Biochem. Physiol. 69B: 311-4.
- Leatherland, J. F. 1984. Reflections on the thyroidology of fishes: from molecules to humankind. Guelph Ichthyol. Rev. 2: 1-67.
- Leloup, J. 1970. Les mecanismes de regulation de l'ioduemie et leur controle d'endocrinien chez les teleosteins en eau douce. Memoires de museum national d'histoire naturelle Paris, Ser. A Zool. 62: 1-108.
- Leonard, J. L. and Visser, T. J. 1986. Biochemistry of deiodination. In Thyroid hormone metabolism, ed., G. Henneman, pp. 189-229. New York: Marcel Dekker, Inc.
- MacKenzie, D. S., Moon, H. Y., Gatlin, D. M., and Perez, L. R. 1993. Dietary effects on thyroid hormones in the red drum *Sciaenops ocellatus*. Fish Physiol. Biochem. 11: 329-335.
- MacLatchy, D. L., and Eales, J. G. 1992a. Intra- and extra-cellular sources of T<sub>3</sub> binding to putative thyroid hormone receptors in liver, kidney and gill nuclei of immature rainbow trout, *Oncorhynchus mykiss*. J. Exp. Zool. 262: 22-29.
- MacLatchy, D. L., and Eales, J. G. 1992b. Properties of T<sub>4</sub> 5'-deiodination systems in various tissues of the rainbow trout, *Oncorhynchus mykiss*. Gen. Comp. Endocrinol. 86: 313-322.
- MacLatchy, D. L. and Eales, J. G. 1993. Effect of T<sub>3</sub> or T<sub>4</sub> challenge on inner- and outer-ring deiodination of T<sub>3</sub> and T<sub>4</sub> in the liver, kidney, and gill of rainbow trout, *Oncorhynchus mykiss*. J. Exp. Zool. 265: 637-645.
- MacMillan, J. R. and Santucci, T. 1990. Seasonal trends in intestinal bacterial flora of farm-raised channel catfish. J. Aquat. Anim. Health. 2: 217-222.
- McLeese, J. M. and Bergeron, M. 1990. Fasting induces modifications of the endoplasmic reticulum in intestinal cells. J. Electron Microsc. Tech. 16: 56-68.

- McLeese, J. M. and Eales, J. G. 1996a. 3,5,3'-triiodo-L-thyronine and L-thyroxine uptake into red blood cells of rainbow trout, *Oncorhynchus mykiss*. Gen. Comp. Endocrinol. 102: 47-55.
- McLeese, J. M. and Eales, J. G. 1996b. Characteristics of the uptake of 3,5,3'-triiodo-L-thyronine and L-thyroxine into red blood cells of rainbow trout (*Oncorhynchus mykiss*). Gen. Comp. Endocrinol. 103: 200-208.
- McLeese, J. M., Wright, G. M., Youson, J. H., and Eales, J. G. 2000. Deiodination activity in extrathyroidal tissues of the Atlantic hagfish, *Myxine glutinosa*. J. Exp. Zool. 287: 445-452.
- McNabb, F. M. A. 1992. Thyroid Hormones. Englewood Cliffs, NJ: Prentice-Hall.
- McNabb, F. M. A., Freeman, T. B., Siegel, P. B., and Dunnington, E. A. 1991. Hepatic 5'-deiodination in chickens from lines selected for high and low body weight and their F1 cross. British Poultry Sci. 32: 841-852.
- Milne, R. S. and Leatherland, J. F. 1980. Studies on the relationship between osmotic or ionic regulation and thyroid gland activity in two salmonid fishes, *Salmo gairdneri* Richardson and *Oncorhynchus kisutch* Walbaum. J. Fish Biol. 16: 349-360.
- Mommsen, T. P., Osachoff, H. L., and Elliott, M. E. 2003. Metabolic zonation in teleost gastrointestinal tract. Effects of fasting and cortisol in tilapia. J. Comp. Physiol. B 173: 409-418.
- Moon, H. Y., MacKenzie, D. S., Gatlin, D. M. III. 1994. Effects of dietary thyroid hormones on the red drum (*Sciaenops ocellatus*). Fish Physiol. Biochem. 12: 369-380.
- Nieto, T. P., Toranzo, A. E., and Barja, J. L. 1984. Comparison between the bacterial flora associated with fingerling rainbow trout cultured in two different hatcheries in the northwest of Spain. Aquaculture. 42: 3-4.
- Ng, T. B., Idler, D. R., and Eales, J. G. 1982. Pituitary hormones distinct from gonadotropin that stimulate the thyroidal system in teleost fishes. Gen. Comp. Endocrinol. 48: 372-389.
- Nguyen, T. T., DiStefano, J. J., Huang, L.-M., Yamada, H., and Cahnmann, H. J. 1993. 5'- and 5-deiodinase activities in adult rat cecum and large bowel contents inhibited by intestinal microflora. Am. J. Physiol. 265: E521-E524.



- Omeljaniuk, R. J., Cook, R. F., and Eales, J. G. 1984. Simultaneous measurement of thyroxine and triiodothyronine in trout plasma using a solid-phase radioimmunoassay. *Can. J. Zool.* 62: 1450-1453.
- Omeljaniuk, R. J. and Eales, J. G. 1985. Immersion of rainbow trout in  $T_3$ : effects on plasma  $T_3$  levels and hepatic nuclear binding. *Gen. Comp. Endocrinol.* 58: 81-88.
- Oppenheimer, J. H., Schwartz, J. L., Mariash, C. N., Kinlaw, W. B., Wong, N. C. W., and Frenkel, H. C. 1987. Advances in our understanding of thyroid hormone action at the cellular level. *Endocr. Rev.* 8: 288-308.
- Osborn, R. H. and Simpson, T. H. 1969. Thyroxine metabolism in plaice (*Pleuronectes platessa* L.). *Gen. Comp. Endocrinol.* 7: 524.
- Parry, J. E., Zhang, C., and Eales, J. G. 1994. Urinary excretion of thyroid hormones in rainbow trout, *Oncorhynchus mykiss*. *Gen. Comp. Endocrinol.* 95: 310-319.
- Peter, R. E. and Fryer, J. N. 1983. Endocrine functions of the hypothalamus of Actinopterygians. In *Fish Neurobiology, Vol. 2, Higher Brain Areas and Functions*, eds., R. E. Davis and R. G. Northcutt, pp. 165-201. Ann Arbor: University Michigan Press.
- Peter, R. E. and McKeown, B. A. 1975. Hypothalamic control of prolactin and thyrotropin secretion in teleosts, with special reference to recent studies on the goldfish. *Gen. Comp. Endocrinol.* 25: 153-165.
- Pimlott, N. J. and Eales, J. G. 1983. *In vitro* study of hepatic iodothyronine deiodination in rainbow trout, *Salmo gairdneri*. *Can. J. Zool.* 61: 547-552.
- Plohman, J. C., Dick, T. A., and Eales, J. G. 2002a. Thyroid of lake sturgeon, *Acipenser fulvescens*. I. Hormone levels in blood and tissues. *Gen. Comp. Endocrinol.* 125: 47-55.
- Plohman, J. C., Dick, T. A., and Eales, J. G. 2002b. Thyroid of lake sturgeon, *Acipenser fulvescens*. II. Deiodination properties, distribution, and effects of diet, growth, and a  $T_3$  challenge. *Gen. Comp. Endocrinol.* 125: 47-55.
- Riley, W. W. and Eales, J. G. 1994. Characterization of 3,5,3'-triido-L-thyronine transport into hepatocytes isolated from juvenile rainbow trout (*Oncorhynchus mykiss*), and comparison with L-thyroxine transport. *Gen. Comp. Endocrinol.* 95: 301-309.
- Rueggamer, W. R., Wagner, B. J., Barstow, M., and Keran, M. M. 1967. Mechanism by which certain dietary substances interfere with the peripheral activity of thyroxine. *Endocrinol.* 81: 49-53.

- Rutgers, M., Huesdens, F. A., Bonthius, F., de Herder, W. W., Hazenburg, W. W., and Visser, T. J. 1989. Enterohepatic circulation of triiodothyronine ( $T_3$ ) in rats: Importance of the microflora for the liberation and reabsorption of  $T_3$  from biliary  $T_3$  conjugates. *Endocrinol.* 125: 2822-2830.
- Sage, M. 1968. Control of the teleost pars distalis. *Am. Zool.* 8: 759-760.
- Sage, M. and Bromage, N. R. 1970. Interactions of the TSH and thyroid cells with the gonadotropic cells and gonads in poeciliid fishes. *Gen. Comp. Endocrinol.* 14: 127-136.
- Sekura, R. D., Kanjii, S., Cahnmann, H. J., Robbins, J., and Jakoby, W. 1981. Sulfate transfer of thyroid hormones and their analogs by hepatic aryl sulfotransferases. *Endocrinol.* 108: 454-456.
- Shields, C. A. and Eales, J. G. 1986. Thyroxine 5'-monodeiodinase activity in hepatocytes of rainbow trout, *Oncorhynchus mykiss*. *Gen. Comp. Endocrinol.* 63: 334-343.
- Shupnik, M. A., Chin, W. W., and Ridgway, E. C. 1989.  $T_3$  regulation of TSH gene expression. *Endocrine Res.* 15: 579-599.
- Sinclair, D. A. R. and Eales J. G. 1972. Iodothyronine-glucuronide conjugates in the bile of brook trout, *Salvelinus fontinalis* (Mitchill). *Gen. Comp. Endocrinol.* 19: 552-559.
- Spira, O., Birkenfield, A., Avni, A., Gross, J., Gordon, A. 1979. TSH synthesis and release in the thyroidectomized rat b) effect of  $T_3$ . *Acta Endocrinol. (Copenh.)* 3: 502-511.
- Spira, O. and Gordon, A. 1986. Thyroid hormone feedback effects on thyroid-stimulating hormone. *Basic Clin. Endocrinol.* 8: 535-578.
- Sternlicht, M., Harris, D. M., DiStefano, J. J. 1984. Enterohepatic circulation and systemic absorption of thyroid hormones from rat intestine. *Ann. Endocrinol.* 45:44.
- St. Germain, D. L. and Croteau, W. 1989. Ligand-induced inactivation of type I iodothyronine 5'-deiodinase: protection by propylthiouracil *in vivo* and reversibility *in vitro*. *Endocrinol.* 125: 2735-2744.
- Survarna, S., McNabb, F. M. A., Dunnington, E. A., and Siegel, P. B. 1993. Intestinal 5'-deiodinase activity of developing adult chickens selected for high and low body weight. *Gen. Comp. Endocrinol.* 91: 259-266.

- Swanson, P., Grau, E. G., Helms, L. M. H., and Dickhoff, W. W. 1988. Thyrotropic activity of salmon pituitary glycoprotein hormones in the Hawaiian parrotfish thyroid *in vitro*. J. Exp. Zool. 245: 194-199.
- Sweeting, R. M. and Eales, J. G. 1992a. HPLC analysis of *in vitro* hepatic deiodination products of thyroid hormones in the rainbow trout, *Oncorhynchus mykiss*. Gen. Comp. Endocrinol. 85: 367-375.
- Sweeting, R. M. and Eales, J. G. 1992b. The acute influence of ingested thyroid hormones on hepatic deiodination pathways in the rainbow trout, *Oncorhynchus mykiss*. Gen. Comp. Endocrinol. 85: 376-384.
- Tata, J. R. 1960. Transiodination of protein during enzymatic deiodination of thyroxine. Naturwissenschaften 187: 1025-1026.
- Taurog, A., Briggs, F. N., and Chaikoff, I. L. 1952. <sup>131</sup>I-labeled L-thyroxine-II. Nature of the excretion product in bile. J. Biol. Chem. 194: 655-668.
- Tong, W. 1974. Action of thyroid-stimulating hormone. In Handbook of physiology, Endocrinology III, Thyroid, eds., M. A. Greer and D. H. Solomon, pp 255-283. Washington, D.C.: Am. Physiol. Soc.
- Ui, N. 1974. Synthesis and chemistry of iodoproteins. In Handbook of physiology, Endocrinology III, Thyroid, eds., M. A. Greer and D. H. Solomon, pp 55-79. Washington, D.C.: Am. Physiol. Soc.
- Vander, A. J., Sherman, J. H., and Luciano, D. S. 1994. Human Physiology, 6<sup>th</sup> ed. McGraw Hill, Inc.
- Van Middlesworth, L. 1974. Metabolism and excretion of thyroid hormones. In Handbook of physiology, Endocrinology III, Thyroid, eds., M. A. Greer and D. H. Solomon, pp. 215-231. Washinton, D.C.: Am. Physiol. Soc.
- Visser, T. J. 1979. Mechanism of iodothyronine-5'-deiodinase. Biochim. Biophys. Acta 569: 302-308.
- Visser, T. J. 1990. Importance of deiodination and conjugation in the hepatic metabolism of thyroid hormone. In The thyroid gland, ed., M. A. Green, pp. 255-283. New York: Raven Press.
- Visser, T. J. 1994. Role of sulfation in thyroid hormone metabolism. Chemico-Biol. Interactions 92: 293-303.

- Whitaker, A. and Eales, J. G. 1993. Comparison of 3,5,3'-triiodo-L-thyronine and L-thyroxine absorption from the intestinal lumen of the fasted rainbow trout, *Oncorhynchus mykiss*. *Fish Physiol. and Biochem.* 10: 431-441.
- Williams, T. C., Kelijman, M., Crelin, W. C., Downs, T. R., and Frohman, L. A. 1988. Differential effects of somatostatin (SRIH) and a SRIH analog, SMS201-995m on the secretion of growth hormone and thyroid-stimulating hormone in man. *J. Clin. Endocrinol. Metab.* 66: 39-45.
- Woo, N. Y. S., Chung, A. S. B., and Ng, T. B. 1991. Influence of oral administration of 3,5,3'-triiodo-L-thyronine on growth, digestion, food conversion, and metabolism in the underyearling red sea bream, *Chrysophrys major* (Temminck & Schlegel). *J. Fish Biol.* 39: 459-468.

### Appendix I

Used to calculate total  $^*T_4$  metabolism in pmoles  $T_4$  converted per hour per mg protein.

#### Numbers from assay:

cpm of  $^*T_4$  metabolism product (MET) = \_\_\_\_\_

cpm of  $^*T_4$  substrate in assay (TCR) = \_\_\_\_\_

contamination of  $^*T_4$  (CONT) = \_\_\_\_\_

specific activity of  $^*T_4$  (S.A.) = \_\_\_\_\_

decay factor of  $^*T_4$  (D.F.) = \_\_\_\_\_

unlabeled substrate (K value) = \_\_\_\_\_  
(where 0.02 nM = 0.3K, 0.16 nM = 2.5K, 1.29 nM = 20K)

#### Numbers predetermined:

2 = correction for unlabeled  $I^-$  removed not detected in radioactive counts

5.2 = correction for dilution in assay volume

1,540,000 = cpm for 1  $\mu$ Ci (2,200,000) corrected for efficiency of gamma counter (70%)

777 = molecular weight of  $T_4$

#### Calculations:

corrected TCR (cTCR) =  $TCR - (CONT \times 5.2)$

corrected S.A. (cS.A.) =  $S.A. \times D.F.$

radioactive substrate (rSUB) =  $1000 / (cS.A. \times cTCR) / 1,540,000$

total substrate (tSUB) =  $(rSUB + (K \text{ value} / 10)) \times (1000 / 777)$

constant =  $((tSUB \times 2 \times 5.2) / cTCR) \times (60 / \text{min of incubation})$

<b>Total <math>^*T_4</math> metabolism</b>	<b>= MET x constant/mg protein</b>
--	------------------------------------

## Appendix II

Used to calculate total  $^*T_3$  metabolism in pmoles  $T_3$  converted per hour per mg protein.

### Numbers from assay:

cpm of  $^*T_3$  metabolism product (MET) = \_\_\_\_\_

cpm of  $^*T_3$  substrate in assay (TCR) = \_\_\_\_\_

contamination of  $^*T_3$  (CONT) = \_\_\_\_\_

specific activity of  $^*T_3$  (S.A.) = \_\_\_\_\_

decay factor of  $^*T_3$  (D.F.) = \_\_\_\_\_

unlabeled substrate (K value) = \_\_\_\_\_  
(where 0.02 nM = 0.3K, 0.19 nM = 2.5K, 1.52 nM = 20K)

### Numbers predetermined:

5.2 = correction for dilution in assay volume

1,540,000 = cpm for 1  $\mu$ Ci (2,200,000) corrected for efficiency of gamma counter (70%)

652 = molecular weight of  $T_3$

### Calculations:

corrected TCR (cTCR) =  $TCR - (CONT \times 5.2)$

corrected S.A. (cS.A.) =  $S.A. \times D.F.$

radioactive substrate (rSUB) =  $1000 / (cS.A. \times cTCR) / 1,540,000$

total substrate (tSUB) =  $(rSUB + (K \text{ value} / 10)) \times (1000 / 652)$

constant =  $((tSUB \times 5.2) / cTCR) \times (60 / \text{minutes of incubation})$

<b>Total <math>^*T_3</math> metabolism</b>	<b>= MET x constant/mg protein</b>
--	------------------------------------

### Appendix III

Used to calculate IP production in pmoles TH converted to IP per hour per mg protein.

#### Numbers from assay:

cpm of \*TH IP product (MET) = \_\_\_\_\_

cpm of \*TH substrate in assay (TCR) = \_\_\_\_\_

contamination of \*TH (CONT) = \_\_\_\_\_

specific activity of \*TH (S.A.) = \_\_\_\_\_

decay factor of \*TH (D.F.) = \_\_\_\_\_

unlabeled substrate (K value) = \_\_\_\_\_  
(where 0.02 nM = 0.3K, 0.16 nM = 2.5K, 1.29 nM = 20K)

#### Numbers predetermined:

5.2 = correction for dilution in assay volume

1,540,000 = cpm for 1  $\mu$ Ci (2,200,000) corrected for efficiency of gamma counter (70%)

777 = molecular weight of T<sub>4</sub>

652 = molecular weight of T<sub>3</sub>

#### Calculations:

corrected TCR (cTCR) = TCR - (CONT x 5.2)

corrected S.A. (cS.A.) = S.A. x D.F.

radioactive substrate (rSUB) = 1000/(cS.A. x cTCR)/1,540,000

total substrate (tSUB) = (rSUB + (K value/10)) x (1000/mole. wt. of TH)

constant = ((tSUB x 2 x 5.2)/cTCR) x (60/min of incubation)

<b>TH IP production</b>	<b>= MET x constant/mg protein</b>
-------------------------	------------------------------------

### Appendix IV

Used to calculate activities of specific  $^*T_4$  metabolism pathways in pmoles  $T_4$  converted to product per hour per mg protein.

#### Numbers from assay:

area under the curve for specific  $^*T_4$  metabolism product (MET) = \_\_\_\_\_

cpm of  $^*T_4$  substrate in assay (TCR) = \_\_\_\_\_

contamination of  $^*T_4$  (CONT) = \_\_\_\_\_

specific activity of  $^*T_4$  (S.A.) = \_\_\_\_\_

decay factor of  $^*T_4$  (D.F.) = \_\_\_\_\_

unlabeled substrate (K value) = \_\_\_\_\_  
(where 0.02 nM = 0.3K, 0.16 nM = 2.5K, 1.29 nM = 20K)

#### Numbers predetermined:

2 = correction for unlabeled  $I^-$  removed not detected in radioactive counts

1,540,000 = cpm for 1  $\mu$ Ci (2,200,000) corrected for efficiency of gamma counter (70%)

777 = molecular weight of  $T_4$

#### Calculations:

corrected TCR (cTCR) =  $TCR - (1 - CONT)$

corrected S.A. (cS.A.) =  $S.A. \times D.F. (1 - CONT)$

radioactive substrate (rSUB) =  $1000 / (cS.A. \times cTCR) / 1,540,000$

total substrate (tSUB) =  $(rSUB + (K \text{ value}/10)) \times (1000/777)$

constant =  $(tSUB) / cTCR \times (60/\text{minutes of incubation})$

Specific $^*T_4$ metabolism pathway = $MET \times \text{constant} / \text{mg protein}$
--



### Appendix V

Used to calculate activities of specific  $T_3$  metabolism pathways in pmoles  $T_3$  converted to product per hour per mg protein.

#### Numbers from assay:

area under the curve for specific  $*T_3$  metabolism product (MET) = \_\_\_\_\_

cpm of  $*T_3$  substrate in assay (TCR) = \_\_\_\_\_

contamination of  $*T_3$  (CONT) = \_\_\_\_\_

specific activity of  $*T_3$  (S.A.) = \_\_\_\_\_

decay factor of  $*T_3$  (D.F.) = \_\_\_\_\_

unlabeled substrate (K value) = \_\_\_\_\_  
(where 0.02 nM = 0.3K, 0.19 nM = 2.5K, 1.52 nM = 20K)

#### Numbers predetermined:

1,540,000 = cpm for 1  $\mu$ Ci (2,200,000) corrected for efficiency of gamma counter (70%)

652 = molecular weight of  $T_3$

#### Calculations:

corrected TCR (cTCR) =  $TCR - (1 - CONT)$

corrected S.A. (cS.A.) =  $S.A. \times D.F. \times (1 - CONT)$

radioactive substrate (rSUB) =  $1000 / (cS.A. \times cTCR) / 1,540,000$

total substrate (tSUB) =  $(rSUB + (K \text{ value}/10)) \times (1000/652)$

constant =  $(tSUB) \times (60/\text{minutes of incubation})$

Specific $*T_3$ metabolism pathways = $MET \times \text{constant}/\text{mg protein}$
--

## Appendix VI

Used to calculate T<sub>4</sub>cORD activity in pmoles T<sub>4</sub> converted to product per hour per mg protein.

### Numbers from assay:

area under the \*I<sup>-</sup> curve (MET) = \_\_\_\_\_  
 cpm of \*T<sub>4</sub> substrate in assay (TCR) = \_\_\_\_\_  
 contamination of \*T<sub>4</sub> (CONT) = \_\_\_\_\_  
 specific activity of \*T<sub>4</sub> (S.A.) = \_\_\_\_\_  
 decay factor of \*T<sub>4</sub> (D.F.) = \_\_\_\_\_  
 unlabeled substrate (K value) = \_\_\_\_\_  
 (where 0.02 nM = 0.3K, 0.16 nM = 2.5K, 1.29 nM = 20K)

### Numbers predetermined:

2 = correction for unlabeled I<sup>-</sup> removed not detected in radioactive counts

1,540,000 = cpm for 1 μCi (2,000,000) corrected for efficiency of gamma counter (77%)

777 = molecular weight of T<sub>4</sub>

### Calculations:

corrected TCR (cTCR) = TCR - (1 - CONT)  
 corrected S.A. (cS.A.) = S.A. x D.F. x (1 - CONT)  
 radioactive substrate (rSUB) = 1000/(cS.A. x cTCR)/1,540,000  
 total substrate (tSUB) = (rSUB + (K value/10)) x (1000/777)  
 constant = (tSUB x 2) x (60/minutes of incubation)  
 Total I<sup>-</sup> production = MET x constant/mg protein  
 T<sub>4</sub>cORD activity (from Appendix V)

T <sub>4</sub> cORD activity	= Total I <sup>-</sup> production - T <sub>4</sub> cORD activity
------------------------------	--

### Appendix VII

Correction factors for blood, plasma, liver, bile, and intestinal loop tissues which were calculated from adding a known amount of  $^*T_4$  to each tissue, extracting radioactivity, and eluting  $^*TH$  from LH-20 columns. The injectate was also eluted from LH-20 columns to serve as a standard reference.

TISSUE	$^*T_4$ RECOVERY (%)	CORRECTION FACTOR
BLOOD	58.4	1.7123
PLASMA	67.9	1.4728
LIVER	69.8	1.4327
BILE	30.5	3.2787
LOOP	80.5	1.2430
INJECTATE	100	1.0000

**Appendix VIII**

Correction factors for blood, plasma, liver, bile, and intestinal loop tissues which were calculated from adding a known amount of  $^*T_3$  to each tissue, extracting radioactivity, and eluting  $^*TH$  from LH-20 columns. The injectate was also eluted from LH-20 columns to serve as a standard reference.

TISSUE	$^*T_3$ RECOVERY (%)	CORRECTION FACTOR
BLOOD	36.5	2.7397
PLASMA	58.8	1.7007
LIVER	94.3	1.0604
BILE	27.2	3.6765
LOOP	85.6	1.1682
INJECTATE	100	1.0000

### Appendix IX

Equations used for linear regression analyses (unbalance ANOVA) to compare TH metabolism activities for the effects of treatments (i; C, T<sub>4</sub> TRT, and T<sub>3</sub> TRT) and time (j; Day 0, 2, and 7) and Tukey's Multiple Comparison used to compute confidence intervals and determine significant differences among treatments over time.

i = TRT:	x1	x2	j = DAY:	x3	x4
C	1	0	Day 0	1	0
T <sub>3</sub> TRT	-1	1	Day 2	-1	1
T <sub>4</sub> TRT	0	-1	Day 7	0	-1

i = TRT

j = DAY

m = response in a cell

a = 3

b = 3

$$Y_{ijm} = \mu + \alpha_1 x_1 + \alpha_2 x_2 + \beta_1 x_3 + \beta_2 x_4 + (\alpha\beta)_{11} x_1 x_3 + (\alpha\beta)_{12} x_1 x_4 + (\alpha\beta)_{21} x_2 x_3 + (\alpha\beta)_{22} x_2 x_4 + \sum_{ijm}$$

#### Testing hypothesis with reduced models:

$$F^* = \frac{SSE(\text{reduced model}) - SSE(\text{full model})}{df_{\text{error}}(\text{reduced model}) - df_{\text{error}}(\text{full model})}$$

if  $F^* \leq F(.984; (df_{\text{error}}(\text{reduced}) - df_{\text{error}}(\text{full}), df_{\text{error}}(\text{full}))$   
then conclude  $H_0$ : no significant effect.

#### Look at pairwise comparisons of factor levels means: Tukey's Multiple Comparison

Estimator example:  $\mu_i = \frac{\sum_i^b Y_i}{b}$

Confidence intervals:

$$(\mu_1 - \mu_2) \pm 1/(\text{sq root } 2) \times q(1 - \alpha; a, n_T - ab) \times \text{sq root } (MSE/b^2 \sum_j^b 1/n_{1j} + 1/n_{2j})$$

$$(\mu_1 - \mu_3) \pm \text{same}$$

$$(\mu_2 - \mu_3) \pm \text{same}$$